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ABSTRACT 
 
Oligodendrocytes (OL)s are the dominant cell type in the white matter and 
are integral for synaptic transmission essential for proper neuronal 
communication between brain areas. Previous studies have shown that 
intravenous administration of the mononuclear fraction of human umbilical cord 
blood (HUCB) cells in rat models of stroke reduced white matter injury, gray 
matter injury and behavioral deficits. Yet the mechanisms used by HUCB cells 
remain unknown in ischemic injury. These studies will investigate both in vitro 
and in vivo approaches to elucidate this mechanism in OLs. When mature 
primary OLs were coincubated with HUCB cells, HUCB cells secreted soluble 
factors that reduced cell death in OLs exposed to OGD. Microarray analysis 
revealed that HUCB cell treatment induced OL gene changes. These changes 
included genes involved in cell proliferation, signaling, anti-oxidant activity, and 
myelination. To extend these findings, the middle cerebral artery occlusion 
(MCAO) model was used to assess the expression profile of protein products of 
gene changes observed in vitro. The in vivo data mirrored in vitro data in that 
metallothionein 3 (Mt3), peroxiredoxin 4 (Prdx4), myelin oligodendrocyte 
glycoprotein (Mog), U2AF homology kinase 1(Uhmk1), and insulin induce gene 
1(Insig1) were upregulated in OLs of the white matter tract adjacent to the infarct. 
Furthermore, double immunofluorescence staining determined that OLs 
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expressed these proteins. Other reports have shown that HUCB cells secrete 
soluble factors related to cellular protection, including interleukin 6 (IL-6), 
interleukin 8 (IL-8), and interleukin 10 (IL-10). Other factors are known for their 
proliferative actions, such as vascular endothelial growth factor (VEGF), BDNF, 
platelet derived growth factor B (PDGF-B), leukemia inhibitory factor (LIF), and 
granulocyte colony stimulating factor (GCSF) all of which converge on the Akt 
survival pathway. Given these findings we hypothesize that Akt activation is 
integral to HUCB cell mediated OL protection. In models of excitotoxicity, the 
addition of Akt inhibitor IV blocked HUCB cell mediated protection in OL cultures 
exposed to 24 hrs OGD. In vivo, HUCB cell treatment increased Akt activation, 
antioxidant protein expression and decreased caspase 3 cleavage in the external 
capsule in a time dependent manner. The next series of experiments determine 
whether the soluble factors secreted by HUCB cells could replace HUCB cells as 
treatment. LIF expression is increased in HUCB cells as compared to peripheral 
blood and as previously mentioned, LIF is secreted by HUCB cells. Additionally, 
LIF rescued OLs from spinal cord and experimental autoimmune 
encephalomyelitis injury. Thus LIF was investigated. LIF protected OL subjected 
to 24 hr OGD, increased antioxidant Prdx4 gene expression and reduced 
reactive oxygen species production. Additionally the inclusion of Akt inhibitor IV 
blocked LIF induced OL protection. Similar results were obtained when GCSF 
was evaluated. All these findings indicate that HUCB cell mediated OL/white 
matter protection is due to the soluble factors secreted by the mononuclear 
population of these cells. These soluble factors including LIF activate cellular 
xi 
 
machinery leading to enhanced cellular survival. Here we found a specific 
survival pathway activated by soluble factors released from HUCB cells, leading 
to Akt activation. Akt activation arrests stroke induced apoptosis and reduced the 
expansion of the infarct, promoting functional recovery from acute ischemic 
injury.  
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CHAPTER ONE 
INTRODUCTION 
 
D.D. Rowe, MS, A.E. Willing, PhD, K.R. Pennypacker PhD. 
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Overview of Stroke 
Each year an estimated 780,000 Americans will experience an initial 
ischemic event, and over 150,000 of these individuals will succumb to 
complications as a direct result of the stroke (Association 2008). According to the 
American Heart Association, stroke is the third leading cause of death in the 
United States. The high incidence of stroke places an enormous financial burden 
on the American health care system, an estimated $69 billion yearly (Lloyd-
Jones, Adams et al. 2009). Therefore the development of effective therapeutics 
to reduce stroke related morbidity and mortality will provide both financial and 
societal benefits.  
Tissue plasminogen activator (t-PA) is currently the only Food and Drug 
Administration (FDA) approved treatment for acute ischemia (Pan, Yu et al. 
2008). t-PA represents a class of thrombolytic agents which restores blood flow 
to ischemic areas by enzymatically dissolving clots, but does not possess 
neuroprotective activity.  In clinical trials, t-PA treatment within 4 hours of stroke 
onset significantly reduced stroke-related morbidities; use beyond this limited 
therapeutic time window is ineffective and could prove detrimental (Hacke, 
Donnan et al. 2004). As a result, only 3-5% of stroke patients are able to use t-
PA (Marler and Goldstein 2003; Association 2008). Effective stroke therapies are 
clearly needed to extend the therapeutic time window providing treatment for a 
larger population of stroke patients.  
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Types of Stroke 
Ischemic Stroke 
The major classifications of stroke are defined as either hemorrhagic or 
ischemic. Ischemic strokes account for 83% of all strokes and occur when an 
obstruction is present within a vessel supplying blood to the brain (Association 
2008; Lloyd-Jones, Adams et al. 2009). Depending on origin and location of the 
clot, an ischemic event can be further classified as thrombotic or embolic. With 
thrombosis, ischemia develops at the point of the clot, whereas in an embolic 
stroke the clot arises from a specific location, travels in the circulatory system 
and is lodged in a narrowed vessel (Association 2008). The severity of a stroke is 
further based on cerebral blood flow (CBF) downstream the obstructed vessel. 
The terms acute, mild, or severe are used to describe the extent of an ischemic 
injury. Normal CBF is typically recorded as 45-110 cm3 × 100 g-1 × min-1. An 
acute ischemic stroke is marked by immediate depletion of oxygen and glucose 
in the affected brain tissue, while mild ischemia is classified as a condition in 
which a residual CBF of 11–20 cm3 × 100 g-1 × min-1 is recorded. This reduction 
in CBF leads to the activation of reversible apoptotic pathways, the target of 
developing therapeutic agents. In severe ischemic events, CBF of ≤ 6 cm3 × 100 
g-1 × min-1 is usually recorded; this condition is classically associated with 
complete energy loss in affected cells, leading to necrosis (Kaufmann, Firlik et al. 
1999). Given that immediate cell death as a result of severe ischemia is not 
reversible, neuroprotective agents will not reduce these infarctions, but may 
target behavior deficits that result from the ischemic insult. 
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Hemorrhagic Stroke 
Accounting for 17% of all strokes, hemorrhagic strokes result from 
ruptured blood vessels leading to severe bleeding, swelling and compression of 
tissue in the affected area. Hemorrhagic strokes are subcategorized depending 
on the location of the hemorrhage; intracerebral and subarachnoid hemorrhages. 
Intracerebral hemorrhages are the result of ruptured vessels leading to bleeding 
within these brain areas, the thalamus, basal ganglia, cerebellum or the pons. 
Subarachnoid hemorrhages denote bleeding from a ruptured vessel into the 
space between the brain and the skull (subarachnoid space). Hemorrhagic 
strokes usually result from weakened blood vessels as a consequence of 
aneurysms, head injuries, high blood pressure and arteriovenous malformations 
(Association 2008).  Because of the pervasive and devastative nature of 
ischemic injury in the current population, this topic will be extensively discussed. 
 
Ischemic Stroke Pathology 
 Energy Depletion 
The brain rapidly metabolizes oxygen and glucose. As a result, immediate 
energy depletion occurs following the occlusion of vessels supplying blood to the 
brain. Within minutes of energy starvation, cellular ATP synthesis is arrested. 
Lack of energy production leads to an imbalanced cellular ion gradient and 
cellular excitotoxicity due to membrane depolarization, sodium influx, calcium 
influx, and potassium efflux into the extracellular space (Doyle, Simon et al. 
2008). These processes trigger the degradation of membranes and proteins 
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essential to the maintenance of homeostasis resulting in the outward radiation of 
cellular depolarization from the ischemic core leading to calcium accumulation 
within cells. Elevated intracellular calcium and sodium increase mitochondrial 
reactive oxygen species (ROS) production, cellular reactive nitrogen species 
(RNS), free radical production and activation of cell death cascades (Coyle and 
Puttfarcken 1993; Doyle, Simon et al. 2008).  
 
Immune Response 
Negligible amounts of proinflammatory cytokines are present in the brain 
under normal physiological conditions.  Energy depletion as a result of ischemia 
triggers activation of the immune system.  Once activated, the resident central 
nervous system (CNS) immune cells, the microglia, secrete cytokines, 
chemokines, matrix metalloproteinases (MMP), nitric oxide (NO) and reactive 
oxygen species (ROS) creating an environment conducive to the recruitment of 
proinflammatory cells (Sharma and Kumar 1998; Wang, Tang et al. 2007). 
Recruitment of these cells increases the secretion of proinflammatory mediators 
resulting in the disruption of the blood brain barrier, infiltration of peripheral 
inflammatory and immune cells such as leukocytes. Microglia along with 
peripheral immune cells accumulate in the infarct area where the inflammatory 
signal is amplified, exacerbate injury and perpetuate the destructive cycle leading 
to the outward expansion of the infarct (Emsley and Tyrrell 2002; Danton and 
Dietrich 2003).  
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Reperfusion 
Stroke pathology is not only a consequence of ischemia which causes 
oxygen and glucose deprivation, but also a result of reperfusion. The reperfusion 
of an occluded vessel increases cellular ROS. ROS are produced by 
dysfunctional mitochondria that generate oxidative stress and release apoptosis 
related proteins upon tissue oxygenation. ROS initiate proinflammatory cytokine 
and chemokine production by immune cells. In response to proinflammatory 
cytokines, inflammatory cells release MMPs, NO and ROS.  This reperfusion led 
inflammatory response results in blood brain barrier disruption, infiltration of 
peripheral immune cells and expansion of the infarct (Emsley and Tyrrell 2002; 
Danton and Dietrich 2003).  
As pointed out, both ischemic insult and reperfusion results in delayed cell 
death by disrupting the blood brain barrier allowing infiltration of peripheral 
immune cells. The initial mechanisms of both injuries are different but converge 
on the modulation of inflammation to amplify and exacerbate disease pathology. 
Therefore animal models used for the development of stroke therapeutics should 
aim to eliminate the over production of these proinflammatory mediators.  
 
Animal Models of Stroke 
An assortment of animal models to evaluate stroke related pathology has 
been developed to assess new therapeutics. Importantly, basic research aims 
specifically to translate beneficial effects of developing therapeutics from the 
laboratory to clinical trials involving humans. Three basic animal models are 
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currently utilized in stroke research: global ischemia, focal ischemia and 
hemorrhagic injury (Richard Green, Odergren et al. 2003). In hemorrhagic animal 
models, bleeding is induced in a specific brain region depending on the 
hemorrhagic classification (intracerebral or subarachnoid). Global and focal 
ischemias are the most commonly used animal models; therefore these topics 
will be discussed further. 
 
 Global Ischemia 
Global ischemia involves the blockage of one or more major arteries 
resulting in significant CBF reduction in areas perfused by the occluded vessel, 
thus mimicking ischemic injury (Traystman 2003). Global ischemia can be 
performed by varying techniques including bilateral carotid occlusion, two vessel 
occlusion plus hypotension, or a four vessel occlusion (Richard Green, Odergren 
et al. 2003). Bilateral carotid occlusions are achieved using an incision to expose 
both carotid arteries, the vessels are isolated and ligated most commonly using a 
silk suture (Fujishima, Morotomi et al. 1979).  
In the permanent occlusion model, the occlusion/ligation is permanent; in 
the transient model, the method of occlusion is reversed following an allotted 
time to restore blood flow. Use of the permanent model aims to investigate stroke 
induced infarct, while the transient model is used to investigate both stroke 
induced infarct and reperfusion injury.  
Two vessel occlusion plus hypotension employs the same technique as 
described in bilateral carotid occlusion, but hypertensive animals are used. This 
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model intends to examine the cumulating effects of both high blood pressure and 
ischemia. Four vessel models incorporate the bilateral carotid model, but also 
added the occlusion of two vertebral arteries (Pulsinelli and Brierley 1979). This 
procedure calls for the occlusion of all four major arteries that supply blood to the 
brain. This method produces a significant decrease in CBF resulting in global 
ischemia (Pulsinelli and Brierley 1979). Although the four vessel occlusion model 
restricts all major vessels supplying the CNS, blood still reaches the brain 
through the collateral and anterior spinal arteries in the para vertebral and 
cervical muscles (Pulsinelli and Buchan 1988). Therefore a complete global 
ischemia is not achieved in the models mentioned, although the four-vessel 
model produces the most significant reduction in CBF. Myocardial infarctions are 
the only method used to produce a complete global ischemia. Although effective 
and easily replicated, global ischemia is not comparable to the human model of 
stroke. Global ischemia is less relevant to the human stroke condition because 
global ischemia is not a common feature of human stroke, but does have a place 
in the study of cardiovascular incidents. In the human population, focal ischemia 
is the major injury pattern observed (Traystman 2003).  
 
Focal Ischemia 
Focal ischemia entails the obstruction of a specific vessel, creating an 
infarct in areas perfused by the vessel. This model is primarily achieved by 
obstructing the middle cerebral artery; a procedure which reduces CBF mainly to 
the striatum and cortex (Garcia, Liu et al. 1995; Kanemitsu, Nakagomi et al. 
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2002). Middle cerebral artery occlusion (MCAO) is achieved by isolating both the 
external and the common carotid, from which the MCA is obstructed either by the 
introduction of a filament, suture or photothrombosis (Carmichael 2005). In the 
filament model, a line is introduced at the base of the internal carotid artery and 
advanced into the MCA. In the suture model, a silk thread is used to tie off the 
internal carotid artery, thus restricting blood flow to areas perfused by the MCA. 
On the other hand, the photothrombosis model involves the use of 
photooxidation to develop a clot in the target vessel, providing the necessary 
occlusion resulting in reduced CBF.  
Following MCAO, cell death is rapid in the striatum and cortex, and the 
expansion of the infarct via apoptotic cascades are time dependent (Garcia, Liu 
et al. 1995; Carmichael 2005). Infarction areas are thus relative to MCAO 
duration. MCAO induced striatum and cerebral cortex dysfunction produces 
motor, autonomic and cognitive deficits (Carmichael 2005). These deficits are a 
result of stroke led degeneration of areas integral to the execution of such 
functions. In humans, occlusion of the middle cerebral artery is the most common 
cause of an ischemic event, therefore occlusion of the MCA in animal models 
serves to develop specific treatments that would benefit a large population of 
patients (Traystman 2003). Like models of global ischemia, the MCAO model of 
focal ischemia can be transient or permanent. In the transient model, the vessel 
is obstructed for a period of time, followed by removal of the obstructive force, 
where in the permanent model the obstruction is not removed. Ischemia plus 
reperfusion is studied in the transient model, where only the ischemic damage is 
10 
 
accessed in a permanent occlusion model (Richard Green, Odergren et al. 
2003).  
All models mentioned produce global or focal ischemia. These models 
provide reproducible effects tailored towards the research of specific 
investigators. Each model provides benefits and drawbacks and is used 
specifically for the length of time required for the ischemic damage as it 
correlates to the region of the brain affected. 
 
Moving Past the Neuron-Centric Perspective 
A primarily neuron-centric approach has influenced the past decade of 
stroke related research.  Specifically, this movement is primarily aimed at 
neuronal preservation and stabilization following ischemic injury. This neuron-
centric approach has led to an overwhelming proportion of research focused at 
limiting ischemic damage to the gray matter; thus the current literature is 
saturated with experimentations studying the effects of stroke on gray matter. As 
a result, very little has been published investigating white matter pathology 
although it plays a significant role in the debilitating disease that is stroke. The 
white matter, like the gray matter, is significantly impacted by ischemic brain 
injury.  Cerebral white matter accounts for 50% total brain volume in humans, 
oligodendrocyte (OL) are the major cell type of the white matter and are integral 
in proper brain function (Miller, Alston et al. 1980).  The significance of this region 
has contributed to an emerging consensus highlighting the importance of OLs 
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and the white matter in research aimed at limiting functional deficits resulting 
from stroke induced pathology (Arai and Lo 2009).  
 
White Matter  
 Overview 
 By volume, the white matter account for 50% total brain volume in humans 
and is responsible for efficient synaptic transmission and proper cerebral 
function. It is of no surprise that white matter damage can be more devastating 
than comparable gray matter injury when similar size areas are affected by 
stroke (Goldberg and Ransom 2003). Mature OLs of the cerebral white matter 
myelinate the central nervous system (CNS). The myelin produced by OL, 
ensheaths neuronal axons to facilitate fast and efficient synaptic transmission.   
 
OL Development 
OL progenitors arise in vivo from cells of the subventricular zone of the 
lateral ventricles, differentiate, then migrate to regions of developing white and 
grey matter until reaching the appropriate axons (Levison and Goldman 1993).  
After reaching their target axons OLs exit the cell cycle, become non-migratory 
and differentiate into myelin producing OLs.  During maturation, OLs begin to 
down regulate precursor OL proteins including platelet derived growth factor 
alpha receptor (PDGF-AA) and NG2 chondroitin sulfate proteoglycan and induce 
the expression of proteins, such as myelin basic protein (MBP) (McTigue and 
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Tripathi 2008). Upon beginning the expression of myelin proteins, OLs have fully 
developed into the mature phenotype. 
Myelination occurs in the following four stages: the recognition and 
adhesion of an OL to an axon, synthesis and transport of myelin to axon, 
wrapping of myelin around axon, and finally compaction of myelin sheath.  During 
the myelination process, only axons with a diameter greater than 0.2µm are 
ensheathed.  Unlike Schwann cells of the peripheral nervous system that 
myelinate axons at a 1:1 ratio, OLs have the ability to myelinate 40-60 different 
axons simultaneously.  During the active phase of myelination, each OL 
produces an estimated 5.50 X 103 µm2 of myelin membrane surface area per 
day, a process requiring a large expenditure of energy (Pfeiffer, Warrington et al. 
1993; Taveggia, Zanazzi et al. 2005; Simons and Trajkovic 2006).   
Myelin sheaths are formed by the coiled wrapping of glial plasma 
membrane extensions around axons followed by the extrusion of cytoplasm and 
the compaction of the stack membrane bilayers.  Myelin sheaths are rich in 
glycosphingolipids and cholesterol to provide insulation of axons to maximize 
conduction velocity (Simons and Trajkovic 2006).  By weight, myelin is composed 
of 30% protein and 70% lipids; the two major protein classes are MBP and 
proteolipid proteins (PLP).  Minor proteins such as CNPases, myelin associated 
glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG) are also 
present (Morell, Greenfield et al. 1972; Larocca and Rodriguez-Gabin 2002).  In 
addition, proteins are synthesized in different regions based on function.  MBP 
and myelin oligodendrocyte associated basic proteins (MOABP) are synthesized 
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close to the site of myelin assembly (Colman, Kreibich et al. 1982; Barbarese, 
Koppel et al. 1995; Gould, Freund et al. 1999).  PLP and MAG are synthesized in 
the endoplasmic reticulum, then transported by vesicles to the Golgi. From the 
Golgi these proteins are transported via COPI and COPII to the forming myelin 
sheath. Cooperatively, both the minor and major proteins of myelin function 
together to maintain the myelin sheath, and the absence of one could be 
destructive to the sheath stability (Townsend and Benjamins 1983; Bizzozero, 
Soto et al. 1984).   
In addition to myelination, OLs serve an important role supporting the 
survival and function of neighboring neurons.  OLs regulate axonal size, ion 
channel clustering such as sodium (Na+) and potassium (K+) and also produce 
trophic factors including insulin like growth factor 1 (IGF-I), nerve growth factor 
(NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and 
neurotrophin 4/5 (NT-4/5) (Du and Dreyfus 2002).  Additionally, failures and 
abnormalities in myelination are implicated in disruptions of normal impulse 
conduction and interference with neurological function and can potentially lead to 
neuronal loss (Noble 2005 ).  The importance of myelination is evident not only in 
demyelination diseases such as multiple sclerosis, but also in mice lacking the 
major proteolipids of myelin. These animals tend to experience axonal swelling 
and degeneration (Du and Dreyfus 2002). 
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Stroke and Oligodendrocytes 
CNS myelination is the primary function of white matter OLs.  As a result, 
the primary consequence of OL death is axonal demyelination.  Axonal 
demyelination leads to delays or complete blockage of axonal conduction, which 
results in impaired neuronal signaling and cell death.  OLs are also responsible 
for normal axonal transport as well as microtubule levels.  Lack of myelin 
contributes to elevated microtubule numbers but a sharp decrease in microtubule 
stability (McTigue and Tripathi 2008). Additionally, OLs like neurons and 
astrocytes are known to have very high metabolic rates. These high metabolic 
demands render OLs inherently susceptible to ischemia. Naturally, of the 
different types of glia, OLs were found to be the most prone to hypoxic and/or 
glucose deprived conditions (Lyons and Kettenmann 1998). OL injury is 
important as it relates to the treatment of stroke. Therefore it is important to 
understand stroke induced OL dysfunction that treatments can be tailored to 
maintenance of cerebral white matter following injury. 
 
Oxidative Stress 
 Oxidative stress is one of the most frequent causes of stroke induced OL 
dysfunction. Cellular stress is increased during anaerobic respiration after 
ischemia, particularly during reperfusion (Dewar, Underhill et al. 2003). Of the 
compounds produced in OGD environments, ROS and RNS are the most 
detrimental to cellular homeostasis. ROS are natural by products of oxygen 
metabolism and are metabolized into benign compounds under normal 
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physiological condition. Yet, under biological stress, ROS are generated to toxic 
levels causing cellular dysfunction (Allen and Bayraktutan 2009). The brain is 
especially prone to ROS induced damage, the abundance of peroxidizable lipids 
and natively high oxygen consumption are the main culprit. In the in vitro stroke 
model OGD, aerobic respiration is disrupted resulting in the accumulation of 
respiratory chain intermediates allowing electron leak to generate ROS 
(Abramov, Scorziello et al. 2007). Superoxide is the primary ROS from which 
other more reactive ROS are generated. Superoxide generates hydrogen 
peroxides, which generates hydroxyl radicals. RNS are also generated from the 
interaction of nitrogen and superoxide. These intermediates include nitric oxide, 
peroxynitrous acid that produces hydroxyl radical. The accumulation of these 
radicals depends on the oxidizable substrate, availability of oxygen and 
antioxidant enzymes (Allen and Bayraktutan 2009). 
OLs are susceptible to oxidative stress due to the large amount of energy 
necessary to synthesize and maintain myelin. Myelination is an energy 
dependent process and requires large amounts of ATP and oxygen consumption. 
As described above, OGD leads to overproduction of superoxide leading to 
hydrogen peroxide and ROS byproducts which if not metabolized cause OL 
deoxyribonucleic acid (DNA) damage, lipid per-oxidation and apoptosis. OL 
susceptibility to oxidative stress is also a result of myelin synthetic enzymes that 
requires co-factors such as iron. Of cerebral cell types, OLs possess the largest 
intracellular iron stores. Iron is highly reactive, when oxidized it reacts vigorously 
resulting in to free radical formation (McTigue and Tripathi 2008). For example, 
16 
 
hydroxyl radical is generated from hydrogen peroxide by ferrous iron that has 
been reduced by superoxide (Allen and Bayraktutan 2009). Following ischemic 
injury, free radical formation as a result of iron oxidation is rapidly increased 
causing lipid peroxidation. In conjunction with elevated iron levels, OLs possess 
low anti-oxidants stores. Glutathione is one such anti-oxidant (McTigue and 
Tripathi 2008). Relative levels of antioxidants are important to maintain the 
balance of ROS without accumulating enough for a toxic effect. OLs low anti-
oxidant stores encourage rapid accumulation of ROS leading to accelerated 
cellular dysfunction. 
 Additionally, sphingolipids are a major component of myelin synthesis and 
play a damaging role in OL injury.  Sphingolipids contain ceramide cores that 
coalesce to form domains enriched in death receptors following injury. These 
death receptors include CD95, tumor necrosis factor receptor. In addition, the 
clustering of ceramide cores increases the sensitivity of OLs to death receptor 
signaling.  But this represents only one way in which ceramides contribute to OL 
injury. Ceramides can also be released intracellularly by enzymatic cleavage of 
membrane sphingolipids by sphingomyelinase (SMase).  This enzyme is 
normally inactive but is activated during CNS injury such as stroke (McTigue and 
Tripathi 2008). 
 Excitotoxicity, in which α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA)/Kainate receptors are over stimulated, also plays a role in ischemic 
OL death.  These receptors are stimulated as a result of glutamate, excessive 
stimulation of these receptors leads to elevated intracellular calcium. Elevated 
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intracellular calcium initiates cascades activating enzymes that degrade 
cytoskeleton proteins causing mitochondrial disruption leading to ROS production 
and cytochrome c release (McDonald, Althomsons et al. 1998).  Following an 
ischemic event, as stated above, a variety of cytokines and chemokines are 
released in the cellular space by a variety of cells. The cytokines interleukin 1 
beta (IL-1β), interleukin 2 (IL-2), interferon gamma (IFNγ) and tumor necrosis 
factor alpha (TNF-α) have all been shown to promote OL death directly or 
indirectly (McTigue and Tripathi 2008).  TNF-α and IFNγ signaling induce free 
radical production, which results in OLs cell death through oxidative stress as 
previously described.  TNF-α can also directly kill OLs by binding to the p55 TNF 
receptor which initiates DNA degradation and caspase independent apoptosis 
(McTigue and Tripathi 2008).  
With the mechanisms of white matter injury outlined above, it is important 
to tailor treatment specific to arrest these processes. Few in vitro treatments are 
efficacious in vivo, and a minute number of these successful treatments are 
assessed in clinical trials.  Below, treatments that have attained some promise in 
clinical trials will be discussed. 
 
Clinical Trials 
Treatment following an ischemic event does not aim to affect the 
immediate necrosis at the core of the infarct, but to prevent the expansion of the 
infarct core. Chemicals identified as potential stroke treatment are first examined 
in a laboratory setting beginning with in vitro stroke models. OGD is the most 
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commonly used in vitro stroke model, where cellular media is devoid of glucose 
and cells are exposed to an oxygen deficient environment for an extended period 
of time. If in vitro trials are successful, in vivo studies are performed using animal 
models, after which, viable therapeutics are scheduled for human clinical trials 
following FDA approval. Over 150 clinical trials investigating therapeutic agents 
targeting ischemic injury have been performed. These therapeutics are classified 
as nonpharmacologic, antithrombotic and neuroprotective agents, all but one 
resulted in failure (Kidwell, Liebeskind et al. 2001). A successful drug is defined 
as a drug approved by the FDA for treatment. So far the only such existing drug 
is the thrombolytic agent t-PA. With limited patients qualifying for treatment with t-
PA, basic scientists like clinicians have recognized the urgent need for new 
therapeutics to combat the ever-growing disease that is stroke. As a result over 
recent decades, not only have clinical trials increased, but the sample size 
attributed to each trial has also increased (Kidwell, Liebeskind et al. 2001).  
 
Neuroprotective Agents 
Neuroprotective trials examined drugs that promote membrane repair, free 
radical scavengers, antiedema, metabolic activations, modulators of calcium 
influx, and modulators of excitatory amino acids (Kidwell, Liebeskind et al. 2001). 
Many of these drugs were successful in vitro and showed promise in several in 
vivo animal models. Yet, the cellular protection and behavioral recovery observed 
in vivo has not transferred to human clinical trials. The lack of success in human 
trials could be attributed to the controlled environment in which animal studies 
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are performed.  In animals, specific stroke models elicit damage in specific areas 
of the brain. Additionally, the success of a drug is usually based on the action of 
treatment in specific brain areas; therefore an overall protective view including 
behavioral recovery is often overlooked.  Also the side effects of these drugs are 
usually not completely understood or evaluated (Richard Green, Odergren et al. 
2003). An example of such a neuroprotective agent is the use of nimodipine, a 
calcium antagonist. Nimodipine specifically blocks the influx of calcium following 
ischemia, thus arresting excessive cellular stimulation and cell death attributed to 
excitotoxicity (Steen, Gisvold et al. 1985). Nimodipine was successful in vitro and 
in animal models at reducing cell death and infarct volume respectively, but 
outcomes following ischemic injury were not improved in human trials (Steen, 
Gisvold et al. 1985; Horn, de Haan et al. 2001). In addition, nimodipine had an 
unintended side effect of lowering patient’s blood pressure and have been shown 
to worsen outcome following stroke. This side effect was identified only after the 
drug was evaluated in human trials (Ahmed, Nasman et al. 2000; Horn, de Haan 
et al. 2001; Richard Green, Odergren et al. 2003).  
 
Addressing Failure 
Nimodipine, like other neuroprotective and nonpharmacologic drugs, 
experienced success in animal studies but failure in human clinical trials.  The 
high failure rate of treatment for ischemic injury could be attributed to the 
monotherapy performed in clinical trials and the neuron-centric view.  Stroke is a 
multicellular disease meaning the entire CNS is affected following an ischemic 
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insult. Neurons and glial cells are adversely affected by ischemia, and responds 
in varying ways. Thus, diverse cellular populations are affected in an ischemic 
attack. Therefore different pathways and substrates contribute to the expansion 
of the infarct and the final outcome of the disease. A narrow focus on the gray 
matter to combat stroke pathology is naive. A broad view addressing both gray 
and white matter injury as a result of stroke is necessary to the development of 
new therapies. 
 
Antithrombotics 
Antithrombotic trials evaluate agents that increase blood flow, many of 
which are anticoagulants, fibrinolytic and antiplatelet compounds (Kidwell, 
Liebeskind et al. 2001). This area of study, thus far, has been the most 
successful, with the advent of t-PA, the only FDA approved treatment for 
ischemic injury. 
 
Tissue Plasminogen Activator 
t-PA was approved by the U.S Food and Drug Administration (FDA) in 
1996, and is still the only thrombolytic drug approved as treatment for an acute 
ischemic injury (Pan, Yu et al. 2008). t-PA is a serine protease enzyme that 
converts plasminogen to plasmin. Thrombotic clots are formed from fibrin and 
platelets by the body to inhibit blood loss, when these clots enter the circulatory 
system a thrombosis can result. t-PA works by cleaving plasminogen into 
plasmin, this cleavage activates plasmin which cleaves fibrin (Slaets, Dumont et 
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al. 2008). Thus, t-PA alike other thrombolytics works by dissolving clots, and 
therefore restores blood flow to ischemic areas. t-PA treatment within 3 hrs of 
stroke onset significantly reduces the effects of stroke (Hacke, Donnan et al. 
2004). This cited study also reported that benefits were also seen 4 hrs following 
stroke but negligible to no benefit was observed when given 6 hrs post stroke. 
Although beneficial, usage of this treatment increased the patient’s risk of a 
possible hemorrhagic event (Wardlaw, Warlow et al. 1997). The American Heart 
Association reports that only 3-5% of stroke patients employ this treatment, 
based on the time qualifications and the specificity of treatment only to ischemic 
injury. To qualify for t-PA treatment, a patient must first recognize the onset of the 
stroke, get to the hospital, have a CT scan performed to specify that the stroke is 
ischemic in nature and then receive treatment if all required criterions are met.  
The most stringent of these qualifications is the 3 hrs time window within which a 
patient must be evaluated and deemed eligible for treatment (Marler and 
Goldstein 2003). 
 
 Stem Cells 
Unlike previously discussed therapeutics, stem cell therapy first aimed to 
reduce the progression of stroke pathology by replacing neurons that have 
succumbed to the ischemic insult, and promote neurogenesis while extending the 
therapeutic time window for treating strokes. Unlike other cell replacement 
therapies, stem cell therapies initially aimed to generate and replace not just one 
specific cell type, but a large and varying population of cells. Thus far various 
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sources of stem cells have been tested to improve function following 
transplantation in animals subjected to stroke. Promising results were shown 
using a mouse neuroepithelial stem cell line, human NTera-3 cell line and human 
bone marrow/mesenchymal stem cells (Fujishima, Morotomi et al. 1979). 
Ischemia potentiates the secretion of neurotrophins and bioactive factors by 
mesenchymal stem cells (MSC) (Oh, Fujio et al. 1998). In animal studies, MSCs 
released bioactive factors in the ischemic boundary, reducing cellular apoptosis 
and induced cellular proliferation. Regeneration was observed, where newly 
formed cells expressed proteins identifiable to progenitor like neuron and 
astrocytes (Chen, Li et al. 2003). Although cellular recovery has been identified in 
vivo following stem cell treatment, evidence shows very little of the transplanted 
cells survive and migrate to the brain (Fujishima, Morotomi et al. 1979). Thus, it 
is now evident that stem cells do not replace dysfunctional cells in the ischemic 
boundary, but promote repair and neurogenesis. 
 Stem cell transplantation in human trials has shown some success; this 
included the use of human neuronal cells derived from a human teratocarcinoma 
line and fetal porcine cells.  The use of human teratocarcinoma showed 
improvements in patients tested on the European stroke scale, but in phase II 
trials, no improvement in outcome as tested by the European Scale after six 
months was reported although improvements were observed in the Action Arm 
Research Test and the Everyday Memory Test (Kondziolka, Wechsler et al. 
2000; Bang, Lee et al. 2005). A small study using fetal porcine cells was quickly 
terminated by the FDA after patients reported seizures and increased 
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neurological deficits weeks following transplantation (Marler and Goldstein 2003).  
The most promising of the stem cell study involved the use of autologous marrow 
stem cells (aMSCs). In experiments where aMSCs were administered 
intravenously 4-5 or 7-9 weeks following initial onset of stroke in humans, 
behavioral recovery was reported using two different exams. When compared 
against control, aMSC treated patients did not show a reduction in infarct volume 
but improvements were observed in both the Barthel index and modified Rankin 
scale (Bang, Lee et al. 2005). Both Barthel and modified Rankin scales are used 
to measure performance in basic activities of daily living, assessing the likelihood 
of being able to live at home independently following discharge from the hospice 
(Mahoney and Barthel 1965; van Swieten, Koudstaal et al. 1988). Distinctly, the 
modified Rankin scale is the most widely used clinical outcome measure for 
stroke. 
 
Human Umbilical Cord Blood Cell 
Origin 
 Human umbilical cord blood (HUCB) cells represent a cellular population 
taken from the placental umbilical cord of newborns. HUCB cells are easily 
retrieved and available unlike cells such as bone marrow that requires the use of 
painfully extraction techniques to access the cells. Furthermore, because of the 
characteristic immaturity of these cells, there is a lower incidence of graft versus 
host disease following cell transplantation compared to other cell based therapies 
(Lewis 2002). An additional benefit is the ability of HUCB cells to be 
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cryopreserved for later use, HUCB cells are effective three years following initial 
cryopreservation (Goodwin, Grunzinger et al. 2003). The mononuclear fractions 
of HUCB cells are typically used in therapy. This mononuclear fraction is 
composed of 77% lymphocytes, 23% monocytes and less than 1% CD34 
hematopoietic stem cells. The lymphocyte population contains approximately 
47% T lymphocytes. (Pranke, Failace et al. 2001).  
 
Cellular Protection 
The use of HUCB cells as a therapeutic treatment for stroke is a growing 
field of study, especially with the initial success of laboratory trials.  OLs co-
incubated with HUCB cells and exposed to OGD showed reduced activated 
caspase 3 immunoreactivity compared to untreated cells. In vivo, white matter 
bundles were preserved in animals treated with HUCB cells compared to MCAO 
groups not treated with HUCB cells (Hall, Guyer et al. 2009). Moreover, following 
MCAO, HUCB cells migrate to the site of injury to reduce infarct volume and 
improve behavioral recovery (Vendrame, Cassady et al. 2004; Newman, Willing 
et al. 2005; Hall, Guyer et al. 2009). The cytokine monocyte chemoattractant 
protein-1 (MCP-1) and macrophage inflammatory protein (MIP-1α) are 
responsible for these chemotactic effects promoting HUCB cell migration to the 
ischemic area ipsilateral to the infarct (Jiang, Newman et al. 2008). In the 
assessment of behavioral recovery, intravenous administration of HUCB cells 48 
hrs post MCAO significantly improved motor recovery as measured by the step 
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test and accelerated rotorod test one-month post stroke (Newcomb, Ajmo et al. 
2006).  
 
Anti-inflammatory Effects 
HUCB cells not only exert effects on the brain of an ischemic animal, but 
also modulate the immune system. Administration of HUCB cells reduced stroke 
induce pro inflammatory response by blocking the infiltration of peripheral 
immune cells such as leukocytes (Vendrame, Gemma et al. 2005). This 
reduction of microglia, macrophage and B cells recruitment to the infarct reduced 
the production of pro inflammatory mediators TNF-α, IL-1β and IL2 expression 
following stroke (Vendrame, Gemma et al. 2005). HUCB cell modulation of pro 
inflammatory effectors was also evident in the spleen. Post MCAO, About 1% of 
HUCB cells were found to migrate to the spleen following intravenous treatment 
(Chen, Sanberg et al. 2001). While, splenectomy before MCAO reduced the 
activation of both peripheral and resident CNS immune cells in the brain. The 
reduction of immune cell activation arrested stroke pathology, where reduction in 
flouro jade positive cells was evident in the infarct area (Ajmo, Vernon et al. 
2008). These experiments identified pleio-effects of HUCB cells; HUCB cells act 
at the point of the CNS but also modulate and suppress the immune response 
following an ischemic insult. 
 
 
 
26 
 
HUCB Cells Secrete Soluble Factors 
The reported protective effects following HUCB cell systemic injection post 
ischemia is attributed to the soluble factors secreted by these cells. Upon 
stimulation of HUCB cells by epidermal growth factor/ fibroblast growth factor-2 
(EGF)/ (FGF-2) or nerve growth factor/retinoic acid (NGF/RA), a vast number of 
soluble factors were secreted by HUCB cells. These factors included interleukins, 
growth factors, chemokines and metalloproteinase inhibitors. Many of the 
secreted factors are known for their pro-survival effects, including interleukin 6 
(IL-6), interleukin 8 (IL-8), and interleukin 10 (IL-10) (Neuhoff, Moers et al. 2007). 
Other factors are known for proliferative effects, such as vascular endothelial 
growth factor (VEGF), BDNF, platelet derived growth factor B (PDGF-B), 
leukemia inhibitory factor (LIF), and granulocyte colony stimulating factor (GCSF) 
among others and are known to activate survival pathways including 
phosphoinositide 3 kinase (PI3)/Akt (Kulik, Klippel et al. 1997; Jin, Mao et al. 
2000; Newman, Willing et al. 2006; Neuhoff, Moers et al. 2007). The 
aforementioned findings established HUCB cell treatment as a possible 
therapeutic candidate for delayed treatment of ischemic injury. Yet, there are 
strong concerns with regards to the use of HUCB cells; these concerns include 
the ethical use of cell based therapy. Therefore, it is of utmost importance to 
investigate and find soluble factors that emulate the effects of HUCB cells; LIF 
represents one such soluble factor. 
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Leukemia Inhibitory Factor 
Here we will discuss LIF, a pleiotropic cytokine secreted by HUCB cells. 
LIF is a 180 amino acid single 4-α-helix glycoprotein (Kurek 2000; Metcalf 2003) 
that works through the LIF cell surface receptor complex which includes the LIF 
receptor β (LIFR) and the gp130 receptor chain (Kurek 2000). Cells throughout 
the body express LIFR. While LIF specifically interacts with the LIFR, it binds at a 
low affinity, but this affinity is increased once LIF is bound to the gp130 (Gearing, 
VandenBos et al. 1992; Kurek 2000). Following LIF binding, LIFR and gp130 
dimerizes and activates the gp130 intracellular signaling cascade. The activation 
of gp130 results in the activation of the Janus kinase signal transducer and 
activator for transcription (JAK/STAT) pathway, Ras mitogen activated protein 
(MAPK) and the phosphatidylinositol 3 kinase (PI3/Akt) (Stahl, Boulton et al. 
1994; Stahl, Farruggella et al. 1995; Oh, Fujio et al. 1998). 
LIF mRNA has been found in both peripheral nervous system (PNS) and 
the CNS.  LIF is expressed by Schwann cells, neurons and glial cells including 
astrocytes and microglia (Lemke, Gadient et al. 1996; Banner, Moayeri et al. 
1997; Cheng and Patterson 1997; Dowsing, Morrison et al. 1999). Thus, LIF has 
pleiotropic effects ranging from the induction of cellular proliferation to the 
maintenance of cultured murine embryonic stem cell totipotentiality (Williams, 
Hilton et al. 1988). Specifically in the CNS, LIF was shown to have both 
proliferative and protective effects on glial cells.  LIF stimulated glial fibrillary 
acidic protein (GFAP) expression in astrocytic progenitors, whereas in OL 
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progenitor cultures, LIF enhanced myelin basic protein expression, survival, and 
maturation (Mayer, Bhakoo et al. 1994; Nakagaito, Yoshida et al. 1995) 
In disease states, LIF have been shown to attenuate the progression of 
pathological disorders.  LIF enhanced neuronal survival when placed at the site 
of axotomized sensory and motor neurons (Oh, Fujio et al. 1998). LIF treatment 
rescued OLs and reduced demyelination following spinal cord injury through 
STAT 3 and PI3/Akt survival pathway activation (Metcalf and Gearing 1989; 
Azari, Profyris et al. 2006). Furthermore, LIF administration attenuated 
demyelination and OL loss in experimental autoimmune encephalomyelitis 
(EAE), the mouse model of multiple sclerosis, where the addition of anti-LIF 
antibody exacerbated EAE disease pathology (Metcalf and Gearing 1989; 
Metcalf and Gearing 1989; Butzkueven, Zhang et al. 2002). LIF rescued mature 
cultured OLs from interferon γ and tumor necrosis factor α induced cell death, 
through the activation of both JAK/STAT and PI3/Akt pathway (Slaets, Dumont et 
al. 2008). 
The release of pro-inflammatory cytokines following ischemic injury leads 
to the expansion of the umbra, via activation of cellular cascades resulting in 
macrophage activation and cell death. Therefore the discovery that LIF inhibits 
the production of pro-inflammatory mediators including TNFα and ROS by 
macrophages is relevant to the development of therapies against the progression 
of stroke pathology (Hendriks, Slaets et al. 2008). Furthermore, endogenous LIF 
peaked between 90 min and 24 hrs following MCAO in the peri ischemia area in 
rats, a result that maybe explained as an intrinsic attempt by the brain to combat 
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the ischemic insult (Suzuki, Tanaka et al. 2000; Slevin, Krupinski et al. 2008). LIF 
is selectively blood brain barrier permeable, thus, under pathological conditions 
such as spinal cord injury, there is an up regulation of LIF transport across the 
blood brain barrier and into the brain (Mayer, Bhakoo et al. 1994). This was 
shown when animals were subjected to lipopolysaccharide (LPS) treatment and 
an up regulation of LIF transport system at the blood brain barrier was identified 
(Pan, Yu et al. 2008). In a subsequent study the site directed treatment of LIF to 
the cerebral cortex adjacent to the necrotic area following MCAO significantly 
reduced infarct volume; this was more so a direct result of JAK stat activation 
and to a lesser extent PI3/Akt activation (Suzuki, Yamashita et al. 2005).  
The promising effects of LIF obtained both in cell culture and animal 
model of different disease pathologies led to the development of a 
pharmacological recombinant LIF. The pharmacological form of LIF was 
developed to treat chemotherapy induced neuropathy. Phase 1 trials began in 
1997 and a phase two trial is currently underway (Kurek 2000). Because of its 
pleiotropic activity, caution is placed on the usage of LIF as a treatment. In 
experiments where LIF was over expressed, animals showed weight loss, 
overgrowth of medullary bone tissue in long bones, calcification of the liver heart 
and skeletal muscle, thymus atrophy and the depletion of spermatogonia from 
males seminiferous tubules of the testes (Metcalf and Gearing 1989; Metcalf and 
Gearing 1989). On the other hand, the deletion of LIF results in an array of 
abnormalities including abnormal development of the hippocampus, olfactory 
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receptor neurons and the inability of females to become pregnant (Escary, 
Perreau et al. 1993; Bugga, Gadient et al. 1998; Moon, Yoo et al. 2002). 
 
AKT Survival Pathway 
HUCB cells secrete growth factors, chemokines, matrix metalloproteinase 
inhibitors and interleukins (Newman, Willing et al. 2006; Neuhoff, Moers et al. 
2007).  Of these soluble factors, many including IGF1, VEGF and LIF are known 
to promote cell survival via Akt phosphorylation/activation (Kulik, Klippel et al. 
1997; Jin, Mao et al. 2000; Neuhoff, Moers et al. 2007). These results implicate 
the serine/threonine kinase Akt as a target of HUCB cell therapy. Upon 
phosphorylation, Akt is an integral part of the cellular machinery involved in 
survival. Phosphorylated Akt promotes survival by inhibiting the activation of 
apoptotic substrates while stabilizing substrates involved in survival pathways 
(Kennedy, Wagner et al. 1997).  Activated Akt phosphorylates Bcl-2-associated 
death promoter (BAD), pro caspase 9, Forkhead, and nuclear factor kappa B 
(NFκb) (Datta, Brunet et al. 1999; Hanada, Feng et al. 2004; Zhao, Sapolsky et 
al. 2006).   
When unphosphorylated, substrates such as BAD targets Bcl-2 in the 
mitochondria, causing cytochrome c release leading to caspase 9 cleavage 
(Datta, Brunet et al. 1999; Zhao, Sapolsky et al. 2006). Caspase 9 is an initiator 
caspase which proteolytically cleaves execution pro caspase 3 and caspase 7 
(Cryns and Yuan 1998; Datta, Brunet et al. 1999). Caspase 3 plays a principal 
role in the early apoptotic cascade leading to the cleavage of downstream 
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substrates such as poly (ADP-ribose) polymerase (PARP) (Nicholson, Ali et al. 
1995; Le Rhun, Kirkland et al. 1998). PARP cleavage and NAD+ depletion as a 
result of oxidative stress and DNA damage, leads to apoptosis inducing factor 
(AIF) translocation to the cytoplasm from the mitochondria. AIF then migrates to 
the nucleus where it induces chromatin lysis and cell death (Yu, Andrabi et al. 
2006). Thus, phosphorylated Akt promotes survival by blocking the 
aforementioned cell death cascades and stabilizing survival-associated 
complexes through kinase activity (Kennedy, Wagner et al. 1997; Zhao, Sapolsky 
et al. 2006). 
 
Antioxidant Expression in the Brain 
Delaying apoptotic cascades are necessary for inhibiting the progression 
of stroke pathology, but combating the production of ROS and RNS also plays a 
vital role. OL susceptibility to oxidative stress highlights an area that could be 
exploited and prove beneficial to cellular homeostasis in the infarct boundary. 
Thus, the identification and regulation of specific antioxidants in the cerebral 
white matter post stroke could be a therapy defining focus. Two such 
antioxidants are Mt3 and Prdx4. HUCB cells modulate both antioxidants 
expression in the cerebral white matter OL (Rowe, Leonardo et al. 2010). 
 
MT3 
Metallothionein 3 (Mt3) is a small 68 amino acid protein that is extensively 
involved in the storage and transport of metals such as copper. Mt3 is primarily 
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expressed in the CNS and maintains cellular homeostasis via detoxification of 
heavy metals such as mercury, and has also been shown to have antioxidant 
functions against ROS and RNS (Hidalgo, Aschner et al. 2001). In disease 
conditions, Mt3 is increased following stab wound in the cortex three days post 
injury and expression is returned to basal levels three weeks following 
experiment (Hozumi, Inuzuka et al. 1995; Hozumi, Inuzuka et al. 1996; Acarin, 
Gonzalez et al. 1999). Using the stab wound model, Mt3 was shown to promoted 
tissue repair following injury (Hozumi, Uchida et al. 2006). In disease states such 
as Alzheimer’s (AD), Mt3 protein expression is significantly decreased. MT3 has 
been postulated to play a role in the accumulation of amyloid beta plaques due to 
the deregulation of zinc as a result of decreased Mt3 expression. Specifically, 
zinc is an active component of plaque formation, thus the accumulation of zinc in 
the absence of Mt3 is believed to exacerbate AD pathology (Uchida, Takio et al. 
1991). A reduction in Mt3 was also observed post stroke. Following MCAO, Mt3 
is gradual reduced until day 7, after which Mt3 gradually increased to basal levels 
by day 28 (Inuzuka, Hozumi et al. 1996). Therefore the maintenance or 
upregulation of Mt3 in affected tissue could play an active role in the attenuation 
of disease progression. 
HUCB cell treatment 48 hrs post MCAO increased Mt3 protein expression 
and reduced apoptosis in the cerebral white matter (Rowe, Leonardo et al. 2010). 
This protection points to Mt3 dual roles, activation of Akt survival pathway and 
antioxidant function. Mt3 binds to TrkA receptor tyrosine kinases to activate the 
PI3K/Akt signaling pathway reducing H2O2 and doxorubicin (Dox) induced 
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caspase activation and cell death (Kim, Hwang et al. 2009). An additional study 
showed that Mt3 protects against oxidative stress via Akt activation and 
upregulating heme oxygenase 1, resulting in decreased ROS generation, 
caspase 3 activation and neuronal cell death (Hwang, Kim et al. 2008). In these 
experiments assessing Mt3 induced Akt activation, the use of Akt inhibitors 
completely abolished the protection conferred by Mt3 treatment (Hwang, Kim et 
al. 2008; Kim, Hwang et al. 2009). Mt3 attenuated glutamate neurotoxicity by 
quenching nitric oxide (NO) elicited by glutamate (Montoliu, Monfort et al. 2000). 
Furthermore, Mt3 knockout animals showed increased susceptibility to kainic 
acid whereas over expression of Mt3 reduced this susceptibility to kainic acid and 
increased resistance to kainic acid (Erickson, Hollopeter et al. 1997). Mt3 has 
also proven to rescue neurons by activating NFκb via the phosphorylation of IκBα 
leading to IκBα degradation (Kim, Hwang et al. 2009). Thus, the regulation of Mt3 
contributes to cellular detoxification and the activation of survival pathways 
leading to cell survival in various disease states. 
 
Prdx4 
Peroxiredoxin (Prdx)4 is an additional antioxidant upregulated following 
HUCB cell treatment in the external capsule of rats subjected to MCAO (Rowe, 
Leonardo et al. 2010). Prdxs are biological antioxidants. This family of antioxidant 
enzymes function through peroxidase activity reducing hydrogen peroxide, 
peroxynitrite and other organic hydroperoxides (Hofmann, Hecht et al. 2002). Six 
different Prdx have been classified to date; all have a common catalytic 
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mechanism of being unfolded, fully folded or a conserved conformation. Prdx4 
mechanism involves the oxidation of a cysteine residue by the peroxide substrate 
causing a conformational change allowing the formation of a disulfide with the 
cysteine residue (Hall, Karplus et al. 2009). This action catalytically convert 
substrates such as hydrogen peroxide to water. This activity detoxifies the 
cellular environment, and the active enzyme is regenerated following reduction of 
the disulfides (Zito, Melo et al. ; Hall, Karplus et al. 2009). This cycle is referred to 
as the thiol/sulfenic acid redox cycle (Tanaka, Hijioka et al. 2004). There have 
been at least six identified peroxiredoxins but only Prdx4 has been shown to 
regulate thromboxane A2 receptor that regulates oxidative stress (Giguere, 
Turcotte et al. 2007). Thromboxane A2 receptor is known to be upregulated by 
oxidative stress and has been shown to contribute to cellular injury upon 
activation during oxidative stress (Valentin, Field et al. 2004). Prdx4 also 
undergoes structural changes in response to oxidation; this activity is thought to 
prevent free radical induced aggregation of proteins (Jang, Lee et al. 2004; Kang, 
Rhee et al. 2005). Oxidative stress leads to protein unfolding in the cytoplasm; 
the chaperone activity of Prdx4 prevents the aggregation of these proteins, 
where protein aggregation is known to facilitate disease pathology. In mouse, the 
over expression of Prdx4 prevented p53 or epidermal growth factor induced 
mitochondrial ROS production (Wong, Chun et al. 2000). The inhibition of ROS 
production by Prdx4 over expression highlights the importance of this protein in 
the prevention of ROS induced cellular dysfunction. The literature has shown the 
importance of antioxidants in the brain following ischemic injury.  Among these, 
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Prdx4 could play a vital role in the preservation of cells and reduction in stroke 
induced morbidity and potential mortality. 
 
HUCB Cells Therapy to Protect the White Matter OL 
Presently, our laboratory is investigating HUCB cells as a potential 
treatment for stroke. In a report published by Hall. et al, our laboratory has 
demonstrated the protective nature of HUCB cell treatment on OLs subjected to 
OGD. Yet, the mechanisms by which HUCB cell rescue OLs remains to be 
established. Here we will examine how these cells protect OLs and evaluate the 
mechanism of action. These experiments are discussed herein. 
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Abstract  
Oligodendrocytes (OLs), the predominant cell type found in cerebral white 
matter, are essential for structural integrity and proper neural signaling.  Very 
little is known concerning stroke-induced OL dysfunction.  Our laboratory has 
shown that infusion of human umbilical cord blood (HUCB) cells protects striatal 
white matter tracts in vivo and directly protects mature primary OL cultures from 
oxygen glucose deprivation (OGD).  Microarray studies of RNA prepared from 
OL cultures subjected to OGD and treated with HUCB cells showed an increase 
in the expression of 33 genes associated with OL proliferation, survival, and 
repair functions, such as myelination. The microarray results were verified using 
quantitative RT-PCR for the following eight genes:  U2AF homology motif kinase 
1 (Uhmk1), insulin induce gene 1 (Insig1), metallothionein ( Mt3), tetraspanin 2 
(Tspan2), peroxiredoxin 4 (Prdx4), stathmin-like 2 (Stmn2), myelin 
oligodendrocyte glycoprotein (MOG), and versican (Vcan).  
Immunohistochemistry showed that MOG, Prdx4, Uhmk1, Insig1 and Mt3 protein 
expression were upregluated in the ipsilateral white matter tracts of rats infused 
with HUCB cells 48 hrs after middle cerebral artery occlusion (MCAO).  
Furthermore, promoter region analysis of these genes revealed common 
transcription factor binding sites, providing insight into the shared signal 
transduction pathways activated by HUCB cells to enhance transcription of these 
genes.  These results show expression of genes induced by HUCB cell therapy 
that could confer oligoprotection from ischemia. 
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Introduction 
Stroke is the third leading cause of death in the United States, with 
ischemic strokes accounting for 83% of all strokes (Lloyd-Jones, Adams et al. 
2009).  Ischemic brain injury affects both white and gray matter.  Although white 
matter integrity is essential to proper neuronal communication, much of current 
research is focused exclusively on neuronal damage.   Accounting for 50% of 
brain volume in humans, white matter and the oligodendroglia that myelinate 
these areas play an integral role in proper brain function (Miller, Alston et al. 
1980).  The myelin produced by OLs not only supports axonal structural integrity, 
but is also essential in impulse integration (Baumann and Pham-Dinh 2001).  
Thus, white matter protection is necessary to dampen stroke-induced injury and 
its progressive pathology (Arai and Lo 2009). 
In addition to myelination, OLs support the survival and function of 
neurons by regulating axonal size and ion channel clustering.  OLs also secrete 
trophic factors such as BDNF, NGF, GDNF and IGF-1, all of which aid in cell 
survival and maintenance (Baron-Van Evercooren, Olichon-Berthe et al. 1991; 
Kaplan, Meyer-Franke et al. 1997; Wilkins, Majed et al. 2003; Noble 2005 ).  Of 
the different types of glia, OLs are the most vulnerable to hypoxic and 
hypoglycemic conditions, yet the precise mechanisms underlying this 
susceptibility are unknown (Lyons and Kettenmann 1998). 
HUCB cell therapy is an emerging treatment for CNS injury.  The 
immaturity of HUCB cells contribute to the characteristic low immunogenicity 
(Sanberg, Willing et al. 2005).  HUCB cells are less immunogenic than other 
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stem cell treatments such as bone marrow and thus elicits lower 
immunomodulatory effects (Sanberg, Willing et al. 2005; Wang, Yang et al. 
2009).  In vivo, HUCB cells migrate to the site of injury, resulting in reduced 
infarct volumes, neuroprotection and preservation of white matter following 
MCAO (Vendrame, Cassady et al. 2004; Newman, Willing et al. 2005; Newcomb, 
Ajmo et al. 2006; Hall, Guyer et al. 2009).  Furthermore, multipotential stem cells 
derived from HUCB cells secrete neuroprotective, angiogenic and anti-
inflammatory factors resulting in a functional recovery in spinal cord injuries 
(Chua, Bielecki et al. 2010). In vitro experiments showed that in addition to 
growth factors, HUCB cells secrete cytokines, matrix metalloproteinase inhibitors, 
and interleukins (Neuhoff, Moers et al. 2007).  Additionally, HUCB cells co-
incubated with OLs reduced OGD-induced apoptosis by decreasing activated 
caspase 3 (Hall, Guyer et al. 2009).  Despite these potent protective actions and 
known soluble factors, the precise pathways involved in HUCB cell-mediated OL 
survival have yet to be elucidated. 
The present study examined changes in the gene expression profiles of 
primary OL cultures subjected to OGD to elucidate the protective pathways 
induced by co-incubation with HUCB cells.  Microarray results revealed that 33 
genes were significantly increased in OLs co-incubated with HUCB cells and 
exposed to OGD.  The upregulation of the following genes were confirmed by 
qRT-PCR:  Uhmk1, Insig1, Mt3, Tspan2, Prdx4, Stmn2, MOG, and Vcan gene 
expression.  Immunohistochemical analysis of tissues from rats treated with 
HUCB cells 48 hrs after MCAO demonstrated increased protein expression of 
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Uhmk1, Insig1, Mt3, Tspan2, Prdx4, and MOG.  Future experiments identifying 
the mechanisms by which HUCB cells enhance the expression of protective 
genes in OLs will provide insight into novel therapies to combat stroke-induced 
white matter injury.   
 
Results 
Characterization of Mature OLs 
Antibodies specific for NG2, O4 and MBP were utilized in double 
immunofluorescence staining to determine OL developmental stage in vitro (Fig. 
1).  NG2 is a reliable marker throughout the course of OL differentiation in vitro, 
while O4 is expressed by immature OLs.  Furthermore, the expression of 
myelinating proteins such as MBP denotes the mature OL phenotype.  Six hours 
following PDGF-AA withdrawal, NG2 and O4 colocalized in OLs with immature 
morphology as indicated by the relatively low number of processes (Fig. 1A). 
MBP was not detected at this time point. By 36 hrs following PDGF-AA removal, 
colocalization of NG2 and MBP (Fig. 1B) was evident in OL cultures. The 
prominent upregulation of MBP and the increased number of OL processes at 36 
hrs signifies the progression of OLs to the mature phenotype that is present in 
the adult rat brain.  
 
Secreted Factors from HUCB Cells Protect Mature OLs 
Cell death is associated with LDH release through the plasma membrane, 
and therefore media levels of LDH were measured to assess OL injury after OGD 
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(Fig. 2). Media from OL cultures exposed to OGD showed significantly increased 
LDH levels compared to that from normoxic controls (p < 0.01, n = 7). 
Furthermore, HUCB cell treatment demonstrated oligoprotection. Media from OL 
cultures co-incubated with HUCB cells and subjected to OGD showed 
significantly reduced LDH levels relative to cultures subjected to OGD alone (p < 
0.05, n = 7). Importantly, the fact that HUCB cells were separated from OLs by 
transwell inserts indicates that HUCB cells exerted these protective effects 
through the release of soluble factors rather than through direct cellular contact.  
 
HUCB Cell Protection is Associated with Changes in Gene 
Expression 
Affymetrix microarray was utilized to detect changes in gene expression 
elicited by HUCB cells that were co-incubated with OLs during OGD.  Of the 33 
genes detected, eight genes encoding proteins associated with OL proliferation, 
survival, and repair functions were selected for further investigation (Table 1, 
bold font):  Uhmk1, Insig1, Mt3, Tspan2, Prdx4, Stmn2, MOG, and Vcan.  Genes 
listed in Table 1 exclude expressed sequence tags and exhibit fold changes ≥1.5 
compared to OGD controls. 
 
qRT-PCR Verification of Microarray Results 
qRT-PCR was performed to validate gene expression data obtained by 
microarray analysis.  RNA was collected from supplementary experiments in 
which HUCB cell co-incubation rescued OLs subjected to 24 hrs OGD.  qRT-
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PCR confirmed results obtained by microarray (Fig. 3). HUCB cell treatment 
increased expression of all selected genes (Fig. 3A-H) when compared to OLs 
subjected to OGD without HUCB cell treatment (p< 0.05).  In addition, OGD 
reduced the expression of Mt3, Tspan2, and Stmn2 (Fig. 3D-F) relative to 
normoxic controls (p< 0.05).  HUCB cells also increased the gene expression of 
MOG, Insig1, Prdx4, Mt3, Stmn2, and Vcan (Fig. 3A-D, F, H) under normoxic 
conditions when compared to normoxia only controls.  Furthermore, a trend was 
also observed whereby HUCB cell treatment during OGD either maintained or 
increased mRNA expression levels relative to those of normoxic controls for all 
genes except Stmn2. 
 
HUCB Cells Reduce Infarct Volume 
 Systemic administration of HUCB cells 48hrs post-stroke significantly 
reduced infarct volume. The fluorochrome Fluoro-Jade was used to detect 
degenerating neurons in coronal brain section taken from rats subjected to 
MCAO and experimental groups that received HUCB cell treatment. HUCB cell 
treatment 48 hrs post-stroke significantly reduced infarct volume as compared to 
MCAO only groups at 72 and 96hrs post stroke (*p<0.05, #p<0.01 respectively 
(Fig.4).  Sham operated groups were not significantly different from HUCB cell 
treated groups (p>0.05). Furthermore, brain tissues of HUCB cell treatment 
groups remained intact whereas tissue sections of MCAO only groups were 
fragile with signs of degradation. 
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HUCB Cells Protect OLs In Vivo 
HUCB cells were administered 48 hrs post-stroke and sections were 
probed with anti-O4, a highly specific marker of OL cell bodies and processes 
(Schachner, Kim et al. 1981; Sommer and Schachner 1982), to determine 
whether this therapy provided oligoprotection (Fig. 5). O4 immunoreactivity was 
ubiquitous throughout the ipsilateral external capsule in sections from animals 
treated with HUCB cells (Fig. 5A) and localized to cell bodies throughout the 
region (Fig. 5D). Sections from vehicle-treated and sham-operated rats also 
showed O4 immunoreactive cells, though they were sparsely distributed when 
compared to the ipsilateral hemisphere of HUCB cell treated rats (Fig. 5B,E). 
Quantification of the percent area occupied by O4 immunoreactivity (Fig. 5C) 
showed that O4 was significantly increased in the ipsilateral hemisphere of 
animals that received HUCB cells relative to vehicle-treated and sham-operated 
controls (p<0.01).  
 
HUCB Cells Induce Protein Expression 
To expand on the microarray data from OL cultures, immuno-
histochemistry was performed to determine whether increased OL gene 
expression in vitro was consistent with increased gene product expression in vivo 
in the white matter rich region of the external capsule (Fig. 6 shows selected 
region). Experiments included sections from rats that were administered either 
vehicle or HUCB cells 48 hrs post-MCAO and rats that were subjected to sham-
MCAO and received vehicle injections. Immunostaining was performed for the 
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following proteins:  Uhmk1 (Fig. 6), Prdx4, Mt3, MOG, Insig1, Tspan2, and Vcan 
(Fig. 7). In general, sham-operated controls (Fig. 6E,F) showed nearly identical 
staining patterns as vehicle-treated controls (Fig. 6C,D) with no apparent 
differences in the expression of any proteins examined. While MOG (Fig. 7E,F) 
and Vcan (Fig. 7K,L) immunoreactivity was present throughout the extracellular 
space, immunoreactivity for all other proteins was restricted to cell bodies. 
Quantification was performed by calculating the mean percent area for each 
treatment group (Fig. 8). The contralateral hemisphere was utilized as an internal 
control to adjust for ipsilateral brain swelling caused by edema. There was no 
significant difference in the expression of any proteins when comparing sham-
operated and vehicle-treated controls. Uhmk1, Prdx4, Mt3, MOG and Insig1 were 
upregulated in rats treated with HUCB cells compared to sham-operated and 
vehicle-treated controls (*p < 0.05, #p< 0.01), while Tspan2 and Vcan expression 
were unchanged.   
 
Protein Expression and Localization 
Double-label immunofluorescent staining was performed on sections from 
animals subjected to MCAO to characterize the cellular expression profile of the 
identified proteins. RIP, CD11b and GFAP were used for labeling of OL, 
microglia and astrocytes, respectively, in conjunction with antibodies raised 
against Prdx4, Mt3, Uhmk1, and Insig1.  RIP colocalized with Prdx4, Mt3, Insig1, 
and Uhmk1. RIP staining was localized in OL membranes as does Insig1, 
whereas, Prdx4 Mt3, and Uhmk1 labeled cytoplasmically (Fig 9).  Although Prdx4 
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did not colocalize with CD11b (Fig. 10A-C), Prdx4-positive cell bodies colocalized 
with GFAP-positive cells that exhibited the classic hypertrophic, stellate 
morphology indicative of reactive astrocytes (Fig. 10D-F). Neither CD11b nor 
GFAP colocalized with Mt3, Uhmk1 or Insig1 (Fig. 11).   
 
Comparison of Gene Promoter 
The promoter regions of genes upregulated in OLs co-cultured with HUCB 
cells during OGD were explored by Genomatix software.  Common transcription 
factor binding sites were identified and included:  EVI1, MZF1, GATA1, NK6.1, 
PAX6, Sox-5, and SRF (Table. 2).  These results suggest that the genes 
identified by microarray are being transcriptionally elevated by similar signaling 
pathways activated by the soluble factors secreted from the HUCB cells. 
 
Discussion 
The present study employed both in vitro and in vivo approaches to test 
the efficacy of HUCB cells in reducing OL cell death and white matter injury, 
respectively. LDH levels in media from OL cultures co-incubated with HUCB cells 
during OGD were reduced relative to OL-only cultures.  As previously reported by 
Newcomb et al 2006. and Vendrame et al 2004,. here we report that HUCB cell 
treatment 48 hrs post-stroke reduced infarct volume.  Separate experiments 
showed that O4 immunoreactivity increased in the ipsilateral external capsule of 
rats treated with HUCB cells 48 hrs after MCAO. Upregulation of this OL marker 
was consistent with the previous report by Hall et al 2009. showing that HUCB 
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cell treatment increased MBP immunoreactivity. Thus, HUCB cells not only 
protect OLs from OGD-induced injury in vitro, but also upregulate the expression 
of white matter-associated proteins after ischemia in vivo. 
Based upon these data, further experiments were conducted to identify 
the mechanisms by which HUBC cells confer protection. Gene expression 
analysis of OL cultures subjected to OGD and treated with HUCB cells revealed 
increased mRNA content of Uhmk1, MOG, Insig1, Mt3, Tspan2, Prdx4, Stmn2, 
and Vcan.  Additionally, the levels of Mt3, Prdx4, MOG, Insig1 and Uhmk1 gene 
products were elevated in the ipsilateral external capsule of animals administered 
HUCB cells 48 hrs after MCAO. Previous reports have demonstrated expression 
of these proteins in OLs (Miyazaki, Asanuma et al. 2002; Jin, Lee et al. 2005; 
Kursula 2008; Sim, Lang et al. 2008).  Here, double-label immunohistochemistry 
showed that the OL specific antibody RIP colocalizes with Prdx4, Mt3, Insig1 and 
Uhmk1 whereas only Prdx4 colocalized with astrocytes, while none of the 
proteins colocalized with microglia/macrophages.  Both the increased gene 
expression in culture and the lack of colocalization with other glial cell types in 
vivo demonstrates that HUCB cells injected into MCAO rats caused OLs seated 
within the cerebral white matter to upregulate these proteins.  
To our knowledge, this is the first study linking upregulated expression of 
genes and gene products with the protective effects of HUCB cell therapy within 
the context of OL susceptibility and white matter injury resulting from ischemia. 
HUCB cell-induced upregulations in Prdx4 and Mt3 observed here are consistent 
with the notion that HUCB cells provide protection to white matter by inducing 
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OLs to express proteins that combat oxidative damage. Oxidative stress is a 
major cause of OL cell death resulting from OGD (Dewar, Underhill et al. 2003). 
The Prdx family of anti-oxidants exerts protective effects through peroxidase 
activity, detoxifying a range of free radical-forming organic hydroperoxides 
(Hofmann, Hecht et al. 2002).  In particular, Prdx4 regulates the thromboxane A2 
receptor, a receptor which is upregulated by oxidative stress and contribute to 
oxidative injury upon activation (Valentin, Field et al. 2004).  Previous work 
showed that thromboxane A2 expression was inhibited during oxidative stress by 
Prdx4 over-expression (Giguere, Turcotte et al. 2007).  In addition, the Prdx 
family has also been shown to undergo structural changes to engage in 
chaperone activity in response to excessive oxidation (Jang, Lee et al. 2004). 
This chaperone activity may be a necessary function in the recovery of 
oxidatively damaged cells by preventing free radical-induced aggregation of 
cytosolic proteins (Jang, Lee et al. 2004; Kang, Rhee et al. 2005).  
Similarly, the antioxidant Mt3 exerts its effects through metal detoxification 
and free radical scavenging activity (Hozumi, Inuzuka et al. 1998; Uchida, Gomi 
et al. 2002; Hwang, Kim et al. 2008).  These mechanisms are of particular 
relevance to the present study since iron is not only a critical co-factor in myelin 
production, but is also highly reactive and can contribute to free radical formation 
and lipid peroxidation (Braughler, Duncan et al. 1986; Connor and Menzies 
1996).  Additionally, OLs possess low concentrations of the antioxidant 
glutathione, and oxidative stress leads to increased iron-mediated production of 
ROS (Juurlink 1997; Juurlink, Thorburne et al. 1998). Thus, the protective effects 
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of HUCB cells likely result, at least in part, from the secretion of a factor or 
factors that ultimately increase the expression of Mt3. 
HUCB cell therapy has previously been shown to target the Akt signaling 
pathway, as Akt inhibition diminishes the protective effects of HUCB cells 
(Dasari, Veeravalli et al. 2008). Importantly, growth factors such as VEGF and 
interleukins such as IL-6, which are secreted by HUCB cells, have also been 
shown to activate Akt, leading to cell migration, angiogenesis, and cell survival 
(Morales-Ruiz, Fulton et al. 2000; Six, Kureishi et al. 2002; Neuhoff, Moers et al. 
2007; Wegiel, Bjartell et al. 2008). The present study identified several common 
transcription factor binding sites within the promoter regions of the genes 
identified by microarray.  In particular, EVI1, MZF1, and GATA1 transcription 
occur downstream of PI3k/Akt activation (Yu, Chiang et al. 2005; Liu, Chen et al. 
2006; Moeenrezakhanlou, Shephard et al. 2008), providing additional evidence 
that Akt is an important upstream activator responsible for the oligoprotective, 
anti-oxidant effects of HUCB cells.  Taken together, these data show that HUCB 
cells release factors that transduce signaling converging on Akt, thereby 
increasing the transcription of oligoprotective genes.  
In addition to combating oxidative stress, data here show that HUCB cell 
treatment alters the expression of proteins involved in microtubule regulation. 
The concerted actions of MOG and Stmn2 inhibit microtubule polymerization, 
and Stmn2 was previously found to increase neurite outgrowth via this 
mechanism (Riederer, Pellier et al. 1997; Johns and Bernard 1999; Chiellini, 
Grenningloh et al. 2008). Thus, these data provide evidence that upregulated 
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expression of MOG and/or Stmn2 acts to inhibit microtubule polymerization in 
OLs, thereby increasing proliferation and/or migration and enhancing white 
matter repair.  
Indeed, previous findings showed that mature OLs retain the ability to 
proliferate following injury (Wood and Bunge 1991). In addition to regulating 
microtubule dynamics through the phosphorylation of Stmn2 (Belmont and 
Mitchison 1996), Uhmk1 induces proliferation and cell cycle progression through 
the phosphorylation of p27kip1(Nakamura, Okinaka et al. 2008). Interestingly, 
Uhmk1 was also upregulated after MCAO in HUCB cell-treated rats.  Here, the 
observed elevations in both Uhmk1 and O4 expression support the notion that 
HUCB cell therapy protects white matter injury by inducing OL proliferation via 
this pathway. 
HUCB cell therapy may also alleviate white matter injury through 
replacement of important somatic and/or axonal membrane lipids that are 
degraded in response to H-I injury. The OL axon sheath is rich in 
glycosphingolipids and cholesterol (Simons and Trajkovic 2006). Insig1 is 
degraded when cholesterol is depleted within a cell (Gong, Lee et al. 2006), and  
hypoxia increases Insig1 expression through a mechanism mediated by hypoxia 
inducible factor 1α (Nguyen, McDonald et al. 2007).  Thus, the elevations in 
Insig1 likely reflect HUCB cell induction of cholesterol biosynthesis aimed at 
remyelination or restoration of the cell membrane.  
Although a role for HUCB cells in remyelination is also supported here by 
increased O4 expression, future experiments are necessary to determine 
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precisely which proteins are associated with restoration of the myelin sheath or 
cell membrane viability in general. For example, Tspan2 is integrated into the 
myelin sheath membrane following active myelination, while Vcan is involved in 
OL migration, proliferation, and structural integrity (Birling, Tait et al. 1999; 
Sheng, Wang et al. 2005). Tspan2 and Vcan mRNAs were upregulated in OL 
cultures subjected to OGD and treated with HUCB cells, yet there was no 
significant difference in protein expression in vivo after MCAO.  These data 
suggest that although Vcan and Tspan may be capable of enhancing axonal 
and/or plasma membrane viability in culture, the complex microenvironment 
present in the stroked brain determines which genes are translated and trafficked 
accordingly. Likewise, these differences in in vitro transcription and in vivo 
translation highlight the importance of combining multiple approaches to 
elucidate the protective pathways elicited by HUCB cells. Future studies 
investigating these pathways will provide insight into the precise factors secreted 
by HUCB cells that protect OLs and cerebral white matter following ischemia.  
 
Experimental Procedure 
Animal Care 
All animal procedures were conducted in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals with a protocol approved by the 
Institutional Animal Care and Use Committee at the University of South Florida.  
Experiments were designed to minimize the number of animals required.  
Sprague-Dawley rats were purchased from Harlan Labs (Indianapolis, IN), 
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maintained on a 12 hr light/dark cycle (7 am – 7 pm) in a climate-controlled room, 
and allowed access to food and water ad libitum.  Neonatal rats birthed from 
untimed-pregnant dams were used for in vitro experiments and 300-350 g male 
rats were used for in vivo experiments. Measures taken to minimize pain and 
discomfort are described in the subsequent methodology. 
 
Mixed Glial Culture Preparation 
Postnatal day 3 rat pups were decapitated, brains removed, and meninges 
dissected away.  Rat cortices were dissociated in a solution of 0.25% trypsin/2.21 
mM EDTA, triturated, and pelleted.  The pellet was re-suspended in DMEM 
(Mediatech, Manassas, VA) supplemented with 2.5% fetal bovine serum, 10% 
horse serum, and 1% antibiotic/antimycotic (DMEM+).  Trypan Blue exclusion 
was used to assess cell viability.  Cells were seeded (1.5 x 107) into poly-L-
lysine-treated 75 cm2 tissue culture flasks.  Media was changed with fresh 
DMEM+ the following day and cultures were incubated for 8 days at 37°C 
(Gottschall, Yu et al. 1995). 
 
OL Culture Purification 
Mixed glial cultures were mechanically shaken for 1 hr to separate 
microglial cells from the OL/astrocyte monolayer and media was discarded.  
Fresh DMEM+ was added and the flask was returned to the incubator for an 
additional 2 days at 37°C.  OLs were purified from mixed glial preparations by 
shaking the preparations for 18 hrs to separate OLs and microglia from the 
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astrocyte monolayer.  The media was removed, the cells were pelleted and re-
suspended in DMEM+. Viable cells were then counted using Trypan Blue 
exclusion.  Microglia- and OL-containing media was added to 10 cm plastic 
tissue culture dishes at a density of 107 cells/dish and incubated for 15 min at 
37°C (procedure repeated 3 times for microglial adherence to the plastic).  After 
incubation, the dishes were gently swirled and media collected.  The remaining 
suspension was pelleted, re-suspended in DMEM+, and plated on glass poly-L-
lysine-treated coverslips at 3 x 105 cells/coverslip (McCarthy and de Vellis 1980).  
The following day, media was changed to Neurobasal complete (Neurobasal 
supplemented with B-27, L-glutamine 0.5mM, and 10ng/ml PDGF AA) (Barres, 
Schmid et al. 1993; Yang, Watanabe et al. 2005).  OLs remained in Neurobasal 
complete and PDGF-AA for 7 days to encourage proliferation.  After the 
proliferation period, PDGF-AA was withdrawn for 5 days to induce OL 
differentiation into the mature phenotype (Yang, Watanabe et al. 2005).  
Experiments were conducted immediately following the 5 day PDGF-AA 
withdrawal. All in vitro experiments were conducted using > 95% pure OL 
cultures, as previously described in (Hall, Guyer et al. 2009). 
 
Oxygen Glucose Deprivation 
OLs were seeded onto glass coverslips and randomly assigned to one of 
two conditions:  OGD (DMEM without glucose) or normoxia (DMEM with 
glucose).  Transwell inserts (0.2 µm: Nalge Nunc International, Rochester, NY) 
were added to 6-well plates containing coverslips. The inserts provided a barrier 
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that prevented OL-HUCB cell contact but was permeable to media and soluble 
factors.  Cryopreserved HUCB cells (ALLCELLS, Emeryville, CA) were rapidly 
thawed, washed, pelleted to remove the cryopreservatives and re-suspended in 
10 ml DMEM with glucose and DNase (Sigma-Aldrich, St. Louis, MO; 50 kunitz 
units/ml).  HUCB cells were seeded onto tissue culture inserts (1x105 cells/insert) 
and placed into the wells containing OL coverslips immediately prior to OGD 
exposure.  Experimental groups not subjected to HUCB cell treatment received 
inserts containing an equal volume of DNase-supplemented DMEM with glucose.  
A negative control of media alone and wells containing 1x105 HUCB cells with 
DNase were included as controls to quantify HUCB cell contribution to the LDH 
assay for each experimental condition.  
 Cells undergoing OGD were placed in an air-tight hypoxica chamber. The 
chamber was then flushed with hypoxic gas (95% N2, 4% CO2, 1% O2; Airgas, 
Tampa, FL) for 15 min and sealed for the duration of exposure.  Normoxic cells 
were maintained in a standard tissue culture incubator.  Cultures were subjected 
to OGD or normoxia for 24 hrs at 37°C.  The media from each well was collected, 
clarified by centrifugation, and LDH analysis was performed immediately. 
 
LDH Assay 
OL cell death in culture was determined using the LDH assay (Takara Bio, 
Inc., Madison, WI).  Briefly, 100 µl of tissue culture media from each experimental 
group was added to a 96-well plate and 100µl of LDH reagent was added to each 
well.  Plates were incubated for 30 min at 25°C and absorbances were read on a 
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microplate reader at a 548 nm wavelength.  The media from HUCB cell only 
cultures served as a control for HUCB cell death.  The absorbance of HUCB cell 
only media, as well as the absorbance of media only, was subtracted from the 
total absorbance of the OL wells to eliminate background LDH activity. 
 
RNA Collection and Purification 
All collection and purification steps were performed under nuclease-free 
conditions using DNAse/RNAse-free materials. For RNA lysate collection, 10 µl 
of β-Mercaptoethanol (Pharmacia Biotech, Uppsala, Sweden) was added to 1 ml 
RTL buffer (Qiagen Inc., Valencia, CA) and 350µl of the resulting mixture was 
added to each OL-containing well to lyse the cells.  Cell lysates were then 
collected and stored at -80°C prior to extracting the RNA. Qiagen’s  RNeasy Mini 
Kit was used to extract total RNA from each cell lysate using the optional Qiagen 
RNase-Free DNase set for DNase digestion (Qiagen Inc).  Following the 
extraction, 1µl of each RNA sample was tested in an Agilent 2100 Bio-analyzer to 
determine the purity and quantity of RNA present. The remaining sample was 
stored at -80°C for subsequent use with gene array. 
 
Gene Array 
Gene array was performed by the H. Lee. Moffitt Cancer Center 
Microarray Core Facility utilizing a GeneChip 3000 Scanner, GCOS 1.4 with an 
Affymetrix MAS 5.0 algorithm to generate signal intensities, and GeneChip Rat 
Genome 230 2.0 Array (Affymetrix inc, Santa Clara, CA).  Microarray data were 
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normalized to RNA from cultures exposed to OGD.  Only genes with ≥ 1.5 fold 
increase and a signal intensity of > 100 were selected for further investigation.  
For investigated treatment groups, samples were pooled (n=5) to obtain the 
necessary RNA quantity and quality to perform this procedure. 
 
Quantitative Real Time Polymerase Chain Reaction  
Primers were ordered for selected sequences in which expression of 
genes deemed vital to OL survival and proliferation were increased at least 1.5 
fold after HUCB cell treatment. Uhmk1, Insig1, Mt3, Tspan2, Prdx4, Stmn2, and 
MOG were purchased from SABiosciences (Frederick, MD; sequences are 
proprietary).  Vcan (Integrated DNA Technologies Coralville, IA) was examined 
using the following primers: 
Reverse 5’ TTT TAG GCA TTG CCC ATC TC 
Forward 5’ ATG ACG TCC CCT GCA ACT AC 
Total RNA (10 ng/µl) from OL cultures were subjected to qRT-PCR.  The 
RT reaction mixture consisted of 3µl Oligo (dT) Primers, 10 µl cDNA Synthesis 
Master Mix (2X), 1 µl of Affinity Script RT/RNase Block enzyme mixture, and 
RNase-free H2O to a total volume of 20 µl (Stratagene, La Jolla, CA).  The 
reaction was incubated at 25°C for 5 min to allow primer annealing, then 
incubated at 42°C for 45 min to allow cDNA synthesis followed by 5 min 
incubation at 95°C to terminate the cDNA synthesis reaction.   
Complementary DNA from the RT reaction was added to a PCR reaction 
mix consisting of 1 µl cDNA, 12.5 µl 2X Brilliant 490 SYBR Green QPCR Master 
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Mix (Stratagene), 2 µl primer, and nuclease-free PCR grade H2O to a total 
volume of 25 µl.  The samples were amplified using a BioRad ICycler (Bio-Rad 
Laboratories, Hercules, CA) with the following protocol: heating to 95°C for 15 
min followed by 40 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 55 
°C, and 30 sec of elongation at 72°C.  GADPH was selected as a reference gene 
and was used to calculate the mean normalized expression. 
 
Determination of Promoter Response Elements 
Accession numbers of OL genes shown by microarray and confirmed by 
qRT- PCR to increase expression were entered into Genomatix software 
(ElDorado/Gene2Promoter v4.7.0;Genomatix Software Inc, Ann Arbor, MI).  The 
promoter regions of selected genes were investigated for common transcription 
factor binding sites.  Transcription factor families were determined and 
transcription factor binding sites conserved across the promoter regions of all 
selected genes were identified.  
 
Laser Doppler Blood Flow Measurement 
Prior to MCAO surgery, animals were anesthetized with 5% isofluorane/O2 
in an induction chamber.  Rats were treated prophylactically with Ketoprofen (10 
mg/kg s.c.), atropine (0.25 mg/kg s.c.) and Baytril (20 mg/kg i.m.) in accordance 
with IACUC guidelines.  Ketoprofen injections were continued 3 days post-MCAO 
to minimize pain and discomfort.  A constant flow of anesthesia was supplied 
with an interfaced scavenging system (3-4% isofluorane, flow rate 1 L/min) 
 73 
 
throughout the procedure.  For Doppler insertion, the head was shaved and an 
incision was made lateral to the midline of the dorsal plates of the skull.  The skin 
was spread and tissue covering the skull bone was pushed aside with a cotton-
tipped applicator.  Using a micro-drill, a small hole was drilled into the skull at 1 
mm posterior and 4 mm lateral to bregma.  A hollow stainless steel guide screw 
was positioned into the hole and a fiber optic filament (500 µm) was inserted 
through the screw guide and secured with Vetbond (3M, St. Paul, MN).  Blood 
perfusion in the brain was monitored using the Moor Instruments (Devon, 
England) Ltd laser Doppler with Moor LAB proprietary Windows-based software. 
 When surgery was complete, the screw guide was removed, bone wax placed in 
the burr hole and the scalp incision was sutured. Rats that did not show ≥ 60% 
reduction in blood perfusion during MCAO were excluded from the study (Hall, 
Guyer et al. 2009) 
 
MCAO and HUCB Cell Treatment 
MCAO surgeries were performed as previously described (Butler, Kassed 
et al. 2002; Vendrame, Cassady et al. 2004; Hall, Guyer et al. 2009).  Following 
implantation of the Doppler probe, the external carotid artery was exposed and 
isolated from the vagus nerve using blunt dissection. The artery was then ligated 
and transected near the bifurcation of the internal and external carotid arteries. 
The stump of the external carotid was then used as a guide to advance a 
monofilament through the internal carotid to the origin of the middle cerebral 
artery. The filament was then sutured secure and the incision closed.  For sham 
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surgeries, the Doppler probe was inserted and the external carotid exposed, but 
no filament inserted.   
To determine whether HUCB cells were protective against stroke-induced 
injury, rats were injected (i.v, penile vein) with either HUCB cells (1x106 HUCB 
cells in 500 PBS (pH 7.4 + DNase) or vehicle (500 μL PBS + DNase only) 48 hrs 
after MCAO surgery.  Sham-operated animals also received vehicle.   Animals 
were then sacrificed 54, 72 and 96 hrs post-stroke and transcardially perfused 
with 0.9% NaCl followed by 4% paraformaldehyde in PBS.  The brains were 
removed and saturated with 4% paraformaldehyde in PB followed by increasing 
concentrations of sucrose in PBS (20%, 30%).  Brains were then sectioned at 30 
μm on a cryostat to include bregma 1.7mm through bregma -3.3, thaw mounted 
onto slides and stored at -20°C. 
 
Fluoro-Jade Histochemistry  
  Brain sections were thawed, dried and rehydrated with 100% EtOH for 3 
min, 70% EtOH for 1min, and 1min in ddH2O. Using a 0.06% KMnO4 solution, 
sections were oxidized for 15 min.  After 3x1min washes in ddh20, brain sections 
were placed in a 0.001% solution of Fluoro-Jade (Histochem, Jefferson, AR) in 
0.1% acetic acid for 30 min.  Following incubation, sections were washed 4x3min 
in ddH2O, dried, cleared in xylene, and cover-slipped with DPX mounting medium 
(VWR International Ltd, Poole, England). 
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Immunohistochemistry 
For peroxidase detection, brain tissue sections were washed with PBS for 
5 min and incubated in 3% hydrogen peroxide for 20 min.  Sections were then 
washed 3 times in PBS, incubated for 1 hr in permeabilization buffer (2% serum, 
0.3% Triton X-100 and 0.3% 1M lysine in PBS) and incubated overnight at 4˚C 
with primary antibody in antibody solution (2% goat serum, 0.3% Triton X-100 in 
PBS).  The following day, sections were washed with PBS and incubated 1 hr at 
room temperature with secondary antibody in antibody solution (2% serum, 0.3% 
Triton X-100 in PBS).  Sections were then washed in PBS, incubated in Avidin-
Biotin Complex (ABC; Vector Laboratories Inc, Burlingame, Ca) mixture for 1hr, 
washed again and visualized using a DAB/peroxide solution (Vector Laboratories 
Inc).  After 3 final washes, sections were dried, dehydrated with increasing 
concentrations of EtOH (70%, 95%, 100%), cleared with xylene and cover-
slipped with DPX. Antibodies consisted of the following:  mouse anti-MOG 
(Abcam, Cambridge, MA; 1:250), rabbit anti-Uhmk1 (Protein tech group, Chicago 
IL; 1:50), rabbit anti-Prdx4 (Abcam; 1:250), goat anti-Vcan (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA; 1:50), rabbit anti-Tspn2 (Sigma-Aldrich), goat 
anti-Insig1 (Santa Cruz Biotechnology Inc; 1:50), and rabbit anti-Mt3 (Sigma-
Aldrich; 1:50).  Secondary detection was achieved using biotinylated secondary 
antibodies (Vector Laboratories; 1:300) corresponding to the respective species 
of primary antibodies. 
For fluorescent labeling, tissue sections and cultured OLs were subjected 
to the same method used for peroxidase detection, prior to the secondary 
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antibody incubation, except that fluorescence samples were not incubated in 
hydrogen peroxide.  Double-label immunohistochemistry was achieved by co-
incubating the tissues or cells with primary antibodies raised in two distinct 
species, followed by co-incubation with secondary antibodies conjugated to 
distinct fluorophores.  Following secondary antibody incubation, sections were 
washed and cover-slipped using VectaShield Hard Set with DAPI (Vector 
Laboratories). Antibodies used for fluorescent detection consisted of the 
following:  mouse anti-RIP (Millipore, Temecula, CA; 1:5000), rabbit anti-Prdx4 
(Abcam; 1:500), mouse anti-O4 (Chemicon, Temecula, CA; 1:1000), mouse anti-
OX-42 (AbD Serotec, Kidlington, Oxford, UK; 1:1000), rat anti-MBP (Abcam; 
1:1000), rabbit anti-NG2 (Chemicon; 1:500), rabbit anti-Uhmk1 (Protein tech 
group; 1:50), goat anti-Insig1 (Santa Cruz Biotechnology Inc; 1:50), rabbit anti-
Mt3 (Sigma-Aldrich; 1:50),  and mouse anti-GFAP (Chemicon; 1:1000). 
 Secondary antibodies used were Alexa Fluor 488 and 594 (Molecular Probes, 
Eugene, OR; 1:1000).  Negative controls were labeled in the absence of primary 
antibody corresponding with respective secondary, as discussed previously. 
 
Image Analyses 
For in vivo image analyses, brain sections from ≥ 3 animals per group 
were used.  Coronal brain sections encompassing the striatum (Bregma 
coordinates +1.7 through -0.3) were taken from each animal.  Images were 
generated using a Zeiss Axioskop2 microscope controlled by Openlab 
(Improvision Ltd, Lexington, MA) software.  Images were captured with a Zeiss 
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Axiocam Color camera.  The ImageJ 1.410 program (National Institutes of 
Health, USA) was used to measure relative total intensity ratios of ipsilateral vs. 
contralateral hemispheres. Ratios were calculated for each animal due to 
ipsilateral brain swelling caused by edema. The group mean total intensity ratio 
for each experimental treatment group was used for comparisons across 
treatments.  Total intensity analysis was conducted where treatment groups were 
blinded. 
 
Statistical Analyses 
Data from all experiments were quantified and analyzed using GraphPad 
Prism 4.0 (GraphPad Software, La Jola, CA) software.  Main effects were 
determined using one-way ANOVAs, followed by Dunnett’s post hoc tests to 
detect significant differences across treatment groups.  When two variables were 
present, two-way ANOVAs were used followed by Bonferroni post hoc tests.  A 
“p” value < 0.05 was used as the threshold for significant differences. 
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Figure 1. OLs Differentiate Into the Mature Phenotype. Photomicrographs 
show immunofluorescent staining of OL cultures at selected time points following 
PDGF-AA withdrawal. (A) 6 hrs after withdrawal, NG2 (red) and O4 (green) 
colocalized in OLs that exhibited both bipolar and immature morphology, as 
indicated by the lateralized orientation of processes and the relatively low 
number of processes, respectively. (B) At 36 hrs, NG2-positive OLs (red) 
expressed MBP (green) and contained greater numbers of processes, indicating 
that this withdrawal period was sufficient for differentiation into the mature 
phenotype. Scale bars = 50μm. 
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Figure 2. HUCB Cells Decrease LDH Release From OLs Subjected to 24 hrs 
OGD. Media from OL cultures subjected to OGD-only contained elevated levels 
of LDH compared to media from normoxic controls, demonstrating OGD-induced 
cellular injury.  OL cultures subjected to OGD were rescued by co-incubation with 
HUCB cells, as LDH release was reduced back to levels of normoxic controls (*p 
< 0.01, n=7). 
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Figure 3. Affymetrix Gene Array Fold Changes are Confirmed by qRT-PCR. 
HUCB cell treatment of OLs exposed to 24 hrs OGD significantly increased gene 
expression of MOG, Insig1, Prdx4, Mt3, Tspan2, Stmn2, Uhmk1 and Vcan (A-H) 
as compared to OLs subjected to OGD alone (* p < 0.05, n = 5).  Additionally, 
HUCB cell treatment of OLs exposed to normoxia increased the expression of 
MOG (A), Insig1 (B), Prdx4 (C), Stmn2 (F), and Vcan (H) as compared to non-
treated normoxic controls (^ p < 0.05 n = 5).  Under OGD conditions, OL 
expression of Mt3 (D), Tspan2 (E) and Stmn2 (F) were significantly reduced in 
non-treated cells compared to both normoxic groups (# p < 0.05, n = 5).  
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Figure 4. HUCB Cells Reduce Infarct Volume. HUCB cells provide 
neuroprotection when given systemically 48hrs post-stroke. Photomicrographs 
depict Fluoro-Jade staining of coronal rat brain sections at time points 54, 72 and 
96 hrs post-MCAO. Infarct volume remained constant in MCAO only groups at 54 
hrs (A), 72 hrs (B), and 96 hrs (C) post MCAO.  Whereas HUCB cell 
administration reduced infarct volume at 72 hrs (E) and 96 hrs (F) post-stroke (* 
p < 0.05, # p < 0.01, respectively n = 4) while not significantly different from sham 
operated animals (G-I) (p > 0.05) at respective time points. Bar graph (G) shows 
the percent volume quantification of the ipsilateral (stroked) hemisphere 
compared to the contralateral (non-stroked) hemisphere for each group. 
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Figure 5. HUCB Cells Rescue OLs of the External Capsule Following 
Ischemic Insult. O4 immunoreactivity was abundant throughout the ipsilateral 
external capsule of animals treated with HUCB cells 48 hrs post-MCAO (A, D). 
Vehicle (B) and sham-operated (E) controls also expressed O4, though 
immunoreactivity was sparsely distributed and less prominent compared to 
HUCB cell-treated animals.  Quantification showed that HUCB cell treatment 
significantly increased O4 immunoreactivity relative to both vehicle-treated and 
sham-operated controls (* p < 0.01, n = 3). Scales bar = 50 μm. Arrows points to 
O4 positive staining. 
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Figure 6. HUCB Cells Increase White Matter Uhmk1 Expression Following 
Ischemic Insult. HUCB cell treatment (A,B) 48 hrs post-MCAO significantly 
increased Uhmk1 expression in the ipsilateral hemisphere of the external capsule 
compared to vehicle (C,D) and sham-operated (E, F) controls (* p < 0.05, n = 3). 
Low magnification scale bars = 100 μm; high magnification inset scale bars = 20 
μm. 
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Figure 7. HUCB Cells Alter White Matter Protein Expression Following 
Ischemic Insult. Photomicrographs show increased expression of Prdx4 (A), 
Mt3 (C), MOG (E) and Insig1 (G) in the ipsilateral hemisphere of animals treated 
with HUCB cells 48 hrs post-MCAO compared to vehicle-treated controls 
(B,D,F,H, respectively).  No differences were observed in the expression of 
Tspan (I,J) or Vcan (K,L) in response to HUCB cell treatment.  Scale bars = 50 
μm. Arrows points to positive staining. 
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Figure 8. Immunohistochemical Quantification of White Matter Protein 
Expression. HUCB cell treatment 48 hrs post-MCAO resulted in increased 
expression of Uhmk1 (A), Prdx4 (B), Mt3 (C), MOG (D), and Insig1 (E) in the 
ipsilateral external capsule compared to vehicle-treated and sham-operated 
controls (*p < 0.05, #p < 0.01 n = 3).  No significant differences were detected for 
Tspan2 (F) or Vcan (G). 
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Figure 9. Prdx4, Uhmk1, Insig1 and Mt3 Colocalized With OL Marker RIP. 
Photomicrographs depicts immunoflourescent double-labeling of OL specific 
antibody RIP (A, D, G, J) and antibodies generated against Prdx4 (B), Mt3 (K), 
Insig1 (E), and Uhmk1 (H). RIP and Insig1 are colocalized (F) in OL membranes, 
whereas Prdx4 (C), Mt3 (L), and Uhmk1 (I) are cytoplasmically localized. Scale 
bars = 50 μm. Arrows points to positive staining. 
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Figure 10. Prdx4 is Expressed in Astrocytes but not Microglia/macrophages 
Following Ischemic Insult. Double-label Immunohistochemistry for Prdx4 (A) 
and CD11b (B) shows that Prdx4 is not expressed in CD11b-positive 
microglia/macrophages (C) contained within the ipsilateral external capsule.  
Prdx4 (E) and GFAP (D) colocalization shows astrocytic expression of Prdx4 (F) 
within the white matter following ischemic insult. Scale bars = 100 μm. 
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Figure 11. Mt3, Uhmk, and Insig1 are not Expressed in 
Microglia/macrophages or Astrocytes Following Ischemic Insult. 
Immunofluorescent double-labeling shows that while expression is evident in the 
ipsilateral external capsule following MCAO, Mt3, Uhmk1, and Insig1 did not 
colocalize with CD11b-positive microglia/macrophages (A, C, E) or GFAP-
positive astrocytes (B, D, F). Scale bars = 50 μm. 
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Table 1. HUCB Cell Treatment Alters Gene Expression in OLs Subjected to 
24 hrs OGD. Table shows OL genes for which HUCB cell treatment during OGD 
caused a fold change ≥ 1.5 compared to non -treated OGD controls. Genes were 
grouped based on functional relevance, and those associated with OL survival, 
proliferation, and myelination (bold font) were selected for further investigation. 
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Table 2. Common Transcription Factor Binding Sites Present in the 
Promoters of Upregluated Genes.  Table shows common transcription factor 
binding sites identified in the promoter regions of Prdx4, Mt3, Insig1, MOG, 
Uhmk1, Tspan2, Vcan and Stmn2.  8/8 denotes transcription factor binding sites 
present in all 8 genes, whereas 7/8 denotes transcription factor binding sites 
present in 7 of the 8 selected genes. 
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CHAPTER THREE 
HUMAN UMBILICAL CORD BLOOD CELLS PROTECT 
OLIGODENDROCYTES FROM BRAIN ISCHEMIA THROUGH AKT SIGNAL 
TRANSDUCTION 
 
 D.D. Rowe, MS, C.C. Leonardo, PhD, L.A. Collier, BS, A.E. Willing, PhD, 
K.R. Pennypacker PhD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
 
Abstract 
Human umbilical cord blood (HUCB) cells protect against ischemic injury, 
yet the mechanism of protection remains unclear. This study examined the role 
of Akt activation in HUCB cell-mediated protection of oligodendrocytes (OLs). We 
have employed the use of in vitro and in vivo models of ischemia to evaluate Akt 
activation following HUCB cell treatment. As previously reported, HUCB cells 
rescued cultured mature OLs from oxygen glucose deprivation (OGD) induced 
cell death, as measured by lactate dehydrogenase (LDH) assay. 
Immunohistochemical analysis showed that HUCB cell treatment enhanced Akt 
phosphorylation in cultured OLs subjected to 24 hrs OGD.  The addition of Akt 
Inhibitor IV to cultured OLs abolished the protective effects of HUCB cells and 
their induction of the antioxidant enzyme peroxiredoxin 4 (Prdx4). Systemic 
administration of HUCB cells 48 hrs post middle cerebral artery occlusion 
(MCAO) activated the Akt kinase through phosphorylation at serine 473, while 
reducing proteolytic cleavage of caspase 3 in the ipsilateral external capsule. 
These results demonstrate that Akt activation is an integral component of HUCB 
cell mediated protection from ischemic injury. 
 
Keywords 
Stroke; white matter; human umbilical cord blood cells; ischemia; anti-
oxidant; Akt activation, Caspase 3 activation. 
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Abbreviations 
 HUCB, human umbilical cord blood; OL, oligodendrocyte; OGD, oxygen 
glucose deprivation; LDH, lactate dehydrogenase; Prdx4, peroxiredoxin 4; 
MCAO, middle cerebral artery occlusion; DMEM, dulbecco modified eagle 
medium; PDGF-AA, platelet derived growth factor-AA; DMSO, dimethyl sulfoxide; 
GADPH, glyceraldehyde-3-phosphate dehydrogenase; PBS, phosphate buffered 
saline; RIP, Receptor interacting protein; Mt3, metallothionein 3; GDNF, glial cell 
derived neurotrophic factor; BDNF, brain derived neurotrophic factor; LIF, 
leukemia inhibitory factor; IL-1β, interleukin-1 beta; IL-6, interleukin-6; IGF1, 
insulin like growth factor 1; VEGF, vascular endothelial growth factor; TIMP-1, 
TIMP metallopeptidase inhibitor 1; BAD, bcl2 associated death promoter; PARP, 
poly (ADP-ribose) polymerase; ROS, reactive oxygen species; RNS, reactive 
nitrogen species. 
 
 
 
 
 
 
 
 
 
 
 102 
 
Introduction 
Until recently, oligoprotection has been largely overlooked in the 
development of new approaches to treat cerebral ischemia. Human umbilical 
cord blood (HUCB) cells have been highly efficacious in treating experimental 
stroke. HUCB cells rescued oligodendrocytes (OL)s subjected to oxygen glucose 
deprivation (OGD) by increasing survival associated and antioxidant gene 
expression while inhibiting apoptotic activators (Rowe, Leonardo et al. ; Hall, 
Guyer et al. 2009). Moreover, HUCB cells reduced infarct volume, promoted 
behavioral recovery and preserved white matter bundles following middle 
cerebral artery occlusion (MCAO) (Vendrame, Cassady et al. 2004; Newman, 
Willing et al. 2005; Hall, Guyer et al. 2009).  
HUCB cells are comprised of proliferative hemopoietic colony-forming, 
endothelial precursor and mesenchymal progenitor cells (Nakahata and Ogawa 
1982; Nieda, Nicol et al. 1997; Erices, Conget et al. 2000). The protective 
properties of this therapy have been attributed to the soluble factors secreted by 
these cells, many of which are known activators of the Akt signal transduction 
pathway (Kulik, Klippel et al. 1997; Jin, Mao et al. 2000; Newman, Willing et al. 
2006; Neuhoff, Moers et al. 2007). Upon phosphorylation at serine 473, Akt 
transduces cellular survival signals by inhibiting apoptotic cascades and 
promoting activation of cell survival pathways. Indeed, previous studies have 
shown that HUCB cell therapy protects cultured neurons from excitotoxic injury 
through activation of Akt (Dasari, Veeravalli et al. 2008) 
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Because converging lines of evidence demonstrate a role for Akt in the 
protection of neural cells, the present study examined whether the protection 
afforded to OLs by HUCB cell therapy occurs through Akt activation. Here we 
report that HUCB cells rescued OLs and increased the expression of 
peroxiredoxin 4 (Prdx4) in an Akt dependent manner. Immunohistochemical 
analysis showed that systemic administration of HUCB cells increased Akt 
phosphorylation and reduced proteolytic cleavage of caspase 3 following MCAO. 
In summary, Akt activation is an integral and necessary transducer of HUCB cell-
mediated white matter protection.  
 
Materials and Methods 
Animal Care 
All animal procedures were conducted in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals with a protocol approved by the 
Institutional Animal Care and Use Committee at the University of South Florida.  
Experiments were designed to minimize the number of animals required.  
Sprague-Dawley rats were purchased from Harlan Labs (Indianapolis, IN), 
maintained on a 12 hr light/dark cycle (6 am – 6 pm) in a climate-controlled room, 
and allowed access to food and water ad libitum.  Neonatal rats birthed from 
untimed pregnant dams were used for in vitro experiments and 300-350 g male 
rats were used for in vivo experiments. 
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Mixed Glial Culture Preparation 
Postnatal day 3 rat pups were decapitated, brains removed, and meninges 
dissected away.  Rat cortices were dissociated in a solution of 0.25% trypsin/2.21 
mM EDTA, triturated, and pelleted.  The pellet was re-suspended in DMEM 
(dulbecco modified eagle medium) (Mediatech, Manassas, VA) supplemented 
with 2.5% fetal bovine serum, 10% horse serum, and 1% antibiotic/antimycotic 
(DMEM+).  Trypan Blue exclusion was used to assess cell viability.  Cells were 
seeded (1.5 x 107) into poly-L-lysine-treated 75 cm2 tissue culture flasks.  Media 
was changed with fresh DMEM+ the following day and cultures were incubated 
for 8 days at 37°C (Gottschall, Yu et al. 1995). 
 
OL Cultures Purification 
Mixed glial cultures were mechanically shaken for 1 hr to separate 
microglial cells from the OL/astrocyte monolayer and media was discarded.  
Fresh DMEM+ was added and the flask was returned to the incubator for an 
additional 2 days at 37°C.  OLs were purified from mixed glial preparations by 
shaking the preparations for 18 hrs to separate OLs and microglia from the 
astrocyte monolayer.  The media was removed, the cells were pelleted and re-
suspended in DMEM+. Viable cells were then counted using Trypan Blue 
exclusion.  Microglia- and OL-containing media was added to 10 cm plastic 
tissue culture dishes at a density of 107 cells/dish and incubated for 15 min at 
37°C (procedure repeated 3 times for microglial adherence to the plastic).  After 
incubation, the dishes were gently swirled and media collected.  The remaining 
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OL suspension was pelleted, re-suspended in DMEM+, and plated on glass poly-
L-lysine-treated coverslips at 3 x 105 cells/coverslip (McCarthy and de Vellis 
1980).  The following day, media was changed to Neurobasal complete 
(Neurobasal supplemented with B-27, L-glutamine 0.5mM, and 10ng/ml PDGF 
AA (Platelet derived growth factor AA) (Barres, Schmid et al. 1993; Yang, 
Watanabe et al. 2005).  OLs remained in Neurobasal complete and PDGF-AA for 
7 days to encourage proliferation.  After the proliferation period, PDGF-AA was 
withdrawn for 5 days to induce OL differentiation into the mature phenotype 
(Yang, Watanabe et al. 2005).  Experiments were conducted immediately 
following the 5 day PDGF-AA withdrawal. All in vitro experiments were conducted 
using > 95% pure OL cultures, as previously described in Hall et al 2009. 
 
Oxygen Glucose Deprivation 
OLs seeded onto glass coverslips were randomly assigned to one of two 
conditions: OGD (DMEM without glucose) or normoxia (DMEM with glucose).  
Akt inhibitor IV (10µM/ml; EMD4Biosciences, Gibbstown, NJ) was added to 
media as treatment required.  Transwell inserts (0.2 µm; Nalge Nunc 
International, Rochester, NY) were added to 6-well plates containing coverslips. 
The inserts provided a barrier that prevented OL-HUCB cell contact but was 
permeable to media and soluble factors.  Cryopreserved HUCB cells 
(ALLCELLS, Emeryville, CA) were rapidly thawed, washed, pelleted to remove 
the cryopreservatives and re-suspended in 10 ml DMEM with glucose and 
DNase (50 kunitz units/ml; Sigma-Aldrich, St. Louis, MO).  HUCB cells were 
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seeded onto tissue culture inserts (1x105 cells/insert) and placed into the wells 
containing OL coverslips immediately prior to OGD exposure.  Experimental 
groups not subjected to HUCB cell treatment received inserts containing an 
equal volume of DNase-supplemented DMEM with glucose.  A negative control 
of media alone and wells containing 1x105 HUCB cells with DNase were included 
as controls to quantify HUCB cell contribution to the LDH assay for each 
experimental condition (Rowe, Leonardo et al.).  Akt inhibitor IV was dissolved in 
Dimethyl Sulfoxide (DMSO).  Akt inhibitor IV was placed in media of groups 
receiving Akt inhibitor IV treatment at final concentration 10µM/ml. Experimental 
groups not subjected to Akt inhibitor IV received equivalent quantity of DMSO.  
 Cells undergoing OGD were placed in an air-tight hypoxia chamber. The 
chamber was then flushed with hypoxic gas (95% N2, 4% CO2, 1% O2; Airgas, 
Tampa, FL) for 15 min and sealed for the duration of exposure.  Normoxic cells 
were maintained in a standard tissue culture incubator.  Cultures were subjected 
to OGD or normoxia for 24 hrs at 37°C.  The media from each well was collected, 
clarified by centrifugation, and lactate dehydrogenase (LDH) analysis was 
performed immediately. 
 
LDH Assay 
OL cell death in culture was determined using the LDH assay (Takara Bio, 
Inc., Madison, WI).  Briefly, 100 µl of tissue culture media from each experimental 
group was added to a 96-well plate and 100µl of LDH reagent was added to each 
well.  Plates were incubated for 30 min at 25°C and absorbances were read on a 
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microplate reader at a 548 nm wavelength.  The media from HUCB cell only 
cultures served as a control for HUCB cell death.  The absorbance of HUCB cell 
only media, as well as the absorbance of media only, was subtracted from the 
total absorbance of the OL wells to eliminate background LDH activity. A 
standard curve was used to quantify OL cell death by extrapolating total numbers 
of dead OLs from LDH values, as previously described (Rowe, Leonardo et al.). 
 
RNA Collection and Purification 
All collection and purification steps were performed under nuclease-free 
conditions using DNase/RNase-free materials. For RNA lysate collection, 10 µl of 
β-Mercaptoethanol (Pharmacia Biotech, Uppsala, Sweden) was added to 1 ml 
RTL buffer (Qiagen Inc., Valencia, CA) and 350µl of the resulting mixture was 
added to each OL-containing well to lyse the cells.  Cell lysates were then 
collected and stored at -80°C prior to extracting the RNA. The Qiagen RNeasy 
Mini Kit was used to extract total RNA from each cell lysate using the optional 
Qiagen RNase-Free DNase set for DNase digestion (Qiagen Inc, Valencia, CA).  
Following the extraction, 1µl of each RNA sample was tested in an Agilent 2100 
Bio-analyzer to determine the purity and quantity of RNA present. The remaining 
sample was stored at -80°C for subsequent use with gene array. 
 
Quantitative Real Time Polymerase Chain Reaction  
Primers specific to Prdx4, were purchased from SABiosciences 
(Frederick, MD; sequences are proprietary). Total RNA (10 ng/µl) from OL 
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cultures were subjected to qRT-PCR.  The RT reaction mixture consisted of 3µl 
Oligo (dT) Primers, 10 µl cDNA Synthesis Master Mix (2X), 1 µl of Affinity Script 
RT/RNase Block enzyme mixture, and RNase-free H2O to a total volume of 20 µl 
(Stratagene, La Jolla, CA). The reaction was incubated at 25°C for 5 min to allow 
primer annealing, then incubated at 42°C for 45 min to allow cDNA synthesis 
followed by 5 min incubation at 95°C to terminate the cDNA synthesis reaction.   
Complementary DNA from the RT reaction was added to a PCR reaction 
mix consisting of 1 µl cDNA, 12.5 µl 2X Brilliant 490 SYBR Green QPCR Master 
Mix (Stratagene), 2 µl primer, and nuclease-free PCR grade H2O to a total 
volume of 25 µl. The samples were amplified using a BioRad ICycler (Bio-Rad 
Laboratories, Hercules, CA) with the following protocol: heating to 95°C for 15 
min followed by 40 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 55 
°C, and 30 sec of elongation at 72°C.  Glyceraldehyde-3-phosphate 
dehydrogenase (GADPH) was selected as a reference gene and was used to 
calculate the mean normalized expression. 
 
Laser Doppler Blood Flow Measurement 
Prior to MCAO surgery, animals were anesthetized with 5% isofluorane/O2 
in an induction chamber.  Rats were treated prophylactically with ketoprofen (10 
mg/kg s.c.), atropine (0.25 mg/kg s.c.) and Baytril (20 mg/kg i.m.) in accordance 
with IACUC guidelines.  Ketoprofen injections were continued 3 days post-MCAO 
to minimize pain and discomfort.  A constant flow of anesthesia was supplied 
with an interfaced scavenging system (3-4% isofluorane, flow rate 1 L/min) 
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throughout the procedure.  For Doppler insertion, the head was shaved and an 
incision was made lateral to the midline of the dorsal plates of the skull.  The skin 
was spread and tissue covering the skull bone was pushed aside with a cotton-
tipped applicator.  Using a micro-drill, a small hole was drilled into the skull at 1 
mm posterior and 4 mm lateral to bregma.  A hollow stainless steel guide screw 
was positioned into the hole and a fiber optic filament (500 µm) was inserted 
through the screw guide and secured with Vetbond (3M, St. Paul, MN).  Blood 
perfusion in the brain was monitored using the Moor Instruments (Devon, 
England) Ltd laser Doppler with Moor LAB proprietary Windows-based software. 
 When surgery was complete, the screw guide was removed, bone wax placed in 
the burr hole and the scalp incision was sutured. Rats that did not show ≥ 60% 
reduction in blood flow during MCAO were excluded from the study (Hall, Guyer 
et al. 2009). 
 
Middle Cerebral Artery Occlusion 
MCAO surgeries were performed as previously described (Butler, Kassed 
et al. 2002; Vendrame, Cassady et al. 2004; Hall, Guyer et al. 2009).  Following 
implantation of the Doppler probe, the external carotid artery was exposed and 
isolated from the vagus nerve using blunt dissection. The artery was then ligated 
and transected near the bifurcation of the internal and external carotid arteries. 
The stump of the external carotid was then used as a guide to advance a 
monofilament through the internal carotid to the origin of the middle cerebral 
artery. The filament was then sutured in place and the incision closed.  For sham 
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surgeries, the Doppler probe was inserted and the external carotid exposed, but 
no filament inserted.   
 
HUCB Cells Treatment 
To determine whether HUCB cells were protective against stroke-induced 
injury, rats were injected (i.v, penile vein) with either HUCB cells (1x106 HUCB 
cells in 500 μL phosphate buffered saline (PBS) (pH 7.4 + DNase) or vehicle 
(500 μL PBS + DNase) 48 hrs after MCAO surgery.  Sham-operated animals 
also received vehicle.   Animals were then euthanized 54, 72 and 96 hrs post-
stroke and transcardially perfused with 0.9% NaCl followed by 4% 
paraformaldehyde in PBS.  The brains were removed and saturated with 4% 
paraformaldehyde in PB followed by increasing concentrations of sucrose in PBS 
(20%, 30%).  Brains were then sectioned at 30 μm on a cryostat to include 
bregma 1.7mm through bregma -3.3mm, thaw mounted onto slides and stored at 
-20°C. 
 
Immunohistochemistry 
For peroxidase detection, brain tissue sections/OL coverslips were 
washed with PBS (pH 7.4) for 5 min and incubated in 3% hydrogen peroxide for 
20 min.  Sections were then washed 3 times in PBS, incubated for 1 hr in 
permeabilization buffer (2% serum, 0.3% Triton X-100 and 0.3% 1M lysine in 
PBS) and incubated overnight at 4˚C with primary antibody in antibody solution 
(2% goat serum, 0.3% Triton X-100 in PBS).  The following day, sections were 
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washed with PBS and incubated 1 hr at room temperature with secondary 
antibody in antibody solution (2% serum, 0.3% Triton X-100 in PBS).  Sections 
were then washed in PBS, incubated in Avidin-Biotin Complex (ABC; Vector 
Laboratories Inc, Burlingame, Ca) mixture for 1hr, washed again and visualized 
using a DAB/peroxide solution (Vector Laboratories Inc).  After 3 final washes, 
sections were dried, dehydrated with increasing concentrations of EtOH (70%, 
95%, 100%), cleared with xylene and cover-slipped with DPX mounting medium 
(VWR International Ltd, Poole, England). Antibodies consisted of the following: 
rabbit anti-Phospho-Akt (Ser473) (1:50; Cell Signaling, Danvers, MA), rabbit anti-
Caspase 3 (1:1000; Sigma-Aldrich, St. Louis, MO).  Secondary detection was 
achieved using biotinylated secondary antibodies (1:300; Vector Laboratories) 
corresponding to the respective species of primary antibodies. 
For fluorescent labeling, tissue sections were not incubated in hydrogen 
peroxide but otherwise subjected to the same method used for peroxidase 
detection, prior to the secondary antibody incubation.  Double-label 
immunohistochemistry was achieved by co-incubating the tissues with primary 
antibodies raised in two distinct species, followed by co-incubation with 
secondary antibodies conjugated to distinct fluorophores.  Following secondary 
antibody incubation, sections were washed and cover-slipped using VectaShield 
Hard Set with DAPI (Vector Laboratories). Antibodies used for fluorescent 
detection consisted of the following: mouse anti-RIP (1:5000; Millipore, 
Temecula, CA), rabbit anti-Phospho-Akt (Ser473) (1:50; Cell Signaling), rabbit 
anti-Caspase 3 (1:1000; Sigma-Aldrich).  Secondary antibodies used were Alexa 
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Fluor 488 and 594 (1:1000; Molecular Probes, Eugene, OR).  Negative controls 
were labeled in the absence of primary antibody corresponding with respective 
secondary. 
 
Image Analyses 
Following in vitro experiments, images were generated using a Zeiss 
Axioskop2 microscope controlled by Openlab (Improvision Ltd, Lexington, MA) 
software. Images were captured with a Zeiss Axiocam Color camera. The 
ImageJ 1.410 program (National Institutes of Health, USA) was used to measure 
total staining intensity and was expressed as ratios of total intensity vs. number 
of cells, thus showing the relative area positive staining per cell. 
For in vivo image analyses, brain sections from ≥ 3 animals per group 
were used. Coronal brain sections encompassing the striatum (Bregma 
coordinates +1.7 through -0.3) were taken from each animal.  Images were 
generated using a Zeiss Axioskop2 microscope controlled by Openlab software.  
Images were captured with a Zeiss Axiocam Color camera. The ImageJ 1.410 
program was used to measure total staining intensity and was expressed as 
percent ratios of ipsilateral vs. contralateral hemispheres. Ratios were calculated 
for each animal to reduce the influence of edema in the brain hemisphere 
ipsilateral to the infarct. The groups mean total intensity ratio for each 
experimental treatment group was used for comparisons across treatments.  
Total intensity analysis was conducted where experimenter was blinded of 
treatment groups. 
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Statistical Analyses 
Data from all experiments were quantified and analyzed using GraphPad 
Prism 4.0 (GraphPad Software, La Jola, CA) software. Main effects were 
determined using one-way ANOVAs, followed by Dunnett’s post hoc tests to 
detect significant differences across treatment groups. When two variables were 
present, two-way ANOVAs were used followed by Bonferroni post hoc tests. A 
“p” value < 0.05 was used as the threshold for significant differences. 
 
Results 
Akt Inhibition Negated HUCB Cell Protection In Vitro 
To assess the role of Akt in HUCB cell protection, Akt inhibitor IV (10 
µM/ml) was used to block Akt activation in OL cultures exposed to normoxia or 
OGD in the presence or absence of the inhibitor (Figure 1). Exposure to 24 hr 
OGD resulted in increased OL cell death as compared to normoxic control (n ≥ 6, 
*p < 0.01), whereas HUCB cell co-incubation reduced OGD-induced cell death (n 
≥ 6, #p < 0.05). The inhibition of Akt phosphorylation eliminated the protective 
effects of HUCB cells, as cell death was elevated relative to HUCB only groups 
and levels were similar to OGD only groups (p > 0.05). Significant differences 
were not observed in OL cell death among the treatment groups exposed to 
normoxic conditions (p > 0.05). 
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HUCB Cells Increased Akt Phosphorylation In Vitro 
Phosphorylation at serine 473 or threonine 308 is essential for Akt-
mediated cell survival (Zhao, Sapolsky et al. 2006). An antibody specific for Akt 
phosphorylated at serine 473 was used to evaluate Akt phosphorylation of 
cultured OLs (Figure 2). Exposure to 24 hrs OGD increased Akt phosphorylation 
compared to normoxic control (n = 3, *p < 0.05).  HUCB cell treatment 
significantly increased Akt phosphorylation relative to OGD alone (n = 3, #p < 
0.05), whereas co-incubation of HUCB cell-treated OLs with Akt Inhibitor IV 
reduced phosphorylation to levels detected under normoxic conditions (n = 3 p > 
0.05). Akt phosphorylation was not different among treatment groups exposed to 
normoxia (Figure 2 E, F, G, H, p > 0.05).   
 
HUCB Cell-Induced Expression of Prdx4 is Suppressed by Akt 
Inhibition In Vitro 
We have previously reported that HUCB cells increased Prdx4 expression 
in OLs exposed to OGD (Rowe, Leonardo et al.). To determine if Prdx4 
expression is dependent on Akt activity, qRT-PCR was performed to quantify 
expression of the Prdx4 gene transcript in OLs subjected to OGD and treated 
with HUCB cells and/or Akt Inhibitor IV (Figure 3). As expected, HUCB cell 
treatment increased Prdx4 mRNA when compared to OLs subjected to OGD 
alone (n ≥ 7, *p < 0.05). Akt inhibiti on reduced Prdx4 mRNA expression both in 
the presence and absence of HUCB cells (p > 0.05), and these levels were not 
different from those observed in OLs subjected to OGD alone. 
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Delayed HUCB Cell Treatment Increased Akt Phosphorylation 
in Cerebral White Matter after MCAO 
In vivo Akt phosphorylation was evaluated in the white matter rich region 
of the external capsule. Rats received HUCB cells or vehicle 48 hrs after MCAO 
or sham-MCAO and were euthanized at 54, 72 or 96 hrs post-stroke (Figure 4) 
for immunochemistry. Constitutive phosphorylation was observed in sham-
operated animals, and levels were not different from vehicle-treated rats at any of 
the time points examined. HUCB cell treatment increased Akt phosphorylation at 
72 hrs (E) and 96 hrs (H) relative to both vehicle controls and 54 hr HUCB cell-
treated rats (B) (n = 3, # p < 0.05 compared to 54 hr HUCB, * and ^p < 0.05 
compared to 72 and 96 hr vehicle, respectively).  
 
HUCB Cells Induce Prdx4 Expression in the External Capsule 
Prdx4 expression was assessed to determine whether increased mRNA in 
vitro was consistent with increased gene product expression in vivo (Figure 5). 
Rats received HUCB cells or vehicle 48 hrs after MCAO or sham-MCAO and 
were euthanized at 54, 72 or 96 hrs post-stroke for immunochemistry. Prdx4 
immunoreactivity was restricted to cell bodies. In general, sham-operated 
controls (Figure 5C,F, I) showed nearly identical staining patterns as vehicle-
treated controls (Figure 5A, D, G) with no apparent differences in Prdx4 
expression over the time course examined. Quantification (Figure 5J) showed 
that Prdx4 was upregulated in rats treated with HUCB cells compared to sham-
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operated and vehicle-treated controls at 72 hrs post MCAO (*p < 0.01), while no 
differences were detected at 54 and 96 hrs.  
 
P-Akt and Caspase 3 Co-localized with OL Marker RIP 
Immunofluorescent staining was performed to determine whether 
activated caspase 3 (MCAO vehicle-treated rats) (Figure 6 D-F) and 
phosphorylated Akt (sham-operated rats) (Figure 6 A-C) expression localized to 
OLs within the cerebral white matter. Anti-RIP was used to double-label OLs in 
conjunction with antibodies raised against activated caspase 3 or phosphorylated 
Akt. Both proteins were expressed by white matter OLs. Phosphorylated Akt was 
evident in OL cytoplasm (Figure 6. C), whereas nuclear staining was observed in 
micrographs depicting caspase 3/RIP co-localization (Figure 6. F).  
 
HUCB Cell Treatment Reduces Caspase 3 Activation in the 
External Capsule Following MCAO 
The cleavage of caspase zymogens initiates and executes programmed 
cell death.  An antibody generated against activated caspase 3 was used to 
identify apoptotic signaling in the external capsule of rats following MCAO (Figure 
7). As expected, sections from sham-operated controls contained low levels of 
activated caspase 3. In vehicle-treated animals, levels of activated caspase 3 
were elevated at 54 and 72 hrs following MCAO compared to HUCB cell-treated 
and sham-operated groups (n = 3, *p < 0.05, #p < 0.01 respectively). However, 
caspase 3 activation returned to basal levels 96 hrs following MCAO in vehicle 
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animals (n = 3, p > 0.05). Additionally, sections from HUCB cell-treated rats 
showed no differences in caspase 3 levels compared to sham-operated rats 
although caspase 3 positive staining was detected at 54hrs.  
 
Discussion 
Oligodendroglias are highly susceptible to ischemic injury (Pantoni, Garcia 
et al. 1996; Lyons and Kettenmann 1998). In previous studies, soluble factors 
from HUCB cells protected OLs from hypoxic injury by reducing caspase 3 
activation and regulating proliferative, myelin-associated and antioxidant genes in 
vitro (Rowe, Leonardo et al. ; Hall, Guyer et al. 2009). In vivo experiments have 
demonstrated that HUCB cell therapy reduced infarct volume and preserved 
cerebral white matter integrity; these effects occurred concomitantly with 
increased expression of the antioxidant enzymes Prdx4 and metallothionein 3 
(Mt3) (Rowe, Leonardo et al.). These experiments provided strong evidence that 
the protection afforded by HUCB cell therapy occurs through the release of 
soluble factors that induce antioxidant enzymes to reduce oxidative stress. Here, 
data demonstrates that phosphorylation of Akt kinase is one mechanism 
responsible for the oligoprotective, antioxidant properties of HUCB cell therapy.  
Numerous factors secreted by HUCB cells have been shown to induce Akt 
activation, including GDNF, BDNF, LIF, IL-1β, IL-6, IGF1, VEGF and TIMP-1 
(Kulik, Klippel et al. 1997; Dolcet, Egea et al. 1999; Jin, Mao et al. 2000; Jin, 
Omori et al. 2003; Lee, Yoo et al. 2003; Lentzsch, Chatterjee et al. 2004; Wegiel, 
Bjartell et al. 2008). The pro-survival actions of Akt are well known. For example, 
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cellular proliferation and survival have been shown to result from Akt-induced 
phosphorylation of BAD, the forkhead related family of mammalian transcription 
factors and glycogen synthase kinase 3β (Zhao, Sapolsky et al. 2006). In the 
present study, HUCB cells rescued cultured OLs subjected to 24 hrs OGD, 
whereas the addition of Akt Inhibitor IV completely blocked this effect. Similar 
results were demonstrated by Dasari et. al., where the ability of HUCB cells to 
rescue neurons from glutamate excitotoxicity was blocked by Akt inhibition. Thus, 
the mechanism of oligoprotection observed after HUCB cell treatment is 
consistent with previous findings and further supports the contention that soluble 
factors activate Akt signal transduction to increase the viability of cells exposed 
to ischemic conditions. 
We also show that systemic treatment with HUCB cells at 48 hrs post-
MCAO increased Akt activation in the external capsule through phosphorylation 
at serine 473. These data are in agreement with previous data showing that Akt 
was rapidly phosphorylated at serine 473 following ischemia in vitro and in vivo, 
specifically 1 hr following MCAO (Noshita, Lewen et al. 2001; Shibata, Yamawaki 
et al. 2002; Zhao, Sapolsky et al. 2006). When Akt is unphosphorylated in 
disease states such as stroke, apoptotic cascades are activated resulting in the 
release of cytochrome c, caspase 3 and PARP (poly (ADP-ribose) polymerase) 
cleavage, thus inducing cell death (Nicholson, Ali et al. 1995; Le Rhun, Kirkland 
et al. 1998; Datta, Brunet et al. 1999; Yu, Andrabi et al. 2006; Zhao, Sapolsky et 
al. 2006). In the present study, the HUCB cell-induced increase in Akt activation 
was associated with decreased caspase cleavage, suggesting that HUCB cell 
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treatment attenuated stroke-induced caspase activation through Akt 
phosphorylation. Furthermore, the lack of phosphorylated Akt in the external 
capsule of vehicle-treated animals at 96 hrs further supports the notion that 
unphosphorylated Akt leads to increased cell death through apoptotic signaling. 
Indeed, activated caspase 3 was abundant within the cerebral infarct of vehicle-
treated rats at this time point.   
The formation of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) is also well characterized in ischemic models. These radicals and 
their associated byproducts produce damage to lipid membranes (Cuzzocrea, 
Riley et al. 2001), oxidation, methylation and depurination, producing DNA 
breaks and mutations that lead to mitochondrial energy failure and subsequent 
cell death (Steenken 1989; Routledge, Wink et al. 1994; Weitzman, Turk et al. 
1994; Cuzzocrea, Riley et al. 2001). Prdx4 is an antioxidant enzyme that 
detoxifies the cellular environment through peroxidase activity (Hofmann, Hecht 
et al. 2002; Dewar, Underhill et al. 2003). Here, Akt inhibition arrested HUCB 
cell-induced Prdx4 mRNA expression in OLs exposed to OGD. Additionally, 
Prdx4 protein expression was significantly increased 24 hrs after HUCB cell 
treatment in the white matter of rats subjected to MCAO, and these elevations 
correlated with increased phosphorylated Akt.  
 
Conclusions 
Previous reports showed that administration of HUCB cells reduced 
behavioral deficits and infarct volume after stroke and spinal cord injury (Saporta, 
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Kim et al. 2003; Vendrame, Cassady et al. 2004; Newcomb, Ajmo et al. 2006; 
Hall, Guyer et al. 2009; Chua, Bielecki et al. 2010), yet the precise mechanisms 
underlying these protective effects remained unknown. The present study 
identified a distinct pathway utilized by HUCB cell therapy to mediate protection. 
Data show that Akt phosphorylation is required for oligoprotection and 
upregulated expression of the Prdx4 gene transcript in vitro. Furthermore, Akt 
phosphorylation is associated with neuroprotection, increased Prdx4 protein 
expression and decreased caspase 3 activation in vivo. Taken together, these 
data provide strong evidence that the effects of HUCB cells on oligoprotection, 
antioxidant enzyme expression and caspase activity converge on Akt signaling. 
Future studies investigating specific factors secreted by HUCB cells and the 
pathways they activate will be instrumental in establishing more detailed 
mechanisms of HUCB cell actions on OLs and the cerebral white matter following 
ischemia. 
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Figure 1. Akt Inhibition Negates the Protective Effects of HUCB Cells on 
Cultured OLs. An increase in OL cell death was detected in cultures subjected 
to 24 hr OGD compared to normoxic controls (n ≥ 6, *p <  0.01), demonstrating 
OGD-induced cellular injury.  OL cultures subjected to OGD were rescued by co-
incubation with HUCB cells, as cell death was reduced back to levels present in 
normoxic controls (n ≥ 6, #p < 0.05). Addition of Akt Inhibitor IV eliminated HUCB 
cells oligoprotective effects in cultures exposed to 24hr OGD (n ≥ 6).  
Additionally, there was no effect of treatment on OLs exposed to normoxic 
conditions. 
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Figure 2. HUCB Cells Increase Akt Phosphorylation in OLs Subjected to 
24hrs OGD. Immunohistochemistry was performed using an antibody generated 
against Akt phosphorylated at serine 473. Micrographs show immunoreactivity in 
OLs exposed to OGD (A-D) or normoxia (E-H). Treatment groups were vehicle 
(A, E), HUCB cells (B, F), Akt Inhibitor IV (C, G) or HUCB cells + Akt Inhibitor IV 
(D, H). Quantification (I) revealed increased Akt phosphorylation in OLs exposed 
to OGD relative to normoxic controls (n = 3, *p < 0.05). Addition of HUCB cells 
resulted in an additional increase in phosphorylation during OGD relative to 
vehicle-treated OGD controls (n = 3, #p < 0.05). Akt Inhibitor IV reduced 
phosphorylation during OGD when added in the presence or absence of HUCB 
cells, such that immunoreactivity was not different from normoxic controls. Scale 
bars = 50 μm. 
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Figure 3. Akt Inhibitor IV Suppresses HUCB Cell Induced Prdx4 Expression 
During OGD. qRT-PCR was performed to quantify mRNA expression of the 
antioxidant enzyme Prdx4. OLs were subjected to OGD and treated with HUCB 
cells in the presence or absence of Akt Inhibitor IV. HUCB cells increased Prdx4 
gene transcript compared to vehicle-treated controls (n ≥ 7, *p < 0.05,). Co -
incubation of the Akt inhibitor with HUCB cells reduced the HUCB cell-induced 
elevation in Prdx4 mRNA back to levels detected in OLs treated with vehicle or 
Akt inhibitor alone. 
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Figure 4. HUCB Cells Increase Akt Phosphorylation In Vivo. 
Immunohistochemistry was performed using an antibody generated against Akt 
phosphorylated at serine 473. Micrographs show immunoreactive cells (arrows) 
in the ipsilateral external capsule of vehicle-treated (A, D, G), HUCB cell-treated 
(B, E, H) and sham-operated (C, F, I) rats. These rats were euthanized at 54 (A-
C), 72 (D-F) or 96 hrs (G-I) after MCAO. Quantification (J) revealed increased 
phosphorylation of Akt in tissues from HUCB cell-treated rats euthanized at 72 
(^p < 0.05) and 96 hrs (*p < 0.05) compared to vehicle-treated rats at the 
respective time points. Additionally, phosphorylated Akt was increased after 
HUCB cell treatment at 72 hrs relative to 54 hrs (n = 3, #p < 0.05), while no 
differences were detected between groups at the 54 hr time point. Scale bars = 
50 μm.  
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Figure 5. HUCB Cells Induce Prdx4 Expression In Vivo. 
Immunohistochemistry was performed to determine the effects of HUCB cell 
therapy on Prdx4 protein expression. Micrographs show immunoreactive cells 
(arrows) in the ipsilateral external capsule of vehicle-treated (A, D, G), HUCB 
cell-treated (B, E, H) and sham-operated (C, F, I) rats. These rats were 
euthanized at 54 (A-C), 72 (D-F) or 96 hrs (G-I) after MCAO. Quantification (J) 
revealed increased expression of Prdx4 in tissues from rats treated with HUCB 
cells and euthanized at 72 hrs post-MCAO relative to vehicle-treated and sham-
operated animals at the same time point (n=3. *p < 0.01). No differences were 
detected across treatment groups at any other time points examined. Scale bars 
= 50 μm. 
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Figure 6. Akt and Caspase 3 are Activated in OLs In Vivo.  Confocal 
micrographs show immunoflourescent co-localization using the OL specific 
antibody anti-RIP (A, D) in combination with antibodies generated against 
phosphorylated Akt (B, MCAO sham-operated vehicle treated rat) or activated 
caspase 3 (E, MCAO vehicle-treated rat) in the external capsule. Merged images 
demonstrate expression of phosphorylated Akt (C) and activated caspase 3 (F) in 
RIP-positive OLs. Arrows denote immunoreactivity. Scale bars = 50 μm.  
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Figure 7. HUCB Cells Reduce Caspase 3 Activation In Vivo. 
Immunohistochemistry was performed to determine the effects of HUCB cell 
therapy on caspase 3 activation. Micrographs show immunoreactive cells 
(arrows) in the ipsilateral external capsule of vehicle-treated (A, D, G), HUCB 
cell-treated (B, E, H) and sham-operated (C, F, I) rats. These rats were 
euthanized at 54 (A-C), 72 (D-F) or 96 hrs (G-I) after MCAO. MCAO induced 
caspase 3 activation was detected 54 (A) and 72 hrs (D) post MCAO. 
Quantification (J) revealed HUCB cell treatment blocked the stroke-induced 
activation of caspase 3 detected in vehicle-treated rats at 54 and 72 hrs (n = 3, 
*#p < 0.05) such that levels were not different from sham-operated controls. No 
differences were detected across groups at the 96 hr time point. Scale bars = 50 
μm.  
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Abstract 
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine with numerous 
effects on cellular survival and function. Human umbilical cord blood (HUCB) 
cells secrete soluble factors to protect neurons and oligodendrocytes (OL)s from 
oxygen glucose deprivation (OGD). LIF is a soluble factor expressed and 
secreted by HUCB cells. We investigated the effect of LIF on OLs exposed to 24 
hrs oxygen glucose deprivation (OGD). Administration of LIF attenuated OGD 
induced OL cell death by increasing expression of antioxidants metallothionein 
(Mt3) and peroxiredoxin (Prdx4). The addition of an Akt inhibitor (Akt inhibitor IV) 
abolished LIF protective effects and blocked LIF induced Prdx4 expression. 
Granulocyte colony stimulating factor (GCSF) reduced OL cell death, an effect 
that was blocked by Akt inhibitor. Additionally LIF/GCSF treatment did not reduce 
cell death appreciable from LIF treatment alone. We have examined two soluble 
factors secreted by HUCB cells and have shown that the optimization of each 
monotherapy is just as efficacious as HUCB cell treatment in vitro. 
 
Introduction 
Following ischemic injury, the white matter alike the gray matter is 
adversely affected by reduced cerebral blood flow. Neuronal death attributed to 
ischemia has been extensively studied, but our knowledge of white matter 
pathology following an ischemic insult remains limited. Oligodendrocytes (OL)s 
predominate the white matter tract and of the glial cells are most susceptible to 
ischemic injury (Lyons and Kettenmann 1998). This susceptibility has been linked 
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to the inherently high metabolic rate, iron content and reduced antioxidant 
production capacity of OLs (Braughler, Duncan et al. 1986; Connor and Menzies 
1996; Juurlink 1997; Juurlink, Thorburne et al. 1998).  
Cell based therapy has shown promise in stroke research, specifically 
human umbilical cord blood (HUCB) cells. HUCB cells migrate to the infarct area, 
reverse stroke induced pathology by rescuing neurons, glial cells and enhancing 
behavioral recovery post stroke  (Vendrame, Cassady et al. 2004; Vendrame, 
Gemma et al. 2005; Hall, Guyer et al. 2009; Rowe, Leonardo et al. 2010). HUCB 
cells attenuate stroke pathology in the white matter tract by halting the activation 
and progression of apoptotic cascades and, increasing the expression of survival 
associated proteins in OLs (Rowe, Leonardo et al. 2010). Although promising, 
cell based therapies are difficult to standardize. Therefore, it is important to 
understand the mechanism by which these cells mediate cellular survival and 
behavioral recovery post stroke. HUCB cells secrete soluble factors to protect OL 
exposed to oxygen glucose deprivation (Rowe, Leonardo et al. 2010). A number 
of these soluble factors have been identified as cytokines, chemokines, 
metalloproteinase inhibitors, growth factors and interleukins (Neuhoff, Moers et 
al. 2007). 
Leukemia inhibitory factor (LIF) is a 180 amino acid single 4-α-helix 
glycoprotein  that binds to the LIF cell surface receptor complex which includes 
the LIF receptor β (LIFR) and the gp130 receptor chain (Kurek 2000; Metcalf 
2003). LIF rescued OLs and reduced demyelination following spinal cord injury 
through STAT 3 and PI3/Akt survival pathway activation (Metcalf and Gearing 
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1989; Azari, Profyris et al. 2006). Furthermore  intravenous administration of LIF 
attenuated demyelination and OL loss in experimental autoimmune 
encephalomyelitis (EAE), the mouse model of multiple sclerosis, the addition of 
antibodies generated against LIF exacerbated EAE disease pathology (Metcalf 
and Gearing 1989; Metcalf and Gearing 1989; Butzkueven, Zhang et al. 2002). In 
ischemic conditions, increased LIF was detected in neuronal cell bodies and 
axons of rats subjected to MCAO. Where in cultures, LIF expression was 
upregulated in astrocytes exposed to OGD (Slevin, Krupinski et al. 2008). 
Furthermore, intracerebral injections of LIF following focal ischemia attenuated 
ischemic brain injury (Suzuki, Yamashita et al. 2005). Specifically in culture, LIF 
administration rescued mature OLs from the pro inflammatory cytokines 
interferon γ and tumor necrosis factor α induced cell death, through the activation 
of both JAK/STAT and PI3/Akt pathway (Slaets, Dumont et al. 2008).  
GCSF is a 19.6 kDa glycoprotein that alike LIF and other HUCB cell 
secreted factors activate the Akt pathway (Nagata, Tsuchiya et al. 1986; Hunter 
and Avalos 1998; Neuhoff, Moers et al. 2007; Slaets, Dumont et al. 2008). 
Specifically in stroke, GCSF has been shown to be neuroprotective (Solaroglu, 
Cahill et al. 2006). Following MCAO, GCSF administration reduced the 
inflammatory response to stroke. This study highlighted the down regulation of 
nuclear factor kappa B (NFκB) and inducible nitric oxide synthase (iNOS) in the 
infarct area (Sehara, Hayashi et al. 2007). Additionally, in a small study 
conducted in 2006 GCSF was proven safe and effective at improving neurologic 
outcomes in patients who experienced strokes affecting the MCA (Shyu, Lin et al. 
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2006). Furthermore, a more recent study (Ax 200) has been completed and the 
results are being prepared for publication. 
In this study, we examined whether LIF can duplicate HUCB cell 
protective effects. We report that LIF attenuated OGD induced OL cell death in 
vitro where the addition of Akt inhibitor IV blocked LIF protection. As with HUCB 
cell experiments, administration of LIF upregulates antioxidants Prdx4 and Mt3 
resulting in reduced oxidative stress. Examining another soluble factor secreted 
by HUCB cells, administration of granulocyte colony stimulating factor (GCSF) 
rescued OL subjected to 24 hrs OGD and again Akt inhibitor IV blocked GCSF 
effects. Thus, HUCB cells release at least two soluble factors that promote 
oligoprotection via Akt and antioxidant enzyme activity. 
 
Materials and Methods 
Animal Care 
All animal procedures were conducted in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals with a protocol approved by the 
Institutional Animal Care and Use Committee at the University of South Florida.  
Experiments were designed to minimize the number of animals required.  
Sprague-Dawley rats were purchased from Harlan Labs (Indianapolis, IN), 
maintained on a 12 hrs light/dark cycle (7 am – 7 pm) in a climate-controlled 
room, and allowed access to food and water ad libitum.  Neonatal rats birthed 
from untimed-pregnant dams were used for in vitro experiments and 300-350 g 
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male rats were used for in vivo experiments. Measures taken to minimize pain 
and discomfort are described in the subsequent methodology. 
 
Mixed Glial Culture Preparation 
Postnatal day 3 rat pups were decapitated, brains removed, and meninges 
dissected away.  Rat cortices were dissociated in a solution of 0.25% trypsin/2.21 
mM EDTA, triturated, and pelleted.  The pellet was re-suspended in DMEM 
(Mediatech, Manassas, VA) supplemented with 2.5% fetal bovine serum, 10% 
horse serum, and 1% antibiotic/antimycotic (DMEM+).  Trypan Blue exclusion 
was used to assess cell viability.  Cells were seeded (1.5 x 107) into poly-L-
lysine-treated 75 cm2 tissue culture flasks.  Media was changed with fresh 
DMEM+ the following day and cultures were incubated for 8 days at 37°C 
(Gottschall, Yu et al. 1995). 
 
OL Cultures Purification 
Mixed glial cultures were mechanically shaken for 1 hr to separate 
microglial cells from the OL/astrocyte monolayer and media was discarded.  
Fresh DMEM+ was added and the flask was returned to the incubator for an 
additional 2 days at 37°C.  OLs were purified from mixed glial preparations by 
shaking the preparations for 18 hrs to separate OLs and microglia from the 
astrocyte monolayer.  The media was removed, the cells were pelleted and re-
suspended in DMEM+. Viable cells were then counted using Trypan Blue 
exclusion.  Microglia- and OL-containing media was added to 10 cm plastic 
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tissue culture dishes at a density of 107 cells/dish and incubated for 15 min at 
37°C (procedure repeated 3 times for microglial adherence to the plastic).  After 
incubation, the dishes were gently swirled and media collected.  The remaining 
suspension was pelleted, re-suspended in DMEM+, and plated on glass poly-L-
lysine-treated coverslips at 3 x 105 cells/coverslip (McCarthy and de Vellis 1980).  
The following day, media was changed to Neurobasal complete (Neurobasal 
supplemented with B-27, L-glutamine 0.5mM, and 10ng/ml PDGF AA) (Barres, 
Schmid et al. 1993; Yang, Watanabe et al. 2005).  OLs remained in Neurobasal 
complete and PDGF-AA for 7 days to encourage proliferation.  After the 
proliferation period, PDGF-AA was withdrawn for 5 days to induce OL 
differentiation into the mature phenotype (Yang, Watanabe et al. 2005).  
Experiments were conducted immediately following the 5 day PDGF-AA 
withdrawal. All in vitro experiments were conducted using > 95% pure OL 
cultures, as previously described in (Hall, Guyer et al. 2009). 
 
Oxygen Glucose Deprivation 
OLs were seeded onto glass coverslips and randomly assigned to one of 
two conditions:  OGD (DMEM without glucose) or normoxia (DMEM with 
glucose).  LIF/GCSF (Millipore, Billerica, MA: 10-1000ng/ml) was added to media 
as treatment required.  Akt inhibitor IV (EMD4Biosciences, Gibbstown, NJ: 
10µM/ml) was added to media as treatment required. Experimental groups not 
subjected to LIF treatment an equal volume of buffer which LIF was dissolved in 
(50mM sodium phosphate/1mMDTT/10% glycerol/250mM Nacl, pH 7.4 and 
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0.02% Tween 20) supplemented DMEM.  A negative control of media alone and 
wells containing LIF or GCSF were included as controls to quantify media and 
buffer solution contribution to LDH assay for each experimental condition.  Akt 
inhibitor IV was dissolved in DMSO.  Akt inhibitor IV was placed in appropriate 
media at final concentration 10µM/ml. DMSO was added to medium in 
experimental groups not subjected to Akt inhibitor IV.  
For treatment with HUCB cells, Transwell inserts (0.2 µm; Nalge Nunc 
International, Rochester, NY) were added to 6-well plates containing coverslips. 
The inserts provided a barrier that prevented OL-HUCB cell contact but are 
permeable to media and soluble factors.  Cryopreserved HUCB cells 
(ALLCELLS, Emeryville, CA) were rapidly thawed, washed, pelleted to remove 
the cryopreservatives and re-suspended in 10 ml DMEM with glucose and 
DNase (50 kunitz units/ml; Sigma-Aldrich, St. Louis, MO).  HUCB cells were 
seeded onto tissue culture inserts (1x105 cells/insert) and placed into the wells 
containing OL coverslips immediately prior to OGD exposure.  Experimental 
groups not subjected to HUCB cell treatment received inserts containing an 
equal volume of DNase-supplemented DMEM with glucose.  A negative control 
of media alone and wells containing 1x105 HUCB cells with DNase were included 
as controls to quantify HUCB cell contribution to the LDH assay for each 
experimental condition (Rowe, Leonardo et al. 2010).  Groups containing LIF 
neutralizing antibody received antibody with respective controls (10µg/ml; R&D 
Systems, Minneapolis, MN) 
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 Cells undergoing OGD were placed in an air-tight hypoxia chamber. The 
chamber was then flushed with hypoxic gas (95% N2, 4% CO2, 1% O2; Airgas, 
Tampa, FL) for 15 min and sealed for the duration of exposure.  Normoxic cells 
were maintained in a standard tissue culture incubator.  Cultures were subjected 
to OGD or normoxia for 24 hrs at 37°C.  The media from each well was collected, 
clarified by centrifugation, and LDH analysis was performed immediately. 
 
LDH Assay 
OL cell death in culture was determined using the LDH assay (Takara Bio, 
Inc., Madison, WI).  Briefly, 100 µl of tissue culture media from each experimental 
group was added to a 96-well plate and 100µl of LDH reagent was added to each 
well.  Plates were incubated for 30 min at 25°C and absorbances were read on a 
microplate reader at a 548 nm wavelength.  The media from LIF only wells 
served as a control for absorbance as a result of LIF. The absorbance of LIF only 
media, as well as the absorbance of media only, was subtracted from the total 
absorbance of the OL wells to eliminate background LDH activity. A standard 
curve was used to quantify OL cell death by extrapolating total numbers of dead 
OLs from LDH values, as previously described in Rowe et.al. 
 
SOD Activity 
SOD activity in culture was determined using the SOD Assay (Kamiya 
Bomedical, Seattle, WA). Tissue culture media from each experimental group 
and supplied reagents were added to a 96 well plate as directed by 
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manufacturer. Plates were incubated for 25 min at 25°C and absorbances were 
read on a microplate reader at a 450 nm wavelength. SOD activity was 
determined from recorded absorbances using the equation provided by 
manufacturer. 
 
RNA Collection and Purification 
All collection and purification steps were performed under nuclease-free 
conditions using DNAse/RNAse-free materials. For RNA lysate collection, 10 µl 
of β-Mercaptoethanol (Pharmacia Biotech, Uppsala, Sweden) was added to 1 ml 
RTL buffer (Qiagen Inc., Valencia, CA) and 350µl of the resulting mixture was 
added to each OL-containing well to lyse the cells.  Cell lysates were then 
collected and stored at -80°C prior to extracting the RNA. The Qiagen RNeasy 
Mini Kit was used to extract total RNA from each cell lysate using the optional 
Qiagen RNase-Free DNase set for DNase digestion (Qiagen Inc, Valencia, CA).  
Following the extraction, 1µl of each RNA sample was tested in an Agilent 2100 
Bio-analyzer to determine the purity and quantity of RNA present. The remaining 
sample was stored at -80°C.  
 
Quantitative Real Time Polymerase Chain Reaction  
Primers were ordered for selected Prdx4 and Mt3, was purchased from 
SABiosciences (Frederick, MD; sequences are proprietary). Total RNA (10 ng/µl) 
from OL cultures were subjected to qRT-PCR.  The RT reaction mixture 
consisted of 3µl Oligo (dT) Primers, 10 µl cDNA Synthesis Master Mix (2X), 1 µl 
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of Affinity Script RT/RNase Block enzyme mixture, and RNase-free H2O to a total 
volume of 20 µl (Stratagene, La Jolla, CA).  The reaction was incubated at 25°C 
for 5 min to allow primer annealing, then incubated at 42°C for 45 min to allow 
cDNA synthesis followed by 5 min incubation at 95°C to terminate the cDNA 
synthesis reaction.   
Complementary DNA from the RT reaction was added to a PCR reaction 
mix consisting of 1 µl cDNA, 12.5 µl 2X Brilliant 490 SYBR Green QPCR Master 
Mix (Stratagene), 2 µl primer, and nuclease-free PCR grade H2O to a total 
volume of 25 µl.  The samples were amplified using a BioRad ICycler (Bio-Rad 
Laboratories, Hercules, CA) with the following protocol: heating to 95°C for 15 
min followed by 40 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 55 
°C, and 30 sec of elongation at 72°C.  GADPH was used as a reference gene to 
calculate the mean normalized expression. 
 
Immunohistochemistry 
For horseradish peroxidase detection, brain tissue sections/coverslips 
were washed with PBS for 5 min and incubated in 3% hydrogen peroxide for 20 
min.  Sections were then washed 3 times in PBS, incubated for 1 hr in 
permeabilization buffer (2% serum, 0.3% Triton X-100 and 0.3% 1M lysine in 
PBS) and incubated overnight at 4˚C with primary antibody in antibody solution 
(2% goat serum, 0.3% Triton X-100 in PBS).  The following day, sections were 
washed with PBS and incubated 1 hr at room temperature with secondary 
antibody in antibody solution (2% serum, 0.3% Triton X-100 in PBS).  Sections 
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were then washed in PBS, incubated in Avidin-Biotin Complex (ABC; Vector 
Laboratories Inc, Burlingame, CA) mixture for 1hr, washed again and visualized 
using a DAB/peroxide solution (Vector Laboratories Inc).  After 3 final washes, 
sections were dried, dehydrated with increasing concentrations of EtOH (70%, 
95%, 100%), cleared with xylene and cover-slipped with DPX mounting medium 
(VWR International Ltd, Poole, England). Antibodies consisted of the following: 
rabbit anti-phospho-Akt (Ser473) (Cell Signaling, Danvers, MA; 1:50), rabbit anti-
caspase 3 (Sigma-Aldrich, St. Louis, MO; 1:1000).  Secondary detection was 
achieved using biotinylated secondary antibodies (Vector Laboratories; 1:300) 
corresponding to the respective species of primary antibodies. 
For fluorescent labeling, tissue sections were subjected to the same 
method used for peroxidase detection, prior to the secondary antibody 
incubation, except that fluorescence samples were not incubated in hydrogen 
peroxide.  Double-label immunohistochemistry was achieved by co-incubating 
the tissues with primary antibodies raised in two distinct species, followed by co-
incubation with secondary antibodies conjugated to distinct fluorophores. 
 Following secondary antibody incubation, sections were washed and cover-
slipped using VectaShield Hard Set with DAPI (Vector Laboratories). Antibodies 
used for fluorescent detection consisted of the following:  mouse anti-RIP 
(Millipore, Temecula, CA; 1:5000), rabbit anti-Phospho-Akt (Ser473) (Cell 
Signaling, 1:50), rabbit anti-Caspase 3 (Sigma-Aldrich, 1:1000).  Secondary 
antibodies used were Alexa Fluor 488 and 594 (Molecular Probes, Eugene, OR; 
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1:1000).  Negative controls were labeled in the absence of primary antibody 
corresponding with respective secondary, as discussed previously. 
 
Image Analyses 
Following in vitro experiments, images were generated using a Zeiss 
Axioskop2 microscope controlled by Openlab (Improvision Ltd, Lexington, MA) 
software. Images were captured with a Zeiss Axiocam Color camera. The 
ImageJ 1.410 program (National Institutes of Health, USA) was used to measure 
total staining intensity and was expressed as ratios of total intensity vs. number 
of cells, thus showing the relative area positive staining per cell. 
For in vivo image analyses, brain sections from ≥ 3 animals per group 
were used.  Coronal brain sections encompassing the striatum (Bregma 
coordinates +1.7 through -0.3) were taken from each animal. Images were 
generated using a Zeiss Axioskop2 microscope controlled by Openlab software.  
Images were captured with a Zeiss Axiocam Color camera. The ImageJ 1.410 
program was used to measure relative total percent intensity ratios of ipsilateral 
vs. contralateral hemispheres. Ratios were calculated for each animal due to 
ipsilateral brain swelling caused by edema. The groups mean total intensity ratio 
for each experimental treatment group was used for comparisons across 
treatments.  Total intensity analysis was conducted where treatment groups were 
blinded. 
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Statistical Analyses 
Data from all experiments were quantified and analyzed using GraphPad 
Prism 4.0 (GraphPad Software, La Jola, CA) software.  Main effects were 
determined using one-way ANOVAs, followed by Dunnett’s post hoc tests to 
detect significant differences across treatment groups.  When two variables were 
present, two-way ANOVAs were used followed by Bonferroni post hoc tests.  A 
“p” value < 0.05 was used as the threshold for significant differences. 
 
Results 
Determination of Efficacious LIF Concentration 
To determine whether administration of LIF attenuates OL cell death as a 
result of OGD, a concentration response was performed as depicted in figure 1. 
LIF was added to media at concentrations ranging from 10ng/ml to 1000ng/ml. 
OL cultures were subjected to 24 hrs OGD, after which cellular cytotoxicity was 
determined by lactate dehydrogenase assay. A concentration of 200ng/ml LIF 
was the most effective at rescuing OLs subjected to 24 hrs OGD (p<0.05, n= ≥3). 
 
Akt Inhibition Blocked LIF Protection 
Akt activation is critical for HUCB cell induced OL survival. Therefore we 
blocked the Akt pathway to determine if this signal transduction pathway was 
used by LIF to rescue OLs subjected to 24 hrs OGD. 10µM Akt inhibitor IV was 
used to block Akt activation in OL cultures exposed to OGD. Increased OL cell 
death occurred in cells exposed to OGD as compared to normoxic controls (n≥6, 
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*p< 0.01), Again 200ng/ml LIF enhanced OLs survival (n≥6, #p<0.05) (Fig 1.). 
This protection was completely blocked by Akt inhibition, where cytotoxicity levels 
were similar to OGD only groups (p>0.05). Significant differences in LDH levels 
were not observed among the treatment groups exposed to normoxic conditions 
(p>0.05). 
 
OGD Increased Akt Phosphorylation 
Antibodies specific for Akt phosphorylated at serine 473 were used to 
evaluate activation of the protein kinase in vitro following LIF treatment. Figure 3 
shows that 24 of hrs OGD exposure increased Akt phosphorylation compared to 
normoxica in OLs (n≥3, *p<0.05).  LIF administration significantly increased Akt 
phosphorylation relative to normoxic controls but not to OGD exposure alone 
(n≥3, #p<0.01, p>0.05) respectively. The introduction of Akt inhibitor IV reduced 
Akt phosphorylation to levels similar to those found in normoxic conditions (n=3 
p>0.05). Akt phosphorylation was not different among treatment groups exposed 
to normoxia (Figure 2 E, F, G, H, p>0.05).   
 
LIF Increased OL Expression of Prdx4 and Mt3 in OL Cultures  
Prdx4 and Mt3 are upregulated by HUCB cell treatment and are known to 
reduce ROS accumulation by scavenging free radicals (Hozumi, Inuzuka et al. 
1998; Hofmann, Hecht et al. 2002; Rowe, Leonardo et al. 2010). To determine if 
Prdx4 and Mt3 expression are linked to LIF mediated oligoprotection, qRT-PCR 
was performed to analyze Prdx4 and Mt3 gene expression in cultured OLs. LIF 
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treatment increased Prdx4 and Mt3 mRNA when compared to OLs subjected to 
OGD (Fig 4. n≥7, *p< 0.01). Prdx4 and Mt3 were increased 6.5±2.5 and 12±4.9 
folds respectively. No significant differences were observed in normoxic groups. 
GDPH was used as control in these experiments.  
 
Akt Inhibitor IV Blocked LIF Induced Prdx4 Expression but 
Increased Mt3 Expression 
Akt inhibitor IV was employed to determine whether activation of Akt is 
linked to expression of antioxidant genes. The addition of Akt inhibitor IV blocked 
LIF induced Prdx4 expression. Differences in Prdx4 expression was not 
observed in OGD only groups compared to OLs exposed to OGD coincubated 
with Akt inhibitor IV + LIF and Akt inhibitor IV only groups (p>0.05, p>0.05) 
respectively. Yet the addition of Akt inhibitor IV increased Mt3 expression as 
compared to OGD alone (p<0.01). Mt3 expression was increased in ODG + LIF + 
Akt inhibitor and OGD + Akt inhibitor groups 39.6±8.8 and 28±4.1 folds 
respectively. This finding was consistent with previous reports in which inhibition 
of Akt and Akt effectors increased Mt3 expression in human hepatocellular 
carcinomas (Datta, Majumder et al. 2007).  
 
LIF Reduced SOD Activity in OL Cultures 
 To determine oxidative stress, SOD activity was measured. We showed 
that LIF treatment significantly reduced SOD activity in media compared to OGD 
alone (p<0.05). Furthermore, addition of Akt inhibitor IV increased SOD activity to 
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levels similar to those found in OGD, where OGD was not different from OGD + 
LIF + Akt inhibitor and OGD+ Akt inhibitor (p>0.05, p>0.05) respectively. 
 
LIF Neutralizing Antibody Did Not Block HUCB Cell Effect 
To evaluate LIF in HUCB cell mediated OL protection, a LIF neutralizing 
antibody was used to block the effects of LIF. Exposure to 24 hrs OGD increased 
OL cell death as compared to normoxic control (n ≥ 6, *p < 0.01), whereas HUCB 
cell co-incubation reduced OGD induced cell death (n ≥ 6, #p < 0.05). The 
addition of 10ug/ml LIF neutralizing antibody with HUCB cell treatment had no 
effect. Additionally, LIF neutralizing antibody did not affect HUCB cell mediated 
reduction of SOD activity as shown in figure 7B. Treatment with HUCB cells and 
HUCB cells + antiLIF significantly reduced SOD activity in OL culture media (*p < 
0.05).Therefore the addition of LIF neutralizing antibody did not block HUCB cell 
induced oligoprotection. 
  
GCSF Rescued OLs from 24 hrs OGD 
Because LIF neutralizing antibody did not block HUCB cell effects, we 
evaluated the ability of an additional soluble factor to attenuate OGD induced OL 
dysfunction. A concentration response was performed. GCSF was added to 
media ranging from 10ng/ml to 1000ng/ml, after which OLs were exposed to 24 
hr OGD. A concentration of 200ng/ml was discovered as the most effective 
GCSF concentration at rescuing OLs subjected to 24 hrs OGD (p<0.05, n ≥4).  
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Akt Inhibitor IV Blocked GCSF Mediated Effects 
We blocked the PI3/Akt pathway using 10µM Akt inhibitor IV in OL 
cultures treated with GCSF and exposed to OGD. OGD exposure resulted in 
increased OL cell death as compared to normoxic controls (n≥6, *p< 0.01), where 
200ng/ml GCSF coincubation increased survival of OLs (n≥6, #p<0.05) (Fig 1.). 
GCSF mediated protection was blocked by Akt inhibition, where cytotoxicity 
levels were similar to OGD only groups (p>0.05). Furthermore, combining LIF 
and GCSF treatment did not increase cell survival relative to LIF treatment alone 
but significant from OGD (p>0.05, p<0.05) respectively figure 9B. Significant 
differences were not observed in OL cell death among the treatment groups 
exposed to normoxic conditions (p>0.05).  
 
Discussion 
We showed that the pleiotropic cytokine LIF attenuated OGD induced OL 
cell death. LIF activity was transduced through Akt activation and upregulated 
antioxidant gene expression leading to reduction of ROS production thus 
increasing cellular survival of primary OLs.  
OGD is a commonly used in vitro model of stroke. Previously, HUCB cells 
has been shown to protect OLs from cell death attributed to OGD by secreting 
soluble factors (Rowe, Leonardo et al. 2010). LIF and GCSF are two soluble 
factors expressed and secreted by HUCB cells (Neuhoff, Moers et al. 2007).  LIF 
activity is modulated through surface receptors, specifically LIF binds LIFR at low 
affinity, but this affinity is increased once LIF is bound to gp130 (Gearing, 
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VandenBos et al. 1992; Kurek 2000). Following LIF binding, LIFR and gp130 
dimerizes to activate the gp130 intracellular signaling cascade relaying the signal 
to the janus kinase signal transducer and activator for transcription (JAK/STAT), 
Ras mitogen activated protein (MAPK) and the PI3/Akt pathway (Oh, Fujio et al. 
1998; Tanaka, Hijioka et al. 2004; Hall, Karplus et al. 2009).  
In the present study, LIF administration attenuated OGD induced OL cell 
death. The optimal concentration of 200ng/ml LIF reduced cellular cytotoxicity in 
OLs exposed to 24 hrs OGD. This result is in agreement with previous studies in 
which LIF rescued OLs in disease states such as spinal cord and EAE injury 
(Kerr and Patterson 2005; Azari, Profyris et al. 2006; Butzkueven, Emery et al. 
2006) . 
HUCB cells mediated oligoprotection through the activation of the PI3/Akt 
survival pathway (See Chapter 3). Additionally, LIF administration activated the 
Akt survival pathway and blocked caspase 3 cleavage post spinal cord injury 
(Azari, Profyris et al. 2006). Our goal was to identify soluble factors that emulate 
the action of HUCB cells. Thus, a specific Akt inhibitor was used to assess the 
role of Akt in LIF mediated OL protection. We report that the addition of Akt 
inhibitor IV abolished LIF protection in OL cultures exposed to OGD. No 
difference was observed in assessing Akt phosphorylation in OLs exposed to 24 
hrs OGD compared to cells treated with LIF. Where OGD alone increased 
phosphorylation of Akt in OLs subjected to OGD. Previous reports showed 
increased Akt activation following OGD, additionally Akt is rapidly phosphorylated 
at serine 473 in various models of ischemia. These results suggest the activation 
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of intrinsic cellular survival mechanisms, where Akt activation enhance cellular 
survival and halt apoptosis. (Zhao, Sapolsky et al. 2006). 
OGD induces ROS production and PI3/Akt activation attenuate 
mitochondrial dysfunction, therefore we investigated the role of antioxidant gene 
expression in LIF protection (Zhao, Sapolsky et al. 2006). The high oxygen 
consumption and availability of peroxidizable lipids renders the brain susceptible 
to oxidative stress post stroke. Superoxide is the primary ROS from which other 
ROS are generated (Allen and Bayraktutan 2009). In ischemia, ROS/antioxidants 
imbalances result in protein denaturation, lipid peroxidation, DNA damage and 
cell death. Furthermore, oxidative stress is a major cause of OL cell death 
resulting from stroke (Dewar, Underhill et al. 2003). This susceptibility has been 
linked to OLs high metabolic rate, high energy consumption, low antioxidant and 
high Iron content (McTigue and Tripathi 2008). OL’s low antioxidant content 
leaves cells unable to cope with the accumulation of ROS/RNS (Juurlink 1997; 
Juurlink, Thorburne et al. 1998). Iron is an important myelin cofactor that is highly 
reactive and conducive to the generation of ROS/RNS to free radical formation 
and lipid peroxidation following stroke (Braughler, Duncan et al. 1986; Connor 
and Menzies 1996; McTigue and Tripathi 2008; Allen and Bayraktutan 2009). 
Therefore the regulation of antioxidants is a potential target in OL protection. 
Previously we showed that HUCB cell rescued OL via regulation of the 
antioxidants Prdx4 and Mt3 (Rowe, Leonardo et al. 2010). 
Prdx4 and Mt3 are members of antioxidant families that act as free radical 
scavengers (Hozumi, Inuzuka et al. 1998; Hofmann, Hecht et al. 2002). Prdx4 
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possess peroxidase activity, detoxifying a range of free radical-forming organic 
hydroperoxides (Hofmann, Hecht et al. 2002). Mt3 is involved in the detoxification 
of heavy metals such as mercury (Hozumi, Inuzuka et al. 1998; Uchida, Gomi et 
al. 2002; Hwang, Kim et al. 2008). Furthermore Prdx family undergo structural 
changes to engage in chaperone activity in response to excessive oxidation 
(Jang, Lee et al. 2004). This chaperone activity prevents free radical-induced 
aggregation of cytosolic proteins (Jang, Lee et al. 2004; Kang, Rhee et al. 2005).  
LIF treatment increased Mt3 and Prdx4 expression in cultured OLs 
exposed to OGD. These reports support previous findings where LIF inhibited the 
production of pro inflammatory mediators including TNFα and ROS by 
macrophages (Hendriks, Slaets et al. 2008). Under biological stress, ROS are 
generated where antioxidant such as SOD are upregulated to combat oxidative 
stress. If ROS are generated to toxic levels, cell death will result (Allen and 
Bayraktutan 2009). Upon further investigation using a superoxide activity, we 
confirmed that LIF treatment reduced ROS generation in media from OL cultures 
exposed to OGD. In these experiments, SOD activity was elevated in cultures 
exposed to OGD. This increase in SOD could be a result of cellular response to 
OGD induced superoxide production. These results suggest that LIF treatment 
reduced ROS production, therefore lowering SOD activity. These results also 
explained the increase in Mt3 expression as a result of Akt inhibition.  Inhibition 
of Akt has been previously shown to increase Mt3, but a rationale has not been 
developed or tested (Datta, Majumder et al. 2007). Thus we postulate that Akt 
inhibitor IV blocked the PI3/Akt survival pathway resulting in the accumulation of 
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ROS as demonstrated by the SOD activity assay, where increased SOD activity 
was observed with the addition of Akt inhibitor.  This accumulation of ROS could 
lead a cellular response increasing antioxidants such as Mt3, thus an increase in 
Mt3 gene expression was observed.  
These results are in opposition to the study done by Slaets et. al where 
LIF rescued OLs from proinflammatory cytokines such as TNFα and IFNγ 
induced apoptosis, but not oxidative stress. This conflict was resolved by 
increasing LIF therapeutic concentration. In the previous study by Slaets et. al, 
15ng/ml LIF was used as treatment. At identical LIF concentrations, LIF did not 
rescue OLs subjected to OGD as shown in figure 1, but at an increased 
concentration of 200ng/ml cellular protection was observed.  
As previously mentioned, HUCB cells secrete a number soluble factor. To 
assess the potency of LIF as compared to other soluble factors secreted by 
HUCB cells, we used a LIF neutralizing antibody to block the effects of LIF. With 
the neutralizing antibody, HUCB cells protection was maintained as previously 
reported by Rowe Et. Al and SOD levels were not affected. These results show 
that other soluble factors secreted by HUCB cells such as GCSF are also 
important 
GCSF promotes proliferation, differentiation and survival (Avalos 1996). 
GCSF alike LIF and other HUCB cell secreted factors activate the Akt pathway 
(Hunter and Avalos 1998; Neuhoff, Moers et al. 2007; Slaets, Dumont et al. 
2008). We showed that GCSF protected OL from OGD induced death, the 
presence of Akt inhibitor IV blocked this effect. These results point to the role of 
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each secreted factor of HUCB cell, where these factors work in synergy to 
activate the PI3/Akt pathway to increase cellular survival. In the absence of LIF 
activity, as shown with the inclusion of a LIF neutralizing antibody, other soluble 
factors compensated. Interestingly, the combination treatment of LIF and GCSF 
did not decrease cellular cytotoxicity compared to LIF treatment alone. Therefore 
it can now be stated that LIF is not solely responsible for HUCB cell protective 
effects. 
Previous studies have highlighted LIF protective effects in disease states 
including spinal cord injury and EAE (Kerr and Patterson 2005; Azari, Profyris et 
al. 2006; Butzkueven, Emery et al. 2006) . Furthermore, LIF expression is 
upregulated in vitro in cells exposed to OGD, and is rapidly expressed in the 
infarct boundary post stroke (Slevin, Krupinski et al. 2008). This upregulation in 
disease states appears to have a protective effect. Here we show that LIF 
rescued OLs subjected to OGD via activation of the Akt pathway.  Furthermore, 
we established that LIF increased OL antioxidant production in an oxygen 
deprived environment. Future studies investigating LIF activity in vivo following 
stroke will be instrumental in establishing more detailed mechanisms of LIF on 
OLs and the cerebral white matter following ischemia. 
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Figure 1. LIF Attenuate Stroke Induce OL Dysfunction. LIF was co-incubated 
with OL at concentrations of 10ng/ml 50, 200 and a final concentration of 
1000ng/ml.  OL cultures were subjected to 24 hrs OGD. OGD increased cell 
death an appreciable amount, and cytotoxic effect was slightly increased with 
10ng and 50ng LIF treatment. 200ng/ml LIF rescued OLs subjected to 24 hrs 
OGD compared to OGD alone (p<0.05, n= ≥ 3), where 10, 50 and 1000ng/ml 
was not different from OGD controls (p>0.05). Beyond 200ng to 1000ng/ml, LIF 
was not protective. Here represents a biphasic effect of LIF. 
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Figure 2.  Akt Inhibition Negates the Protective Effects of LIF on Cultured 
OLs. An increase in OL cell death was detected in cultures subjected to 24 hr 
OGD compared to normoxic controls (n ≥ 6, *p < 0.01), demonstrating OGD -
induced cellular injury.  OL cultures subjected to OGD were rescued by co-
incubation with 200ng/ml LIF (n ≥ 6, #p < 0.05), cell death was reduced back to 
levels present in normoxic controls (p>0.05). Addition of Akt Inhibitor IV 
eliminated LIF oligoprotective effects in cultures exposed to 24hr OGD (p > 0.05).  
Additionally, there was no effect of treatment on OLs exposed to normoxic 
conditions. 
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Figure 3. OGD Increased Akt Phosphorylation in OLs Subjected to 24 hrs 
OGD. Immunohistochemistry was performed using an antibody generated 
against Akt phosphorylated at serine 473. Micrographs show immunoreactivity in 
OLs exposed to OGD (A-D) or normoxia (E-H). Treatment groups were vehicle 
(A, E), LIF (B, F), Akt Inhibitor IV (C, G) or LIF + Akt Inhibitor IV (D, H). 
Quantification (I) revealed increased Akt phosphorylation in OLs exposed to 
OGD relative to normoxic controls (n ≥3, *p < 0.05). Addition of LIF resulted in an 
additional increase in phosphorylation during OGD relative to vehicle-treated 
normoxic controls but not OGD (n ≥ 3, #p < 0.001, p > 0.05) respectively. Akt 
Inhibitor IV reduced phosphorylation during OGD when added in the presence or 
absence of LIF, such that immunoreactivity was not different from normoxic 
controls. Scale bars = 50 μm. 
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Figure 4. LIF Increased OL Expression of Prdx4 and Mt3 in OL Cultures. 
qRT-PCR was performed to quantify mRNA expression of the antioxidant 
enzyme Prdx4 and Mt3. OLs were subjected to OGD or normoxia and treated 
with LIF. LIF increased Prdx4 (6.5±2.5 folds (A) and Mt3 (12±4.9) folds (B) gene 
transcript compared to vehicle-treated controls (n ≥ 7, *p < 0.01,). No differences 
were observed in normoxic controls. 
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Figure 5. Akt Inhibitor IV Suppresses LIF Induced Prdx4 Expression but 
Increased Mt3 expression. OLs were subjected to OGD and treated with LIF in 
the presence of Akt Inhibitor IV. Akt Inhibitor IV blocked LIF induced Prdx4 
expression across all treatment groups as compared to OGD (p> 0.05). Akt 
inhibitor IV increased MT3 expression compared to vehicle-treated controls (n ≥ 
7, *p < 0.01). Mt3 expression was increased in ODG + LIF + Akt inhibitor and 
OGD + Akt inhibitor groups 39.6±8.8 and 28±4.1 folds respectively. 
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Figure 6. LIF Reduced SOD Activity in Primary OL Cultures. OGD causes 
SOD activity in OL cultures subjected to 24 hrs OGD. LIF treatment significantly 
reduced SOD activity compared to OGD controls (n ≥ 5, *p < 0.05). The presence 
of Akt inhibitor IV in groups OGD + LIF + Akt inhibitor and OGD + Akt inhibitor  
increased SOD activity where no differences in SOD activity was observed 
compared to vehicle-treated controls (p> 0.05). 
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Figure 7. LIF Neutralizing Antibody Did not Block HUCB Cell Effect. Media 
from OL cultures subjected to OGD-only contained elevated levels of LDH 
compared to media from normoxic controls, demonstrating OGD-induced cellular 
injury (n ≥ 6, *p < 0.01).  OL cultures subjected to OGD were rescued by c o-
incubation with HUCB cells (n ≥ 6, #p < 0.05). The addition o f 10ug/ml LIF 
neutralizing antibody with HUCB cell treatment maintained HUCB cell protection 
compared to OGD alone, and not different from HUCB cell treatment (p < 0.05, 
p>0.05) respectively. In figure (B), neutralizing antibody did change SOD levels 
associated with HUCB cell treatment. HUCB cells and HUCB cells + LIF reduced 
Sod activity (* p < 0.05). 
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Figure 8. GCSF Rescued OLs from 24 hrs OGD. In our trial, 10, 50, 200 and 
1000ng/ml GCSF was used to assess the drug efficacy.  Here, 200ng/ml GCSF 
rescued OLs subjected to 24 hrs OGD, when compared to OGD only groups 
(p<0.05, n ≥4).  
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Figure 9. Akt Inhibitor IV Blocked GCSF Mediated Effects. 10µM Akt inhibitor 
IV was used to block Akt phosphorylation in OL cultures exposed to OGD. 24 hr 
OGD exposure resulted in increased OL cell death as compared to normoxic 
controls (n≥6 , *p< 0.01). 200ng/ml GCSF coincubation rescued OGD exposed 
OLs (n≥6, #p<0.05) (Fig 1.). GCSF mediated  protection was blocked by Akt 
inhibition, where cytotoxicity levels were similar to OGD only groups (p>0.05). As 
depicted in figure 9B, combining 200ng LIF and 200ng GCSF treatment did not 
increase cell survival relative to LIF treatment alone but significant from OGD 
(p>0.05,* p<0.05). These results demonstrate that LIF is not the only HUCB cell 
secreted factor that rescues OL subjected to 24hr OGD. Significant differences 
were not observed in OL cell death among the treatment groups exposed to 
normoxic conditions (p>0.05).  
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Overview 
The serine protease t-PA is currently the only Food and Drug 
Administration (FDA) approved treatment for acute ischemia (Pan, Yu et al. 
2008). t-PA restores blood flow to ischemic areas by enzymatically dissolving 
clots by catalyzing the conversion of plasminogen to plasmin, but this treatment 
does not possess neuroprotective activity. Furthermore, t-PA treatment must be 
administered within 4 hours of stroke onset to benefit stroke patients (Hacke, 
Donnan et al. 2004). As a result, only 3-5% of stroke patients are able to use t-
PA (Marler and Goldstein 2003; Association 2008). Additionally, t-PA 
administration beyond this limited therapeutic time window is ineffective and 
could prove detrimental. The main concern of t-PA use outside 4 hrs of stroke 
onset is the increased risk of hemorrhages that accompanies delayed treatment 
(Hacke, Donnan et al. 2004). Thus, new stroke therapies are needed to extend 
the therapeutic time window providing treatment for a larger population of those 
who has suffered an ischemic stroke.  
Cell based therapy represents a growing area of viable treatments for an 
array of neurological diseases including stroke. Previously, cell based therapy 
was reserved for life-threatening injuries mainly because of the associated graft-
versus-host disease and related infections. Such diseases are a direct result of 
immune suppressive techniques such as chemotherapy and irradiation, 
techniques necessary to reduce host rejection of foreign engrafted cells 
(Sanberg, Willing et al. 2005). The use of HUCB cells circumvents the 
aforementioned immunogenic issues partly because they possess low 
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immunogenicity (Wang, Yang et al. 2009). HUCB cells also have major 
histocompatibility complex I (MHC I) but not MHC II, CD40, CD80 or CD86 co-
stimulatory molecule, these proteins are known to be expressed by antigen 
presenting cells and tissues (Wang, Yang et al. 2009). The low 
immunomodulatory effects of HUCB cells give it an advantage over other cell 
based therapies as a potential therapeutic. 
HUCB cells were first shown to improve behavioral recovery when 
treatment was given systemically 24 hrs following stroke. In this study, implanted 
cells migrated to the infarct boundary and localized in the cortex, subcortex and 
the striatum where significantly less transplanted cells were found in the 
contralateral hemisphere (Chen, Sanberg et al. 2001). To extend the therapeutic 
time window, HUCB cell treatment was assessed 48 hrs post stroke. Intravenous 
administration of HUCB cell (1x106) 48 hrs post middle cerebral artery occlusion 
(MCAO) resulted in reduced infarct volume, and behavioral recovery compared 
to stroked animals (Vendrame, Cassady et al. 2004; Newman, Willing et al. 2005; 
Hall, Guyer et al. 2009). The cytokines MIP-1α and MCP-1 were found to 
modulate HUCB cell movement to the site of injury. Specifically, MCP-1 and 
Mip1α receptors are constitutively expressed by HUCB cells, whereas these 
proteins are significantly upregulated in the ischemic brain (Jiang, Newman et al. 
2008). In vitro, HUCB cells rescued oligodendrocytes (OL)s subjected to 2 hrs 
OGD as demonstrated by reduced OGD induced caspase activation. 
Furthermore striatal white matter tracts were preserved in animals subjected to 
MCAO that received HUCB cell treatment 48 hrs post-surgery (Hall, Guyer et al. 
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2009). These experiments highlighted the potential of HUCB cells to protect not 
only the gray matter but also the white matter following an ischemic insult. 
The narrow focus on gray matter preservation following ischemia has 
resulted in few therapies showing success in human trials when moved from 
rodent models. In rodents, the gray matter occupies 90% of the brain volume 
while the white matter occupies the other 10%. In large animals including 
humans, the white matter and gray matter each occupy 50% of total brain volume 
(Miller, Alston et al. 1980). OLs of the white matter produce myelin to support 
axonal structural integrity for impulse propagation and integration (Baumann and 
Pham-Dinh 2001). Thus, white matter protection is not only necessary but 
essential to the maintenance of communication between brain areas (Arai and Lo 
2009).  
 
HUCB Cells Rescued OLs 
The protective effects of HUCB cells on the gray and white matter 
indicated that these cells are an ideal therapeutic candidate for stroke. The first 
important finding of the studies reported herein is that HUCB cells rescued OL 
subjected to 24 hrs OGD. When 1x106 HUCB cells were co-incubated with 3x105 
primary OLs then subjected 24 hrs OGD, OL cytotoxicity was significantly 
reduced as tested by Lactate Dehydrogenase assay (LDH). LDH is restricted to 
the cytoplasmic space, therefore its presence in cellular media denotes damaged 
cells. HUCB cells possess major therapeutic potential because unlike other cell 
based therapies, HUCB cells are readily available and elicit very low 
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immunogenic response. Therefore HUCB cells are easily administered without 
the concerns of painful retrieval as with bone marrow cells or the potential to elicit 
a graft versus host response. There are concerns in regards to cell based 
therapy. One such concern is the ethical use of cell based therapy, these 
apprehensions centers on the issue of morality. But also, there is a concern of 
how to standardize cell based therapy. With such concerns, limitation maybe 
placed on HUCB cells as an effective therapy. Therefore it is important to discern 
the active components of HUCB cell mononuclear fraction that possess neural 
protective properties.  
The use of transwell inserts in the current studies identified that HUCB 
cells secrete soluble factors that mediate these protective effects. The use of 0.2 
µm transwell inserts allowed only soluble factors secreted by HUCB cells to 
interact with primary OLs. Cytokines, chemokines, interleukins, metalloproteinase 
inhibitors and growth factors are secreted by HUCB cells (Newman, Willing et al. 
2006; Neuhoff, Moers et al. 2007). These factors secreted by HUCB cells are 
known to alter gene expression (Rowe, Leonardo et al. 2010). Many gene 
changes were observed by microarray and confirmed by qRT-PCR. HUCB cells 
increased Prdx4, Mog, Stmn2, Mt3, Tspan2, Vcan, and Insig1 gene expression in 
OLs subjected to 24 hrs OGD.  
From these experiments, HUCB cells protected OLs subjected to OGD by 
altering gene expression. But the question remains, do gene changes in vitro 
result in altered protein expression in OLs, and what are the consequences of 
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these changes? We look to answer these questions in the in vivo experiments 
that follow. 
 
HUCB Cells Enhance Survival Protein Expression 
 HUCB cells given intravenously post MCAO migrate to the infarct and 
reduce infarct volume and behavioral deficits (Chen, Sanberg et al. 2001; 
Vendrame, Cassady et al. 2004). As pointed out in chapter 2, when HUCB cells 
were given intravenously 48 hrs post MCAO, in brain tissues analyzed, only a 
fraction of the protein products of genes identified by microarray analysis 
changed. HUCB cell treatment increased Prdx4, Mt4, Uhmk1, Mog, and Insig1 
protein expression in OLs residing in the external capsule of the white matter 
tract adjacent to the infarct. One possible explanation is that protein translation is 
not entirely dependent on changes in gene transcription. Double staining of brain 
sections identified that OLs were indeed expressing each individual protein.  
Prdx4 and Mt3 represent two family of antioxidant enzymes actively 
involved in cellular detoxification. Prdx4 exerts protective effects through 
peroxidase activity, mainly detoxifying free radical-forming organic 
hydroperoxides such as hydrogen peroxide and peroxynitrite (Hofmann, Hecht et 
al. 2002). Prdx4 interactions with substrates convert these substrates to water 
(Zito, Melo et al. ; Hall, Karplus et al. 2009). Furthermore, Prdx4 regulates the 
thromboxane A2 receptor, thromboxane A2 is upregulated by oxidative stress 
and contributes to oxidative injury upon activation (Valentin, Field et al. 2004). 
The overexpression of Prdx4 inhibits thromboxane A2 expression (Giguere, 
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Turcotte et al. 2007).  In addition, the Prdx family has also been shown to 
undergo structural changes to engage in chaperone activity in response to 
excessive oxidation, a function that prevents free radical-induced aggregation of 
cytosolic proteins (Jang, Lee et al. 2004; Kang, Rhee et al. 2005). Similarly to 
Prdx4, the antioxidant Mt3 exerts its effects through metal detoxification and free 
radical scavenging activity (Hozumi, Inuzuka et al. 1998; Uchida, Gomi et al. 
2002; Hwang, Kim et al. 2008). Mt3 detoxifies cells by reducing heavy metals 
such as mercury and cadmium (Hidalgo, Aschner et al. 2001). Furthermore, Mt3 
activates the PI3K/Akt signaling pathway reducing H2O2 induced caspase 
activation and cell death (Kim, Hwang et al. 2009). In the same study, Mt3 
treatment resulted in the upregulation of heme oxygenase 1, where inhibition of 
Akt abolished Mt3 effect (Hwang, Kim et al. 2008).  
HUCB cell treatment also altered the expression of proteins involved in 
microtubule regulation, cell proliferation and cholesterol biosynthesis. MOG is a 
late stage myelinating protein that has been shown to inhibit microtubule 
polymerization (Johns and Bernard 1999). The protein Uhmk1 induces 
proliferation and cell cycle progression through the phosphorylation of p27kip1 
(Nakamura, Okinaka et al. 2008). Previous findings showed that mature OLs 
retain the ability to proliferate following injury. This result was obtained following 
white matter damage where new cells were generated. This study postulated the 
dedifferentiation and proliferation of OLs in the white matter (Wood and Bunge 
1991). Additionally, Insig1 as previously mentioned was upregulated in the white 
matter tract following HUCB cell administration post stroke. Insig1 is degraded 
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when cholesterol is depleted within a cell (Gong, Lee et al. 2006), Hypoxia 
increases Insig1 expression through a mechanism mediated by hypoxia inducible 
factor 1α (Nguyen, McDonald et al. 2007).  Thus, the elevations in Insig1 likely 
reflect HUCB cell induction of cholesterol biosynthesis aimed at remyelination or 
restoration of the cell membrane. This result is not surprising with the increased 
proportion of O4 positive cells following HUC B cell treatment. 
The results obtained in this study demonstrated that HUCB cells increased 
OL antioxidant enzyme expression of Prdx4 and Mt3 post MCAO. Myelin was 
also maintained in the peri-infarct region following the increased expression of 
proteins such as Uhmk1, Mog and Insig1. This maintenance of myelin was 
evident where a significant increase in O4 positive cells were detected in the 
external capsule of HUCB cell treated groups; O4 is a specific OL/myelin marker 
that is expressed by both immature and mature cells. 
 
Mechanism by Which HUCB Cells Exert Beneficial Effects 
Both in vitro and in vivo findings led us to investigate the pathway utilized 
by HUCB cells to induce protein expression and OL survival. Upon intravenous 
administration, HUCB cells enter the circulatory system and the brain as the 
blood brain barrier is open at this time point post stroke. HUCB cells migrate to 
the infarct boundary where soluble factors are secreted (Chen, Sanberg et al. 
2001; Vendrame, Cassady et al. 2004; Neuhoff, Moers et al. 2007; Jiang, 
Newman et al. 2008). These secreted factors include growth factors, 
metalloproteinase inhibitors, interleukins, cytokines and chemokines (Neuhoff, 
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Moers et al. 2007). The aforementioned interleukins, growth factors, 
metalloproteinase inhibitors and cytokines are known for specific yet merging 
functions. These functions include angiogenic, chemotactic, neuroprotective and 
anti-inflammatory actions which contribute to the therapeutic effect of HUCB 
cells. Eleven factors secreted by HUCB cells have been shown to induce Akt 
activation, these soluble factors include GDNF, GCSF, BDNF, LIF, IL-1β, IL-6, 
IGF1, VEGF and TIMP-1 (Kulik, Klippel et al. 1997; Dolcet, Egea et al. 1999; Jin, 
Mao et al. 2000; Jin, Omori et al. 2003; Lee, Yoo et al. 2003; Lentzsch, 
Chatterjee et al. 2004; Wegiel, Bjartell et al. 2008). In addition to Akt activation, 
factors such as VEGF, BDNF, PDGF-B, LIF and GCSF are known for their 
proliferative and anti-inflammatory effects (Kulik, Klippel et al. 1997; Jin, Mao et 
al. 2000; Newman, Willing et al. 2006; Neuhoff, Moers et al. 2007). 
Akt is quickly phosphorylated following ischemic injury. This rapid 
activation of Akt is thought to be an intrinsic survival mechanism (Zhao, Sapolsky 
et al. 2006). When phosphorylated at serine 473, Akt transduces cellular survival 
signals by inhibiting apoptotic cascades and promoting activation of cell survival 
effectors and pathways. (Kennedy, Wagner et al. 1997; Zhao, Sapolsky et al. 
2006). Activated Akt phosphorylate BAD, pro caspase 9 Forkhead and nuclear 
factor kappa B (NFκB) in a manner inhibiting apoptosis. Specifically, Akt inhibits 
the activation of BAD and Forkhead family of transcription factor by direct 
phosphorylation thus preventing the upregulation of pro apoptotic molecules such 
as Fas ligand (FasL) and BCL-2 interacting mediator of cell death (Bim). 
(Hanada, Feng et al. 2004; Zhao, Sapolsky et al. 2006). In contrast, inactivated 
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Akt results in mitochondrial dysfunction leading to cytochrome c release, caspase 
9 and poly (ADP-ribose) polymerase (PARP) cleavage (Nicholson, Ali et al. 1995; 
Le Rhun, Kirkland et al. 1998; Datta, Brunet et al. 1999; Yu, Andrabi et al. 2006; 
Zhao, Sapolsky et al. 2006). These substrates activates initiator caspase (2, 8, 9, 
10) followed by the activation of execution caspases (3, 6, 7) resulting in 
apoptosis (Zhao, Sapolsky et al. 2006). Once activated, caspase 3 is extensively 
involved in the apoptotic cascade, actively cleaving a number of substrates. Two 
such substrates are caspase 6 and 7. Upon cleavage, these substrates execute 
programmed cell death via the disruption of the electron transport chain, causing 
DNA fragmenting and cell shrinkage (Porter and Janicke 1999; Ricci, Gottlieb et 
al. 2003). 
Growth factors effectively bind to respective receptors activating tyrosine 
kinases leading to activation of the PI3/Akt pathway. In vitro, HUCB cells rescued 
OL subjected to 2 hrs OGD via caspase regulation (Hall, Guyer et al. 2009). 
Furthermore, it was previously shown that HUCB cell protected neurons from 
glutamate induced apoptosis via activation of the PI3/Akt pathway. Thus to 
investigate the mechanism of HUCB cell mediated protection, the PI3/Akt 
pathway represented an ideal target (Dasari, Veeravalli et al. 2008).  
In the studies described herein, the addition of Akt inhibitor IV blocked 
HUCB cell mediated protection of OLs subjected to 24 hrs OGD. Furthermore, in 
groups treated with Akt inhibitor, HUCB cell induced Prdx4 gene expression was 
blocked. In OL cultures treated with HUCB cells, Akt phosphorylation was 
significantly increased, but was significantly reduced in Akt inhibitor treatment 
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groups.  These results demonstrated that protection of OLs by HUCB cells is 
transduced through Akt activation. Additionally, in vivo application of HUCB cells 
48 hrs post MCAO increased phosphorylated Akt when compared to untreated 
groups. Thus, it was not a surprise to find that activated caspase 3 was robust in 
animals subjected to MCAO, but treatment with HUCB cells blocked caspase 
activation in the external capsule. 
Results from these experiments suggest that Akt plays a major role in 
HUCB cell mediated oligoprotection. The soluble factors secreted by HUCB cells 
activated Akt leading to the transduction of cellular survival signals. The concerns 
questioning the standardization of cell base therapy is unavoidable, thus 
alternatives to cell based therapy such as HUCB cells are needed. An ideal 
group of therapeutic targets are HUCB cell secreted factors that mimicked HUCB 
cellular protective effects. The following experiments examined two such soluble 
factors. 
 
LIF Replaced HUCB Cell Treatment. 
Next we investigated whether a soluble factor secreted by HUCB cell 
would elicit similar effects. LIF is a 180 amino acid single 4-α-helix pleiotropic 
glycoprotein that interacts with a surface receptor and the gp130 receptor chain 
(Kurek 2000). LIF activates Jak/Stat, Ras, MAPK and the PI3/Akt pathways 
(Stahl, Boulton et al. 1994; Stahl, Farruggella et al. 1995; Oh, Fujio et al. 1998). 
In unpublished data in collaboration with faculty, LIF is upregulated in HUCB cells 
compared to peripheral blood (Dr Willing’s unpublished data). Additionally, of the 
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factors secreted by HUCB cells LIF was chosen because of the lack of research 
on the effects of this cytokine in stroke. But also comprehensive research had 
been done assessing LIF action at rescuing OLs in different disease states. LIF 
rescued OLs and reduced demyelination following spinal cord injury through 
STAT 3 and PI3/Akt survival pathway activation (Metcalf and Gearing 1989; 
Azari, Profyris et al. 2006). LIF rescued mature cultured OLs from the pro 
inflammatory cytokines interferon γ and tumor necrosis factor α, through the 
activation of both JAK/STAT and PI3/Akt pathway (Slaets, Dumont et al. 2008). 
These studies showed the effects of LIF on OLs but also pointed out LIF ability to 
activate the PI3/Akt pathway. 
First, a concentration response curve was developed to find the most 
effective concentration of LIF that would attenuate OL cell death induced by 24 
hrs OGD. As shown in chapter 3, LIF concentration of 200ng/ml rescued OL 
subjected to 24 hrs OGD. The data represents a small concentration dependent 
window in which LIF is effective.  This result could be attributed to the pleiotropic 
effects of LIF at varying concentrations.  
LIF treatment increased Mt3 and Prdx4 gene expression as well as Akt 
activation in OLs exposed to OGD. As discovered with HUCB cell treatment, the 
inclusion of Akt inhibitor IV blocked LIF mediated OL protection. Furthermore the 
inclusion of Akt inhibitor IV blocked LIF induced Prdx4 gene expression but 
significantly increased Mt3. Therefore we postulate that Akt inhibitor blocked 
cellular protection thereby increasing cellular reactive oxygen species (ROS) 
production. As a response to this increased ROS, Mt3 is upregulated as part of 
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an intrinsic cellular protection mechanism. To test this hypothesis, a superoxide 
dismutase (SOD) kit was used. In the presence of ROS specifically superoxide 
production, cells react by increasing the production of SOD to eliminate free 
radicals. Therefore, in a ROS rich environment, we expected increased SOD 
activity as compared to treatment in which antioxidant production is increased as 
a result of treatment. In our experiments, SOD activity in OL media was similar in 
OGD and Akt inhibitor groups. In comparison, SOD activity was significantly 
reduced in LIF treatment groups. Therefore as expected, LIF treatment reduced 
ROS production, which is increased by the inclusion of Akt inhibitor. These 
results confirm the hypothesis that LIF treatment increased Akt activation and 
antioxidant activity leading to cellular survival. In contrast the inhibition of Akt 
phosphorylation increased cellular ROS production, thus increasing SOD activity 
and Mt3 expression to combat ROS accumulation.  
 
LIF Neutralizing Antibody Did Not Block HUCB Cell Effect 
To assess whether LIF is a major contributing soluble factor in the cocktail 
secreted by HUCB cells in ischemic protection, LIF was blocked using a 10 µg/ml 
neutralizing antibody. This antibody concentration was used particularly because 
it was above was what necessary to block the 200ng LIF used to protect OLs 
exposed to OGD. In these experiments we showed that LIF neutralizing antibody 
did not block HUCB cell effect in vitro. SOD activity was not affected by the 
inclusion of LIF neutralizing antibody in groups treated with HUCB cells.  
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 GCSF Protected OLs Exposed to OGD 
To elaborate on this effect, we also evaluated granulocyte colony-
stimulating factor (GCSF), another factor secreted by HUCB cells. GCSF is a 
pleiotropic factor shown to promote proliferation differentiation and survival 
(Avalos 1996). GCSF like LIF and the multitude of HUCB cell secreted factors 
activate the PI3/Akt pathway (Hunter and Avalos 1998; Neuhoff, Moers et al. 
2007; Slaets, Dumont et al. 2008). In these experiments we showed that GCSF 
protected OLs subjected to OGD specifically at a concentration of 200ng/ml. In 
previous reports GCSF has been shown to be neuroprotective following ischemia 
(Solaroglu, Cahill et al. 2006). Both GCSF and GCSF receptors are upregulated 
in neurons exposed to hypoxia, suggesting an autocrine response to neuronal 
injury. Furthermore, GCSF exerts its protective actions through neurogenesis, 
the inhibition of apoptosis and by blocking the inflammatory response following 
an insult (Solaroglu, Jadhav et al. 2007). GCSF modulation of inflammatory 
mediators was evident where following MCAO, GCSF administration down 
regulated NFκB and inducible nitric oxide synthase (iNOS) in the infarct area 
(Sehara, Hayashi et al. 2007). Additionally, GCSF was proven safe and effective 
in a pilot study conducted in 2006 where neurological outcomes were improved 
in patients that received treatment (Shyu, Lin et al. 2006). These studies have 
highlighted the therapeutic effects of GCSF, an effect that was confirmed by the 
experiments discussed herein. Alike LIF, the presence of Akt Inhibitor IV blocked 
GCSF protective effects. Also unexpected, the inclusion of the Akt inhibitor also 
significantly elevated OL cell death as compared to OGD only controls. These 
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results again identified the importance of the PI3/Akt survival pathway in the 
mediation of OL survival. 
Interestingly, a combination treatment of GCSF/LIF did not reduce cellular 
cytotoxicity as a result of OGD compared to LIF treatment alone. There was no 
synergistic or additive effect of combining the two soluble factors at the optimal 
concentration of their individual doses. Because the Akt signal transduction 
pathway is integral to cellular protection, these results suggest that this pathway 
is maximally activated in OLs at the 200ng/ml concentration of LIF and GCSF. 
Furthermore, these experiments showed that LIF is not the only soluble factor 
secreted by HUCB cells, and that it is also not the only effective factor at blocking 
OGD induced OL cell death.  
Thus, we have highlighted two soluble factors secreted by HUCB cells that 
promote oligoprotection via Akt and antioxidant enzyme activity. Following 
optimization, both LIF and GCSF is just as efficacious as HUCB cells at 
attenuating OGD induced OL cell death. These results therefore effectively 
remedied the concerns associated with cell based therapy, and elevate these 
factors as potential therapeutics. 
 
Implications and Limitations  
Here we have shown a viable use of cell based therapy by using HUCB 
cells as potential treatment for ischemic stroke. First we identified that HUCB 
cells protect not only the gray matter, but also the white matter following an 
ischemic insult. With the identification of a defined pathway activated by HUCB, 
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therapies can be developed to target this pathway and mimic these cells 
protective effects. In addition to the finding that secreted soluble factors of HUCB 
cells can have similar effects, the use of cells can be replaced by optimizing a 
cocktail of soluble factors. This is important because of the current concerns with 
the use of cell based therapy. 
As depicted in Figure 1-3, from the experiments described here in, HUCB 
cell treatment elicits therapeutic effect by secreting soluble factors. These factors 
altered OL gene expression resulting in the upregulation of antioxidant, 
myelinating and proliferative proteins such as Mog Mt3, Prdx and Uhmk1. The 
secreted soluble factors activated Akt, where activated Akt as well as antioxidant 
enzymes reduced ROS production and oxidative stress by inhibiting 
mitochondrial dysfunction lead caspase induced apoptosis as a result of 
ischemic. In a survival feedback loop, proteins such as Mt3 activates Akt and 
upregulated other antioxidants such as heme oxygenase 1 (Hwang, Kim et al. 
2008). 
Soluble factors secreted by HUCB cells elicit respective effects on the 
PI3/Akt pathway. In the experiments discussed, Akt appears to be the major 
pathway utilized in OLs. As mentioned previously, soluble factors such as LIF 
also activate STAT 3 and MAPK (Stahl, Boulton et al. 1994; Stahl, Farruggella et 
al. 1995; Oh, Fujio et al. 1998). But these pathways appear to play no or minor 
roles in oligoprotection. LIF is a pleiotropic factor, with receptors located 
throughout the body. Thus, treatment with LIF could cause undesired side 
effects. Overexpressed LIF in animals showed weight loss, overgrowth of 
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medullary bone tissue in long bones, calcification of the liver heart and skeletal 
muscle, thymus atrophy and the depletion of spermatogonia from male 
seminiferous tubules of the testes (Metcalf and Gearing 1989; Metcalf and 
Gearing 1989). The side effects mentioned above highlights chronic LIF 
expression, in our treatment and disease model, single dose LIF was explored. 
The aforementioned side effects therefore may be avoided but must be 
considered nonetheless. Although this study has highlighted a specific cytokine 
that has activity protecting the cerebral white matter, further investigation is 
necessary to determine the safety of this drug. Timing of therapies is critical to 
successfully treat a disease. Thus, implementation of LIF treatment in vivo, by 
first addressing the dose response of LIF in animals subjected to MCAO, 
measuring infarct volume and behavioral deficits following MCAO is to be 
considered. 
In addition, a long term assessment of LIF for treatment is essential. A 
long term study would assess the permanence of LIF beneficial effects. Such 
assessments could be made using reliable and time proven motor and memory 
exams. Different variation of water maze, rotorod, and step test are typically used 
to assess recovery following stroke. 
Another important note is the fact that LIF is not the only potent factor 
secreted by HUCB cells. As shown in this study, LIF neutralizing antibody does 
not abolish the effect of HUCB cells. This finding was of no surprise primarily 
because HUCB cells are known to secrete a vast number of soluble factors 
(Newman, Willing et al. 2006; Neuhoff, Moers et al. 2007). This result implicates 
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that LIF is not relatively more potent than other secreted factors. Furthermore, 
GCSF was also shown to be effective at similar concentration as LIF in blocking 
stroke induced OL cell death. Thus, it would be important to optimize each 
individual factor secreted by HUCB cells, and if necessary create an effective 
cocktail that not only mimics the effect of HUCB cells, but improve upon the 
effects discussed. Stroke is an acute but progressive disease, where the growth 
factors, interleukins, metalloproteinase inhibitors and cytokines could be effective 
at halting disease progression, but it is important to identify the time period in 
which these factors could prove most efficacious.  
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Figure 1. Mechanisms of OL Cell Death Following Ischemia and the Effect 
of HUCB Cells. Figure depicts potential mechanisms of OL cell death as a result 
of hypoxic ischemic injury and the effect of HUCB cell treatment. OL possess low 
antioxidant content and operate at a high metabolic rate. Ischemia results in 
energy depletion which reduces antioxidant content. Akt is dephosphorylated in 
effect blocking its protective property. OL high metabolic and decrease 
antioxidant store results in the accumulation of ROS/RNS resulting in oxidative 
stress leading to mitochondrial disruption caspase activation and apoptosis. 
HUCB cell treatment increase antioxidants Metallothionein 3 and Peroxiredoxin 
4, this provides an increase in OL antioxidant stores thus attenuating the 
accumulation of ROS. HUCB cells secretants increases Akt phosphorylation 
reducing caspase activation and preventing apoptosis. It is important to note that 
the mechanism proposed is not static, many of the processes mentioned 
influences various areas of the cell death cascade. 
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Figure 2. Mechanisms of HUCB Cell Protection of OLs. Figure depicts 
potential mechanisms of OL protection as a result of HUCB cell treatment. HUCB 
cells secrete soluble factors that activate the Akt survival pathway and enhance 
protein expression. Akt phosphorylation reduces caspase activation and ROS 
production thus preventing apoptosis. These soluble factors also increase gene 
regulation and protein expression leading to cellular repair and detoxification. 
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Figure 3. Mechanisms of LIF Protection of OLs Subjected to Ischemia. LIF 
binds to receptor gp130 and LIFR which dimerizes and activates PI3/Akt 
pathway. Akt activation increase antioxidant enzyme expression (Prdx4, Mt3) 
and arrest mitochondrial dysfunction induced caspase 3 activation. Antioxidant 
enzymes inhibit ROS production and caspase 3 activation thus blocking ischemia 
induced apoptosis.  
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